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ABSTRACT 
In response to a major gap in evidence regarding treatment outcomes among asylum-based 
refugees. the primary objective of the thesis was to investigate adherence to highly active 
antiretroviral therapy (HAART) and virological outcomes among refugees and to compare these 
outcomes with local host communities in one urban, Southeast Asia setting (Sungai Buloh, 
Kuala Lumpur, Malaysia) and one remote sub-Saharan refugee camp (Kakuma. Kenya) setting. 
Given limited resources for expanding treatment, questions have been raised as to whether 
refugees can achieve sufficient levels of adherence and viral suppression to justify sustaining 
and expanding access. Data sources included a structured questionnaire with self-reported 
adherence measures, a pharmacy-based prescription refill measure, HIV viral loads, and in-
depth interviews. Analyses made use of quantitative and qualitative approaches. The thesis 
begins by presenting the rationale, aims, research questions, and a description of preparatory 
work. Paper One presents the results of a systematic review of the literature on adherence to 
HAART and treatment outcomes among conflict-affected and forcibly displaced populations. 
finding only 17 reports, five of which included less than <100 clients, adherence estimates in the 
range of 87-99.5%, and good treatment outcomes. Papers Two and Three present the 
quantitative findings from both settings, finding no differences in outcomes between refugees 
and the host community in either setting, but a large difference between the settings. In 
Malaysia, 83% of clients on HAART for 2:25 weeks were suppressed while only II % were 
suppressed in Kenya. Female sex, longer time from HIV diagnosis to HAART start, and optimal 
adherence pharmacy refill schedule were protective in the Malaysian setting while temporary 
migration for 2: I month (in the previous year) and 2: I hour average transit time to clinic were 
independent risk factors. Larger household sizes were protective in the Kenyan setting. Paper 
Four offers an account of patient experiences based on the qualitative findings from both 
settings, and suggests that systemic barriers and resilient strategies were prevalent in both 
settings; however. intensive systemic barriers appeared to overwhelm personal resilience in the 
camp setting. Paper Five positions the work in the context of previous and future research and 
makes recommendations for programs and policy. The thesis concludes by suggesting that. just 
as good treatment outcomes were shown to be achievable in a range of forcibly displaced 
groups. asylum-based refugees were also capable of treatment success and maintain outcomes 
similar to those of the host communities. There is a clear public health and humanitarian interest 
in guaranteeing access to ART, promoting optimal adherence. and sustaining viral suppression 
in all who are in need of treatment. When problems in achieving and sustaining viral 
suppression occurred, they were not typically due to previous forced displacement, or refugee 
status itself. Overall, refugees ought to have equal access to HIV treatment based on the 
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principles of fairness, human rights, and individual and population-based public health benefits. 
Since HIV-positive individuals on HAART with good adherence will rarely transmit HIV to 
their sexual partners, it is in the enlightened self-interest of host country governments to support 
HIV programs that serve HIV -positive refugees and host clients equally. 
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GENERAL INTRODUCTION 
Highly active antiretroviral therapy (HAART) has transformed HIV I AIDS in the developed 
world into a treatable chronic condition. yet it is not without its challenges. Adherence to 
therapy is a crucial determinant of overall treatment success: sustained optimal adherence is 
essential for the prevention of onward transmission of virus [1]. drug resistance [2.3]. treatment 
failure [4.5). disease progression [6]. and mortality [7,8]. Refugees are unique insofar as they 
have been forcibly displaced across an international border and have been granted a legal status 
that entitles them to access the local standard of medical care. Yet, they are often accused of 
importing and transmitting disease despite [9.10]. and are similarly prone to the claim that they 
may be unable to sustain adherence to treatment, and therefore experience inferior treatment 
outcomes in relation to other groups. These accusations may be linked to assumptions about 
pre- or post- migration stresses [11], treatment interruptions [12] during previous episodes of 
forced displacement, and the inherent hardships [13] of life in asylum. These arguments are 
disputed by advocates who invoke human rights principles such as access to essential medicines 
[ 14], humanitarian law that instructs States to provide refugees with a standard of public relief 
equivalent to what is received by host nationals [15,16], and the demonstrated feasibility of 
delivering HAART to similar groups [17,18]. A very small number of studies conducted among 
other conflict-affected groups showed that good adherence and treatment outcomes were 
feasible in these groups [19,20,21]. However, data on adherence and treatment outcomes among 
refugees residing in asylum settings was notably lacking. Moreover, only one study [22] sought 
to compare refugees with local host communities in resource-limited settings to verify that 
outcomes were acceptable and equitable. 
In response to these challenges, this thesis investigated adherence to HAART and treatment 
outcomes in refugees and local host communities attending the same HIV treatment clinic in 
one urban setting (Kuala Lumpur, Malaysia) and one camp setting (Kakuma. Kenya), and to 
explore the reasons for any differences in treatment outcomes among these groups. These field 
sites provided variation with respect to the major types of protracted refugee situations and were 
logistically feasible. In addition to generating thi~ evidence, this work was intended to inform 
strategy related to the United Nations High Commissioner for Refugees' (UNHCR) 
Antiretroviral Therapy Policy for Refugees [23] by evaluating the continuity and sustainability 
of HAART for refugees. By investigating adherence in surrounding host communities, the 
findings were also intended to bolster the evidence-base informing equitable and high quality 
treatment and care in refugee and local host community groups. Lastly, it was hoped that the 
findings would assist Ministries of Health, implementing partners. and providers in host 
countries. to formulate or revise policy and programmes for these groups. 
12 
DEFINITIONS 
This work draws on two essential definitions. The term .. refugee" explicitly refers to 
individuals who meet an internationally recognised. legal definition regarding persons who. 
"owing to well-founded fear of being persecuted for reasons of race. religion. nationality. 
membership of a particular social group or political opinion. is outside the country of his 
nationality and is unable. or owing to such fear. is unwilling to avail himself of the protection of 
that country; or who. not having a nationality and being outside the country of his former 
habitual residence as a result of such events. is unable or. owing to such fear. is unwilling to 
return to it". By the end of 2010. there were 10.6 million refugees globally. who were displaced 
largely into camps and urban settings. Two-thirds were residing in "protracted situations". 
defined as 25,000 or more refugees of the same nationality living in exile for five years or more 
in an asylum country [24]. The average stay of a refugee in an asylum country is 17 years [25]. 
Refugees are distinguished from other displaced groups including internally-displaced persons 
(lOPs) who have not crossed international borders. and economic migrants who are not 
displaced as a result of conventional forms of persecution and violence. "Asylum-seekers" refer 
to persons who are seeking refugee status. but are awaiting a formal interview. called a 
"Refugee Status Determination" to determine their eligibility. 
The term "adherence" was defined by WHO as "the extent to which a person' s behaviour-
taking medications. following a diet. and/or executing lifestyle changes. corresponds with 
agreed recommendations from a health care provider" [26. p.3]. In the present work. 
"adherence" is used to refer to medication adherence. and specifically to adherence to HAART. 
unless indicated otherwise. "Optimal adherence" will refer to adherence that is measured at a 
level 95% or more. in line with a body of research that has consistently shown superior 
outcomes at these very high levels [5.27.28]. 
AIMS 
The primary aim of this study was to assess and compare HAART adherence and treatment 
outcomes among refugees and host communities. Secondary objectives sought to explore the 
factors associated with viral failure in each study setting. The study also aimed to bolster these 
findings with qualitative work detailing the experiences of refugees and host communities in 
attempting to sustain adherence over time, and to make recommendations for policy. 
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RESEARCH QUESTIONS AND HYPOTHESES 
The primary research questions for this work were: 
1. Do refugees adhere to treatment and achieve viral suppression while in asylum at levels 
that are comparable to local host communities? 
2. If differences in treatment outcomes between refugees and local host communities exist. 
why do the outcomes vary? What are the risk factors for lack of viral suppression in the 
study settings? 
3. How do refugees and host nationals experience their treatment while in asylum and 
what do they perceive to be the major threats and barriers to good adherence? 
4. What policies can improve adherence to HAART in clinics shared by refugee and host 
community groups? 
Table I lists the key questions and hypotheses. Hypotheses were generated based on an 
overview of relevant literature and initial preparatory fieldwork. 
Table 1: Research questions, hypotheses, and methods 
Research question Research hypothesis (HI) Metbod(s) 
Do refugees adhere to treatment and 
achieve viral suppression while in 
asylum at levels that are comparable to 
local host communities? 
Refugees will adhere to prescribed 
regimens less well and elthibit worse 
treatment outcomes when companed 
with host community popUlations. 
Structured questionnaire on adherence 
Pharmacy refill adherence 
Viral load 
2 If differences in treatment outcomes 
between refugees and local host 
communities eltist. why do the 
outcomes vary? What are the risk 
factors for lack of viral suppression in 
the study sellings? 
Sub-optimal adherence will be a slrOng 
independent risk factor for virological 
failure in both refugee and host 
community clients. Other important 
risk factors in both sites may include 
serostatus disclosure and recentlravel. 
Structured questionnaire on adherence 
Pharmacy refill adherence 
3 
4 
How do refugees and host nationals 
eltperience their treatment and what do 
they perceive to be the major threats. 
barriers. and facilitators of adherence? 
What policies can improve adherence 
to HAART in clinics shaned by refugee 
and host community groups? 
PARTNERS, ROLES, AND FUNDING 
Shaned adherence challenges in both 
sellings will include stigma and 
discrimination. Refugees will 
eltperience challenges pertaining to 
forced displacement and sequelae. 
The evidence will suppon 
recommendations for earlier initiation 
of therapy. adherence monitoring 
programs. and access 10 appropriate 
counselling services. to optimise 
adherence and treatment outcomes. 
Viral load 
Client semi-stnlClUred interviews 
All data collected 
The proposed study is the result of collaboration between the doctoral candidate and his 
supervisor based at the London School of Hygiene and Tropical Medicine (LSHTM) and 
colleagues at the Public Health and HIV Unit of the United Nations High Commissioner for 
Refugees (UNHCR). LSHTM provided research supervision and doctoral support, sponsored 
the study, and provided professional indemnity. UNHCR covered research costs, provided a 
"daily subsistence allowance" (DSA) to cover living costs during time spent in the field and 
provided logistical support. The DSA was valued at approximately 250 USD/day in Malaysia 
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and 100 USD/day in Kenya (65,000 USD for all field time). Research costs supported by 
UNHCR included all air travel, staff salaries, translations, lab fees, and miscellaneous research 
materials. This amounted to approximately 100,000 USD inclusive of both field sites; the most 
expensive single budget item was viral load testing (approximately lOOUSD/test and almost half 
of the total project cost). The study was also supported by a Canadian Institutes of Health 
Research Doctoral Research Award (84,000 Canadian dollars over three years), the Parkes 
Foundation (3000 GBP), the Department of Infectious Disease Epidemiology (LSHTM) 
research funds (3000 GBP), the University of London Central Research Fund (900 GBP), and 
the University College London Graduate Research Fund (500 GBP). The candidate was 
responsible for designing the study protocol, securing all research clearances and ethical 
approvals, implementing the data collection strategy, statistical and qualitative analyses and 
syntheses, interpreting findings, drafting manuscripts, updating manuscripts in light of 
comments and feedback from the thesis advisor, co-authors, and Advisory Committee members. 
Technical support was received by the Advisory Committee on aspects of the thesis germane to 
their particular areas of expertise. Alison Grant and Egbert Sondorp provided support on 
technical aspects of protocol design, analyses. and interpretation for Papers Two and Three. 
Natasha Larke provided all statistical support for Papers Two and Three. On Paper Four. Tim 
Rhodes provided support for qualitative study design, analyses and interpretation of results. 
Colleagues at UNHCR including Paul Spiegel and Marian Schilperoord sat as external members 
of the Advisory Committee and supported protocol and survey design and interpretation of 
results on Papers One, Two and Three. Protocol and questionnaire feedback was also received 
from the Upgrading Committee including Bayard Roberts, Judith Glynn, and Richard White and 
National Ethics Committees. David Ross (thesis advisor), supported every aspect of the project 
from design through implementation and reporting. Other co-authors on the manuscripts were 
key local collaborators and assisted with research tasks related to data collection and 
interpretation of findings on Papers Two, Three and Four. These collaborators included 
Susheela Balasundaram (UNHCR Malaysia), Chunting Wong (UNHCR Malaysia), Christopher 
Lee (Hospital Sungai Buloh, Malaysia), Anuradha Radhakrishnan (Hospital Sungai Buloh, 
Malaysia). Bosco Muhindo (UNHCR Kenya), Irene Mukui (NASCOP). Ibrahim Mohammed 
(NASCOP), John Burton (UNHCR) and Njogu Patterson (UNHCR). Chunting Wong also 
assisted with analyses of qualitative data for Paper Four. 
THESIS STRUcrURE 
The thesis is structured according to manuscripts drafted for submission to specific peer-
reviewed journals. The first section, Genera/Introduction outlines the basic rationale for the 
work. aims, research questions, hypotheses, partners, roles, and funding. It goes on to offer a 
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synopsis of preparatory work conducted before the start of the main study including preparatory 
field missions. survey design. training. pre-testing. and pilot-testing of instruments. Paper One 
presents the results of a systematic review of the literature on adherence to HAART and 
treatment outcomes among conflict-affected and forcibly displaced populations and has been 
provisionally accepted by BMC Conflict and Health pending minor discretionary revisions. 
Paper Two and Paper Three present the quantitative findings from the Malaysian and Kenyan 
settings. respectively. PLoS Medicine agreed to review Paper Two after a pre-submission 
inquiry. At the time of writing, this paper had been reviewed and approved by all but one co-
author. Paper Three is currently designated for submission to The Lancet in anticipation of a 
possible special issue on conflict and health. Paper Four offers an account based on the 
qualitative findings from both settings and has been designated for AIDS Care. Finally. Paper 
Five is a summative manuscript that aims to position the work in the context of previous and 
future research and to make recommendations for programs and policy. Paper Five has been 
written with submission to PLoS Medicine's "Policy Forum" section in mind. At the time of 
writing, Papers Three, Four, and Five were with co-authors for review prior to submission for 
publication. Appendix A contains the final instruments from the Malaysian setting in English 
(including the structured questionnaire, in-depth interview topic guides, medical records and 
pharmacy data collection forms). Appendix B presents the same material used in the Kenyan 
setting. Appendix C contains all ethical approvals, information sheets and consent forms used in 
both settings. 
PREPARATORYlNORK 
Collaborations and fteld site selection 
The project concept originated at a UNHCR Satellite Conference to the International AIDS 
Conference (2006) in Toronto, Canada. I heard presentations at that Satellite Event that helped 
to clarify the key research questions and where they fit into the literature on HIV, conflict and 
displacement. At the main conference, I approached Paul Spiegel of UNHCR who invited a 
proposal. Initially, I proposed four ideas, one of which was a comparative study of adherence 
and treatment outcomes. This idea was a priority for UNHCR and was eventually supported by 
their Regional HIV Coordinators. UNHCR Headquarters ultimately decided to support the 
project financially and logistically. The next step was to design the project. apply for external 
funding, agree on the main research questions, develop a general outline of the methods and 
choose the location of the field sites. Initially, Kenya, Uganda, Rwanda, South Africa, Zambia, 
Ivory Coast and Malaysia were all proposed as possible field options. In order to be considered 
feasible as a field setting for this project, sufficient numbers of identifiable refugees had to be 
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accessing HAART from a single facility and facility managers had to have expressed interest in 
supporting the project and UNHCR Representatives (Heads of Mission) had to commit to 
supporting the effort. Early efforts were made to develop collaborations in Ivory Coast and 
South Africa on the basis of the number of forcibly displaced persons in the sampling frame. 
After initial contacts were developed in Ivory Coast. the project partners decided that 
distinguishing refugees from lOPs would be difficult and most of the persons of concern in 
Ivory Coast were. in fact. IDPs. We had agreed that the focus of the work would be refugees. 
Collaboration was also organised with Nazareth House (johannesburg. South Africa). an urban 
clinic that had been treating a large number of Zimbabwean refugees and migrants. However. 
the political situation in South Africa was tense given the large migration influx from 
Zimbabwe, the status of many of these migrants was contested, and some tensions existed 
between civil society and UNHCR on these issues. Therefore. the project partners decided that 
this location was not politically feasible. Ultimately. Kenya and Malaysia were selected as the 
field settings as they fulfilled all key feasibility criteria. They also offered some geographic 
variation, and the opportunity to study both an urban and a refugee camp setting. Next, in 
consultation with collaborators and the contracts teams of both organisations. I developed a 
Memorandum of Understanding (MOU) to be agreed and signed by LSHTM and UNHCR. This 
MOU used an LSHTM contract template and is available upon request. The process took a full 
six months to negotiate, approve at both institutions, finalise and sign. From there. field 
missions were organised individually, with Terms of Reference issued by UNHCR and PT8s (an 
internal UNHCR contract type) issued and signed for the field missions indicating the dates, 
flights. and amount of DSA to be paid. Research expenditures were also usually claimed back 
from these contracts. Expenditures were either covered initially by the Candidate and 
reimbursed later by UNHCR or paid directly by the UNHCR (e.g. viral load testing). 
Preparatory field work 
The study was conducted in two phases. The first phase included an analysis of relevant reports 
and publications, an in situ preliminary assessment of both field sites (8-20 September 2008. 
Kenya; 8-12 December 2008, Malaysia), and a one-day coordination workshop held in Geneva 
(31 October 2008). These trips were undertaken to facilitate study planning, familiarisation with 
logistical and technical issues in each field setting including recruitment, data protection, 
research governance, budgets, timeline, and development of the research instruments. Informal 
meetings with providers. officials, and clients were undertaken in each setting and formal 
reports were generated for the funder. The second phase of work consisted of the two main sub-
studies conducted in Malaysia 12 January - 4 September 2010 and in Kenya from 29 November 
2011 - 21 March 2011. 
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Survey development 
The survey was developed in advance of the main study, using a variety of sources, previously 
validated instruments and feedback from stakeholders. Table 2 credits the sources from where 
survey questions were drawn or adapted by question category (see Appendices A and B for full 
questionnaires). 
Table 2: Study outcomes and covarlates, and Instrument sources 
Variable 
Primary outcome 
Secondary 
outcomes 
Covariates 
Translation 
Category 
Virological outcomes 
Phannacy refill adherence 
Self-reponed adherence 
Source instrllllltnt (where applicable) 
COBAS Ampliprepffaqman (using full plasma samples in 
Malaysia; dried blood spots on Whatman 903 filter paper in Kenya) 
Nachega et al. (28) 
One-month recall. Visual Analogue Scale: Lu et aI. (29); Oyugi et 
al. (30) 
Four-day dose-by-dose recall - ACTO questionnaire: Chesney et aI. 
(31) 
Sociodemographic and UNHCR (32) 
displacement 
Beliefs about HIV and medications Chesney et aI. (31) 
Clinical factors ACTO questionnaire (31) 
Kiboneka et al. (33) 
Medications and side-effects 
Adherence barriers 
AlcohoV Substance use 
Food insecurity 
Self -efficacy and social suppon 
Social trust 
Patient-provider relationship 
Clinic factors 
Serostatus disclosure and stigma 
Chesney et aI. (31) 
Chesneyet aI. (31) 
Mollica et al. (34) 
Antelman et al. [3S) 
Chesney et aI. (31) 
Kendall et aI. [36) 
Chesneyet aI. (31) 
Kawachi et al. (37) 
Nilsson Schonnesson et aI. [38) 
Ramsey et al. [39) 
Nyblade et al. [40) 
Translation of questionnaires and topic guides followed a five-stage process for each language. 
First, the original English questionnaire was translated into target languages. Second, each 
translated instrument was independently back-translated to English. Third, a meeting was 
convened with both independent translators for each language where the back-translated and 
original English version of each instrument was compared, any points of disagreement were 
discussed, and a reconciled translation was produced. In the fourth stage, the research team were 
solicited for detailed feedback on the cultural and semantic validity of reconciled instruments, 
and translations were updated accordingly. Fifth, questionnaires were pre-tested in each 
language with pre-HAART clients, with adjustments made as appropriate. 
Study power 
Power calculations were initially completed based on the expected numbers of patients on 
HAART and the expected proportions with HIV viral suppression in each setting (Table 3). 
They were re-calculated post-hoc using the actual numbers recruited in each setting. Using viral 
suppression as the outcome, the absolute prevalence difference detectable in each setting was 
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15% in Malaysia, and 21 % in the Kenyan setting. In other words, in Malaysia, if the proportion 
of hosts with viral suppression had been 80%, the study would have had an 80% chance of 
detecting a true proportion of refugees with viral suppression of 65% as statistically significant 
at the 5% level. Sub-group analyses were not conducted using multi variable analyses due to the 
relatively small numbers of study participants and resulting lack of power. 
Table 3: Power calculations for detecting differences in viral suppression between refugee and host 
populations with 95% conftdence, 80% power 
Setting N. (hosts) Nl (rerugees) Proportion vinl Absolute prevaleoce 
suppression In hosts difference 
Malaysia - initial 81 81 0.80 0.21 
Malaysia - final 148 153 0.80 0.15 
Kenya - inilial 59 59 0.80 0.26 
Kenya· final 86 73 0.80 0.21 
Survey pre-testing 
Given the limited numbers of refugees on HAART in each setting, pre-HAART clients were 
chosen for pre-testing to avoid giving eligible participants a "preview" of the questionnaire. The 
aims of pre-testing were threefold: to check that the translations were accurate and easily 
understood by clients in the interview context; to check that interviewers administered all 
questions in a consistent manner; and to give interviewers further practice in administering the 
informed consent procedure and the questionnaire. Pre-tests were conducted in pairs. Clients 
were recruited and interviewed in the same language, independently, by two members of the 
research team. Pairs of questionnaires were then assessed for differences to assess whether 
interviewers had asked questions in a uniform manner such that the same responses were 
elicited from a single client. The second interviewer of the pair administered the questionnaire 
in either full-length form or in an abridged form that focused on questions relating to key factors 
of interest, outcomes, or questions that had proven difficult to understand or were potentially 
"lost in translation." Where clients consistently gave varied answers to the same question asked 
by independent interviewers, the translation was reviewed and Updated if a better formulation 
could be agreed by two members of the research team. As pre-test clients were not on HAART, 
they instead were directed to answer adherence questions while thinking about their 
cotrimoxazole, multivitamins, or other chronic medications. At the end of each pre-testing 
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session, a debriefing was held with the research team to discuss problems that arose in the 
administration or understanding of the questionnaire. Topic guides for in-depth interviews were 
not pre-tested directly with clients. Rather, they were tested by research staff in mock interview 
scenarios. 
In Malaysia, 54 pre-tests (15 in English, six in Mandarin; nine in Malay; 22 in Burmese, and 
two in Falam, a dialect of Chin State, Burma) were conducted with 27 clients. Each interviewer 
completed at least two pre-tests (range 2, 9) and the average number completed by each 
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interviewer was 4.4. The Tamil questionnaire was late in development and pre-tested twice by 
each Tamil speaking interviewer prior to the start of the study. It was also thoroughly tested by 
the Tamil-speaking interviewers during the pilot-testing period. The main outcome of the 
Malaysian pre-test was to highlight and remedy any remaining semantic defects in the 
questionnaire. For example, in the Mandarin version pre-testing, it became clear that different 
vernaculars and levels of Mandarin were spoken by Chinese Malaysians whose mother tongues 
were Hakka or Cantonese. As a result, some of the written questions were updated to reflect 
colloquial pronunciations. In the Burmese version, a question stem that began "How confident 
are you that ... " was altered after feedback suggested that "confidence" was misunderstood in the 
context of humility in Burmese culture. Burmese clients were simply more likely to answer 
"no" to any question that asked them to assess their own confidence. This question was updated 
to read ..... how likely ... " The options associated with a question about UN registration were also 
revised in light of the distinction between registration and refugee status determination, the 
former naturally occurring before the latter. 
In Kenya, 58 pre-tests (13 in Nga'turkana, 23 in Kiswahili, four in English; two in French; eight 
in Somali, three in Amharic, and five in Juba Arabic) were conducted with 28 clients (two were 
unpaired). Each interviewer who panicipated in the main study completed at least two pre-tests 
(range 2, 7). The average number completed by each interviewer was 4.7. The pre-testing 
suggested that some Somalis in the refugee camp only ever attended language/religious school 
and had never attended regular schooling such as "primary school." As it was difficult to 
ascertain the comparability of language and routine schooling, a separate option was added to 
the questionnaire. An option was also added to distinguish prima facie refugees from those had 
completed a refugee status determination interview. Prima facie refugees, such as Somalis, are 
automatically accorded refugee status upon entry into a host country on account of a 
deteriorating political situation in their home countries. 
Development ofstandard operating procedures (SOPs) 
Fo\1owing the pre-testing phase and prior to pilot-testing, all standard operating procedures 
(SOP) were re-assessed in light of what had been learned and finalised. The SOPs emphasised 
the following: 
1. Pre-screening and recruitment in the clinic and scripts for telephone recruitment 
2. Registration of participants 
3. Procedures for guiding clients to routine clinic appointments if these were called in the 
middle of a research interview. and retaining them after routine appointments 
4. Confidentiality, and checking to ensure that interview spaces were confidential 
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5. Judging whether a client was sufficiently fluent in a language for which translated 
instruments were available, usually by having a regular conversation in advance of 
administering the information sheet 
6. Correct and consistent administration of the information sheet and informed consent 
procedure 
7. Administration of the questionnaire, accurate data collection, and effective interview 
probing skills. 
8. Confirming the client's HAART prescription from medical records and comparing this 
information to self-reports in real-time 
9. Guiding the client to the phlebotomy centre in order to draw blood samples. In 
Malaysia, this procedure called for using clinic phlebotomists and routine procedures; in 
Kenya, the procedure involved skin-prick and dried-blood spot techniques 
10. Reviewing questionnaires for quality assurance 
II. Collecting supplementary data from the medical and pharmacy records 
12. Double-entering data and reconciling mistakes 
13. Selecting clients for in-depth interviews 
14. Contact, scheduling, and administering in-depth interviews including all consent 
procedures 
15. Research team codes of conduct 
These standard operating procedures were drafted into a Training Manual and distributed to all 
members of the research team in advance of training. 
Staff recruitment and training 
Staff recruitment, interviewing. and hiring were the first tasks undertaken in each setting during 
the main study phase. Research team candidates were located through open advertisements and 
recommendations by study partners. The Training Manual was used to guide training sessions. 
In Malaysia, the basic research training consisted of 6 days, plus an additional refresher day for 
interviewers chosen to conduct qualitative research. Training consisted of basic principles of 
research. in-depth review and feedback on the survey questionnaires and topic guides and their 
translations. and considerable practice in administering the survey and improving accuracy and 
quality. In Malaysia. potential team members were required to pass an assessed. knowledge-
based examination in advance of signing a contract. In Kenya. training was 7 days long and 
candidates were assessed by observation of their interviewing skills and the quality of practice 
surveys. 
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Survey and protocol pilot-testing 
Once these SOPs were finalised, pilot-testing was initiated. The goal of pilot-testing was to 
ensure the proper functioning of all study procedures. Pilot-testing in Malaysia was completed 
with 10 Malaysians from the host community including 6 conducted in English, one in 
Mandarin; and three in Malay; and 15 refugees including II conducted in Burmese, and four in 
Falam. In Kenya, pilot-testing was completed with 9 Kenyans from the host community 
including 7 surveys conducted in Nga'turkana, one in Kiswahili, and one in English; and 7 
refugees including three surveys conducted in Kiswahili, one in Somali, one in Amharic, and 
two in Juba Arabic. As no major problems were detected during the pilot test in either setting, 
all data from the pilot tests were advanced into the main dataset. Most staff involved in the pre-
testing and pilot testing were also involved in the main survey. In Malaysia two new members 
of staff were hired during the study period, In Kenya, one additional staff member was added. 
Each new member read all SOPs, and practiced administering questionnaires with the Principal 
Investigator and at least two volunteer clients. If this process was completed satisfactorily, they 
were admitted to the rota. 
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We are pleased to submit our manuscript entitled: "Adherence to antiretroviral therapy and 
treatment outcomes in conflict-affected and forcibly displaced populations: a systematic 
review." 
We believe that this work is appropriate for your Reviews section for the following reasons: 
• We report on a systematic review of adherence to antiretroviral therapy and treatment 
outcomes for a key vulnerable group (forcibly displaced persons). Discussion of this 
group is currently under-represented in the health science literature. We are not aware 
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your consideration and hopeful that this piece can find a place in your journal. 
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ABSTRACT 
Background. Optimal adherence to highly active antiretroviral therapy (HAART) is required to 
promote viral suppression and to prevent disease progression and mortality. Forcibly displaced 
and conflict-affected populations may face challenges succeeding on HAART. We performed a 
systematic review of the literature on adherence to HAART and treatment outcomes in these 
groups, including refugees and internally-displaced persons (lDPs), assessed the quality of the 
evidence and suggest a future research program. 
Methods. Medline, Embase, and Global Health databases for 1995-2011 were searched using 
the Ovid platform. A backward citation review of subsequent work that had cited the Ovid 
results was performed using the Web of Science database. ReliefWeb and Medecins Sans 
Frontieres (MSF) websites were searched for additional grey literature. 
Results and conclusion. We screened 297 records and identified 17 reports covering 15 
quantitative and two qualitative studies from 13 countries. Three-quarters (11115) of the 
quantitative studies were retrospective studies based on chart review; five studies included <100 
clients. Adherence or treatment outcomes were reported in resettled refugees, conflict-affected 
persons, internally-displaced persons (IDPs), and combinations of refugees, IDPs and other 
foreign-born persons. The reviewed reports showed promise for conflict-affected and forcibly-
displaced populations; the range of optimal adherence prevalence reported was 87-99.5%. 
Treatment outcomes, measured using virological, immunological and mortality estimates, were 
good in relation to non-affected groups. Given the diversity of settings where forcibly-displaced 
and conflict-affected persons access ART, further studies on adherence and treatment outcomes 
are needed to support scale-up and provide evidence-based justifications for inclusion of these 
vulnerable groups in national treatment plans. Future studies and program evaluations should 
focus on systematic monitoring of adherence and treatment interruptions by using facility-based 
phannacy records, understanding threats to optimal adherence and timely linkage to care 
throughout the displacement cycle, and testing interventions designed to support adherence and 
treatment outcomes in these settings. 
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INTRODUCTION 
It is widely accepted that for HIV -positive persons on highly active antiretroviral therapy 
(HAART), high levels of adherence to treatment regimens are essential for promoting viral 
suppression and preventing drug resistance. However, conflict-affected and forcibly displaced 
populations such as refugees and internally-displaced persons (IDPs) may face unique 
challenges in sustaining good adherence to HAART and treatment outcomes [1-2] while the 
potential for onward displacement presents a risk of pharmacy defaulting and treatment 
interruptions. An expectation of difficulty has clouded efforts to provide HAART in these 
settings [3]. Forcibly displaced populations consist mainly of refugees and IDPs, however, 
definitions are often confused. According to the Convention relating to the Status of Refugees, a 
refugee is a person who: 
... owing to well-founded fear of being persecuted for reasons of race, religion, 
nationality, membership of a particular social group or political opinion, is outside 
the country of his nationality and is unable, or owing to such fear, is unwilling to 
avail himself of the protection of that country; or who, not having a nationality and 
being outside the country of his former habitual residence as a result of such 
events, is unable or, owing to such fear, is unwilling to return to it [4]. 
The Inter-agency Standing Committee defines IDPs as: 
... persons or groups of persons who have been forced or obliged to flee or to leave 
their homes or places of habitual residence, in particular as a result of or in order to 
avoid the effects of armed conflict, situations of generalized violence, violations of 
human rights or natural or human-made disasters, and who have not crossed an 
internationally recognized State border [5]. 
"Conflict-affected persons" are defined as persons residing in active or recent conflict zones or 
in a post-conflict setting [6-8]. Around the world, some 1.5 billion people live in countries 
affected by violent conflict, 14.7 million people are internally displaced and 10.6 million are 
refugees. Of refugees, 68% had been living in exile for ~5 years in "protracted situations" [9-
10]. The primary aim of this review was to aggregate the available evidence on adherence to 
HAART and treatment outcomes in refugees, IDPs and conflict-affected persons, to assess the 
quality of work undertaken so far and to suggest future research needs. 
METHODS 
A systematic review of the published literature was conducted between 20 December 2011 and 
20 January 2012 using a four step procedure. First, a search ofthe Cochrane Database of 
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Systematic Reviews yielded no previous reviews. Second, we applied our search strategy to the 
Medline, Embase, and Global Health databases (including conference abstracts) using the Ovid 
platform. The search strategy incorporated five themes: "HIV", "antiretroviral therapy", 
"adherence", "outcomes", and "forced migration." Key words were combined with medical 
subject headings (MeSH) to assess synonyms applicable to each theme. The terms "refugee", 
"internally-displaced", "conflict-affected", and "forced migration" were used to search the 
forced migration theme. Table I presents a complete list of key words and MeSH terms used. 
As adherence results are often reported in papers where the primary aim is to report on clinical 
or treatment outcomes, "disease" and "treatment" themes were combined using the "OR" 
operator to create a broad pool which could be cross-referenced using the "AND" operator with 
the "forced migration" theme (see Supp.Table i). Searches were limited to studies in English 
I 
reported from 1995 onwards. Third, a backwards citation search was performed using the Web 
of Science "times cited" feature that identified all work cited by any previously identified report 
in the health science databases. Lastly, a check for sources that may have been posted online but 
omitted from health science databases was made by searching ReliefWeb and Medecins Sans 
Frontieres (MSF) websites and three experts were consulted for additional sources. On the 
ReliefWeb and MSF-UK websites, we used the expressions "antiretroviral and refugee" and 
"antiretroviral and IDP." On ReliefWeb, we searched under the "Analysis", "Assessment", 
"Evaluation", "Situation Report", "UN document" and "Other" content categories. Abstracts of 
papers retrieved from all the above steps that were not editorials, commentaries, case reports or 
had irrelevant titles were subjected to a full-text review. Both qualitative and quantitative 
studies of adult populations were included in the final dataset if they presented relevant primary 
data, secondary analyses on adherence to HAART or treatment outcomes, and included adult 
conflict-affected or forcibly displaced populations. We extracted and presented basic study 
information and data related to adherence and treatment outcomes. PRISMA guidelines were 
followed in the reporting of this review [11]. 
RESULTS 
Figure I presents the outcome of the search: out of 297 reports retrieved using the search 
strategy, 17 reports con~ucted in 13 countries with 8,930 clients were retained for this review. 
Table 1 summarises the data extracted from selected reports. Three studies reported results for 
IDPs only. Kiboneka and colleagues [12] conducted a prospective cohort study to measure 
clinical and immunological outcomes of HAART clients in Gulu District, northern Uganda, the 
I 
site of civil strife and conflict between the Ugandan government and the Lord's Resistance 
Army guerrilla group. Adherence was measured by combining pharmacy monitoring, pharmacy 
refill records and patient self-reports, and dichotomised at the ~95% level. Over a median 
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follow-up time of 13.7 months for clients with complete adherence data (n= 1.521). 92.2% had 
~95% adherence. Among patients with <95% adherence. 9.3% died compared with 1.2% of 
patients with ~95% adherence. In an adjusted analysis. mortality was less likely among women 
(Hazard ratio. HR=0.7. 95% confidence interval. 95%CI 0.55. 0.91; p=O.02) and clients with 
>200 CD4 at treatment start (HR=0.14. 95%CI 0.06. 0.34; p<O.oo I). A second cross-sectional 
study of lOPs in Gulu District reported a high (99.5%) mean self-reported four-day adherence to 
HAART [\3]. In this study. clients who were on first-line therapy (Odds ratio. OR=22.22. 
95%CI 1.53. 333.33; p=0.02) or who reported that clinic staff were "condemning" (OR=22.22. 
95%CI 1.53. 333.33; p=O.02) were more likely to report non-adherence. A study of mortality 
among Kenyan lOPs in the post-election violence period of 2007-2008 found increased 
mortality in HIV -positive lOPs when compared with mortality during the same period among 
HIV-positive residents captured in the same Demographic Surveillance Survey catchment area 
prior to the violence [14]. 
We identified six studies that reported on conflict-affected. mixed refugee and lOP populations. 
or unspecified foreigners. including both refugees and asylum-seekers. O'Brien and colleagues 
[2]. reporting on a pooled analysis of 12 MSF conflict and post-conflict HAART programs 
(n=2.572). found a median probability of survival at 12 months of 0.89 (95%CI 0.88. 0.91). 
Two further MSF studies of individual programs found good survival outcomes. In a post-
conflict program in the Republic of Congo [15]. the survival probability at 12 months was 0.89 
(95%CI 0.82. 0.93). In a study from Bukavu. Democratic Republic of the Congo (DRC) during 
an active conflict involving the central government. insurgents and proxy armies from 
neighbouring states [16]. optimal HAART adherence (defined as missing less than 5% of pills 
between clinic visits) measured by pill counts was attained by 99% of participants. although the 
limitations of this method in this setting were not specified. The conflict setting had higher 12-
month mortality (7.9%. 95%CI 3.6, 12.1) than comparison settings, but the six-month median 
CD4 cell gain of 163 cells/mm3 compared favourably with cohorts from a resource-limited 
setting (106 cells/mm3) and a resource-rich setting (103 cells/mm\ In the Equatorial province 
of Sudan, Salami and colleagues [17] found that 88% of refugees and lOPs on HAART for ~6 
months self-reported ~95% adherence. A South African study comparing self-identified 
foreigners with local citizens reported that foreigners were less than half as likely (OR=O.45, 
95%CI 0.23, 0.87; p= 0.017) to have suffered viral failure. defined as ART cessation, any 
decrease in CD4 from pre-ART levels, a viral load of >1000 copieslmL, or death [18]. In a 
Kenyan study that used a pre-post design to investigate treatment interruptions (TI) (defined as 
the proportion visiting pharmacy ~48 hours after ARTs completed), 16.1 % experienced a TI 
during post-election violence compared with 10.2% in the comparison period [19J. For clients 
who overlapped between the two periods, the odds of TI were elevated by 71 % during post-
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election violence (95%CI 34.118. p<O.OOI]. Men (OR=1.37. 95%CI 1.07. 1.76;p=O.0l) and 
clients travelling more than three hours to the clinic (OR=1.86. 95%CI 1.28.2.71; p=O.OOI) also 
were more likely to experience a TI. 
Four studies were conducted among HIV -positive refugees in high income settings. An HIV-
positive refugee cohort in Rhode Island, USA, had lower odds of initiating HAART when 
compared with non-refugees (OR=O.37, 95%CI 0.13.0.92; p=O.03) and had a lower attendance 
at scheduled appointments relative to non-refugees (75% v. 86%, p=O.17) [20]. In a New 
Zealand-based refugee cohort on HAART. 61 % had an undetectable HIV viral load after one 
year of treatment [21]; a US study reported undetectable viral load in 87% of refugees receiving 
HAART [22]. In a Canadian study, 80% of a cohort consisting of native-born clients, refugees 
and other immigrants from Sub-Saharan African and elsewhere were virologically suppressed 
[23]. In this study, the rate of progression to new opportunistic infections or AIDS-defining 
events was higher among the former group (0.1 v. 0.06 events/lOoo patient-days) while the 
mortality rate restricted to HIV-related deaths was higher among the latter group (0.8 v. 1.2 
deaths/lOOO patient-months). 
Two studies dealt exclusively with pregnant mothers taking ART for prevention of mother-to-
child transmission (PMTCT). The first study, conducted among a resettled group of refugees on 
HAART during pregnancy in Rhode Island, USA, reported a reduction in median viral load at 
the time of delivery [24]. A study conducted in a Tanzanian refugee camp reported a 98% 
(185/189) uptake of nevirapine at the time of delivery, but women who initially refused the 
medication or who were repatriated to their native countries prior to delivery were not included 
[25]. 
Two additional qualitative studies were also eligible for review. One study conducted in Teso, 
northern Uganda [26], identified security while attending clinics, food security, distance to 
health centres and access to health providers as the main concerns of clients and health workers 
in relation to HAART adherence. Respondents noted that food insecurity and single daily meals 
made multiple daily dosing a challenge during famines and floods. A second study from 
northern Uganda [27] reported on the impact of social networks on long-term provision of 
antiretrovirals. This study reported that community-based volunteers and health workers were 
effective in supporting adherence and the formation of social support groups, while social 
networks assisted in overcoming challenges that were independently related to displacement and 
stigma. Notably, but perhaps unsurprisingly, the study identified inadequate planning in the 
return phase of the forced displacement cycle as presenting significant challenges in patient 
monitoring, missed appointments, and loss to follow-up. Finally, in a qualitative sub-study 
(counted as a quantitative study for the purposes of Figure 1), Pyne-Mercier and colleagues [19] 
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reported that 61 13 interviewed clients had been attacked by mobs or had their homes or 
businesses vandalised during post-election violence in Kenya. Lack of transport and inflated 
transport costs were identified as barriers to accessing treatment. while personal commitment 
and support from family and clinic social workers facilitated access to treatment. 
[*** Figure I. p.42. and Table I. p.43-46. near here ***] 
DISCUSSION AND CONCLUSIONS 
This review revealed a limited number of studies on adherence to HAART and treatment 
outcomes. however the outcomes observed in the reviewed studies showed promise for conflict-
affected and forcibly displaced populations. The range of optimal adherence prevalence of 87-
99.5% compared favourably with other settings. A meta-analysis of 84 observational studies 
reported a 62% average reporting rate of ~90% adherence [28]. A second meta-analysis 
comparing resource-limited and resource-rich settings [29] reported that 55% of North 
American populations and 77% of sub-Saharan African populations achieved adequate 
adherence. In this study, factors negatively affecting adherence in sub-Saharan Africa included 
non-disclosure of HIV status to a loved one for fear of stigma, alcohol abuse, and difficulty 
following complex drug regimens. In a separate review of barriers to adherence. pooled results 
from ten quantitative studies in developing countries identified financial constraints (52%, 
95%CI 16, 88) and forgetfulness (36%, 95%CI 19, 55) as major barriers [30J. A review of 
African studies [31] reported that 68-99% of patients were ~95% adherent but found no studies 
documenting the use of formal adherence intervention programs. The present review identified 
one study [13J that compared conflict-affected or forcibly displaced groups to a local host 
community or that assessed potential barriers to, and facilitators of adherence and/or treatment 
outcomes. Garang and colleagues found no significant differences in adherence between IDPs 
and non-IDPs (99.6% v. 99.5%) and reported that being on first-line treatment and clients' 
perceived condemnation by medical staff reduced the odds of optimal adherence. Barriers to 
adherence in this study included depression after losing a child, forgetfulness, travelling. and not 
refilling medications on schedule. 
We located one study that specifically studied treatment interruptions [19]. Understanding the 
prevalence and consequences of treatment interruptions is highly relevant for conflict-affected 
and forcibly displaced groups given their previous displacement history and the potential for 
onwards travel including resettlement or repatriation after initiation of therapy. Studies in other 
population groups that investigated interruptions as therapeutic alternatives to continuous 
therapy such as intentional treatment holidays and unintentional interruptions have found 
harmful results. Initial concerns about long-term safety and reports of a lack of improved 
3S 
virological response in trials of structured interruptions [32-33] were confirmed by the 
Strategies for Management of Antiretroviral Therapy (SMART) study, which found that C04-
guided episodic therapy increases the risk of opportunistic disease or death in relation to 
continuous treatment [34]. A review of unstructured TIs found an increased risk of opportunistic 
infections, virological failure, drug resistance, poor immunological recovery and death [35]. 
Future studies on forcibly displaced and conflict-affected groups should facilitate the 
monitoring of TIs by combining data from facility-based pharmacy records and mobile phone 
follow-up contact with clients that confirm TIs when clients fail to report for routine pharmacy 
refill appointments. 
The studies included in this review were conducted in a variety of contexts including camps, 
rural, and urban areas in low-income settings and urban areas in high-income settings. Although 
the studies did not describe the specific features of the clinics where HAART was delivered, 
these were likely variable in relation to the type of institutional provider, which ranged from 
publicly-run hospitals to non-governmental organisations, and their respective resource levels. 
Given the importance of context for outcomes, the variation in settings may have affected the 
reported findings and merit further study. The majority (14/15) of the reviewed quantitative 
studies were facility-based. When clients present at new treatment facilities, HIV testing and 
counselling is routinely administered where indicated and HAART is initiated according to 
national guidelines, regardless of treatment history. With the exception of the MSF study 
settings where no previous HIV testing had taken place, there was no way to verifty whether 
treatment start at the study facility was equivalent to treatment initiation, or if treatment had 
been started elsewhere prior to onwards displacement and arrival at the study facility. 
Establishing the date and location of HAART initiation is challenging in any setting where 
medical records are not routinely shared and client recall of their complete treatment history 
may be compromised. Where possible, investigations that attempt to address these shortcomings 
will be useful for estimating the effect of forced displacement on adherence and treatment 
outcomes and for correctly interpreting findings. Moreover, the categorisation of displaced 
persons presents additional challenges; definitions may affect the network of providers, the 
availability of particular services, and the extent of co-payments (if any). For example, in non-
refugee camp settings a lack of documentation or xenophobic attitudes may present obstacles to 
accessing key services including HIV counselling, testing, and ART. To facilitate 
generalisability to similar settings and population groups, future studies should be mindful of 
these categorizations and their impact on outcomes. 
There were some limitations to this review. Although we searched health databases and grey 
literature, it is possible that relevant studies were omitted; moreover, we limited our search to 
reports published in English. To minimise this risk of exclusion, we used a backwards citation 
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search and expert consultation. Most identified studies used a single adherence indicator, which 
suggested a possibility of measurement bias. Self-report and pharmacy refills are the most 
commonly used instruments in resource-limited settings; however there is no widely accepted 
standard for measuring adherence [36-37]. Triangulation is one way to enhance confidence in 
measurement validity, especially in challenging multi-linguistic or complex emergency settings. 
Guidelines developed by an International Association of Physicians in AIDS Care Panel 
recommended routine use of both self-reports and pharmacy refill measures [38]. Where 
possible, multiple adherence measurements should be used, especially when more objective 
measures such as medication event monitoring systems (MEMS) are not feasible and 
biomarkers are not available from medical records or are too difficult or expensive to collect. 
The geographic breadth of quantitative studies was limited: 53% (8115) of the studies were 
conducted with asylum-based refugees and IDPs in African settings. Notably, only one study 
dealt with documented refugees in low-income settings [17]. The limited number of studies, 
small sample sizes (five included <100 clients), lack of comparison groups and varied outcomes 
and indicators suggest that estimates may have suffered from selection and response biases. We 
did not undertake a meta-analysis due to substantial differences between client groups, methods 
and outcomes across studies. Despite these difficulties, the reviewed studies were designed 
around local circumstances: samples were either limited by the absolute number of clients with 
available records to review, the study was facility-based and only had access to a limited pool of 
clients, or an evaluation of adherence and treatment outcomes was not the primary aim. 
Response bias was likely to have been less of a concern in the study by Kiboneka and 
colleagues [12], where a comprehensive adherence assessment of all HIV -positive clients 
attending one hospital was undertaken. However, the risk that the small number of studies 
available for review were conducted in settings more suitable for research, for example where 
data existed in a form particularly conducive to chart reviews, may have biased the findings 
towards better outcomes. 
If HAART is to be scaled-up in conflict-affected and forcibly displaced clients, studies designed 
to assess adherence and treatment outcomes will be critical for optimising treatment outcomes 
and preventing drug resistance, the latter associated with widespread distribution of 
medications, the use of less tolerated regimens, restricted virological monitoring, and the 
potential for inconsistent drug supply [39]. The World Health Organisation's public health 
strategy to mitigating drug resistance recommends providing highly effective first-line 
regimens, prescribing previously unused drug classes when switching after first-line treatment 
failure, reserving the drugs that are least likely to provoke resistance for patients whose first-line 
treatments are no longer effective, and administering regimens that encourage adherence [40). 
For forcibly-displaced and conflict-affected clients, these principles raise important questions. 
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What is the most effective first-line regimen for these settings [41]? When clients are displaced 
and have a poor knowledge of their treatment history, which HAART regimen should be used? 
Are HIV -positive individuals who were started on HAART prior to displacement identified 
quickly in the host setting, linked to care in a timely manner, and succeeding on treatment? Are 
best practices correctly implemented prior to voluntary repatriation or resettlement to a third 
country? Which factors, regimen-related or otherwise, encourage good adherence? Recent 
intervention studies in resource-limited settings have shown that counselling services and 
mobile phone-based reminders helped to maintain adherence and viral suppression [42-43]. 
Although trials have not been conducted among conflict-affected and forcibly-displaced 
populations, a useful basis for intervention consisted of 7-step support package delivered by 
MSF in Musina, South Africa. tailored to the needs of migrants. refugees. and asylum-seekers. 
This report. published after our review period, found that 92% (95%CI 75.2. 97) of clients were 
virologically suppressed «400 copieslmL) at 12 months after receiving this intervention, which 
included a patient-held record ("health passport"). an alternative treatment site road map. 
anticipation of travel at regular clinic visits. a safe travel pack (including buffer stock of ARVs. 
a washout regimen. and a transfer letter). migrant-adapted treatment counselling. a questionnaire 
for returning patients and migrant-adapted monitoring of retention in care [44]. 
The limited evidence from the small series of studies available for this review suggests that 
HAART adherence and treatment outcomes among conflict-affected and forcibly displaced 
adults may be as good as outcomes attained in unaffected population groups. Future research 
should consider stronger study designs that address TIs throughout the displacement cycle, more 
geographic variation, the use of a systematic. replicable. and triangulated approach to adherence 
measurement and monitoring and the design and testing of interventions to improve adherence 
and treatment outcomes. Given that refugees in asylum countries tend to remain for an average 
of 17 years [45]. there is a strong national interest and humanitarian rationale for ensuring 
universal access to HIV treatment and care, promoting optimal outcomes among all vulnerable 
groups and developing a consensus approach to achieving these goals [46]. For effective 
HAART scale-up in conflict-affected and forcibly displaced clients. assessing adherence and 
treatment outcomes will be critical for promoting viral suppression, preventing drug resistance 
and reducing transmission. 
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disolaced. or on ART 16) 
Full-text reports assessed 
for eligibility (N=26) 
1 1 
Studies included in Studies included in 
qualitative review (N=2) quantitative review (N=15) 
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SUPPLEMENTARY MATERIALS 
Submiued as an Additional file. 
Supp. Table I: Systematic review search strategy used In MEDLlNE* 
Step Scan:h theme 
Forced migration 
1 HlVdlseue 
J Adherence 
4 Andretrovlral therapy 
5 Trutment outcomes 
6 Adherence AND Trutment 
oUkomes 
7 Adhereace AND HIV dI_ 
Key word(s) Ind MeSH term(s) 
[refugee·) or [forced migra·) or [internally·displaced) or [conflict-affected) or [exp 
Refugees/] 
[HIV) or [AIDS) or [exp HIVI) or [exp HIV-2/] or [exp HIV-II) 
[adherence) or [compliance) or [exp Medication Adherence!) or [exp Patient 
Compliance/] or [treatment interruption") 
[anliretroviraltherapy) or [HAARn or [ARn or[ cART) or [exp Anti-HIV 
Agents/] or [exp Anliretroviral Therapy. Highly Active/] 
[treatment outcome·) or [exp Treatment Outcome/] or [exp RNA. Virall) or [exp 
Viral Load/] or [cd4) or [ellp Antigens. CD41) or [viral load) 
[adherence) or [compliance) or [exp Medication Adherencel) or [exp Patient 
Compliance!] or [treatment interruption") AND [antiretroviral therapy) or 
[HAART) or [ARn or[ cARn or [exp Anti-HIV Agents!) or [exp Antiretroviral 
Therapy. Highly Active!] 
[adherence) or [compliance) or [exp Medication Adherencel) or [exp Patient 
Compliance!] or [treatment interruption·) AND [HIV) or [AIDS) or [exp HIVI) or 
[exp HIV-2/] or [exp HIV-II) 
• Andretrovlral therapy AND [antiretroviral therapy or HAART or ART or cART) OR [exp Anli-HIV Agents! 
Tratment outcomes OR exp Antiretroviral Therapy. Highly Active!] AND [treatment outcome·) or 
[exp Treatment Outcome/] or [exp RNA. Virall) or [exp Viral Load/] or [cd4) or 
[exp Antigens. CD41) or [viral load] 
9 HIV dlleue AND TrutmeDt [HIV] or [AIDS] or [exp HIVI) or [exp HIV-2/] or [exp HIV-II) AND [treatment 
outcomes outcome·) or [exp Treatment Outcome/] or [exp RNA. Virall) or [exp Viral Load/] 
or [cd4] or [exp Antigens. CD4f) or [viral load] 
10 Forced migratioD AND all [Forced migration) AND [(Adherence AND Treatment outcomes) or (Adherence 
themes AND HIV disease) or (Antiretroviraltherapy AND Treatment outcomes) or (HIV 
disease AND Treatment outcomes)] 
II UlDita Umited to English studies from 1995 onwards 
"or" preceded "AND" in order of operationl 
expooexplode a MeSH term 
.. '''-included all MeSH subheadings 
·similar strategies were used in Olobal Health and Embase databases. with the exception of differences in MeSH terms 
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PLoS Medicine (UK/European Office) 
Public Library of Science 
Carlyle House. Carlyle Road 
Cambridge. CB4 30N. UK 
Dear Editor: 
Joshua B. Mendelsohn 
Department of Infectious Disease Epidemiology 
london School of Hygiene and Tropical Medicine 
Keppel Street. london. WC1E 7HT. UK 
TEl: +44(0)7725987777 
EMAil: joshua.mendelsohn@lshtm.ac.uK 
1 September 2012 
We are pleased to submit our manuscript entitled: "Good adherence and treatment outcomes in 
refugee and host communities on highly active antiretroviral therapy in urban Kuala Lumpur. 
Malaysia." We believe that this work is suitable for PLoS Medicine and will be of interest to its 
audience for the following reasons: 
• Your general readership will find the subject matter of interest given current debates 
around the feasibility of HIV treatment as prevention in various community settings. the 
importance of adherence to treatment outcomes in a wide range of chronic conditions. 
and the general interest in refugee health in spite of the lack of coverage in non-
specialist journals. 
• Both researchers and practitioners in the field of conflict epidemiology. refugee health. 
and HIV treatment and care will find this paper of particular interest as it is the first 
study that we are aware of that has investigated adherence and viral outcomes in the 
large and increasing number of asylum-based refugees residing in an urban setting. 
• Many urban clinics around the world treat refugees. The few previous studies on the 
subject have been undertaken with internally-displaced persons or resettled refugees. 
Therefore. the contribution is novel and PLoS Medicine's open access format and 
visibility will make it widely accessible to a range of end-users in the primary care and 
humanitarian communities. 
• We report excellent clinical outcomes in the Burmese refugees accessing HAART from 
this urban clinic setting. and these were comparable to the outcomes found in the local 
host community. This evidence supports a policy of equal provision of treatment for 
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refugees and local host communities. This finding will be of interest to policymakers 
and researchers in migration-related fields. 
We thank you for your consideration of our manuscript. 
Sincerely. 
Joshua Mendelsohn (on behalf of the co-authors) 
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ABSTRACT 
Background. In response to a dearth of data among refugees and host communities accessing 
HAART in urban settings, our objective was to compare adherence and virological outcomes 
among clients attending a public clinic in Kuala Lumpur, Malaysia. 
M~thods and findings. A cross-sectional survey was conducted among adult clients ~ 18y). 
Data sources included a structured questionnaire measuring self-reported adherence, a 
pharmacy-based measure of HAART prescription refills over 24 months (Rx), and HIV viral 
loads. The primary outcome was unsuppressed viral load (cut-off <40 copieS/mL). We recruited 
90% of all eligible refugees (n=153) and 81 % (n=148) of host clients. Refugees were younger 
(median age 35y (IQR 31, 39) v.40y (IQR 35.48); p<O.OOl). more likely to be female (36% 
v.21%;p=()'()04). and to have been on HAART for less time (61 weeks (IQR 35,108) v. 153 
weeks (lQR 63.298); p<O.OO I). Similar proportions of those on treatment for ~25 weeks from 
both groups had achieved viral suppression (81 % v.84%; p=O.54). Optimal adherence to Rx was 
74% v.66%; p=O.15. Refugee status was not independently associated with the outcome 
(ORadj= 1.28. 95%CI 0.52. 3.14; p=O.60). Female sex (ORadj=O.39. 95%CI 0.14. 1.05; p=O.05). 
optimal adherence to Rx (ORadj=O.47. 95%CI 0.27, 0.81; p=O.OO7), and longer time from 
diagnosis to HAART start were protective (ORadj=O.64. 95%CI 0.41, 0.99; p=O.04). Temporary 
migration for one consecutive month in the past year (ORadj=4.12, 95%CI 1.70,9.99; p=O.OO2) 
and clinic transit times ~Ihr (ORadj=3.05, 95%Cll.09, 8.49; p=O.02) increased the odds of 
unsuppressed viral load. 
Conclusions. The proportions of refugee and host community clients with optimal adherence to 
HAART and viral suppression were similar and at reasonably good levels. The results support 
the hypothesis that refugees in protracted asylum situations are able to sustain adherence to 
HAART and good treatment outcomes, and should explicitly be included in the HIV strategic 
plans of host countries with a view to expanding access for all in accordance with national 
guidelines for HAART. 
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INTRODUCTION 
For HIV -positive persons, optimal adherence ~95% of tablets taken as prescribed) to highly 
active antiretroviral therapy (HAART) is essential for achieving and sustaining viral 
suppression. Estimates suggest that 6.6 million people in low- and middle income-countries, or 
47% of 14.2 million eligible, are now receiving treatment [1]. Refugees have a recognised 
international legal status that should enable them to receive access to public relief on an 
equivalent basis to host nationals in countries of asylum, where 10.6 million refugees were 
situated as of 2010 [2,3]. However, there are concerns as to whether refugees who are on 
HAART in asylum are sufficiently stable and therefore capable of sustaining optimal adherence 
and good treatment outcomes in the face of potential obstacles such as language barriers, lack of 
employment, fractured support networks, and onwards displacement [4,5]. In some instances, 
States may be reluctant to provide treatment to refugees, citing the prerogatives of supplying 
their own citizens and concerns about stability among refugees. Previous studies of adherence 
and treatment outcomes in other conflict-affected groups have reported high levels of adherence 
and acceptable outcomes, suggesting that such obstacles may be overcome [6,7,8]. Yet there are 
few data available to verify the acceptability of treatment outcomes in relation to local host 
communities in asylum settings. In addition, most previous work on forced migration and HIV 
treatment outcomes has been conducted in sub-Saharan Africa, or with refugees based in high-
income countries [9]. In response, our objective was to study adherence and treatment outcomes 
in a refugee and local host community accessing HAART from the same clinic in Kuala 
Lumpur, Malaysia. 
METHOD 
Study settlnl 
Sungai Buloh Hospital, Kuala Lumpur, Malaysia was chosen as the study setting as it met our 
criteria of an urban, Southeast Asian setting, with sufficient numbers of refugees accessing HIV 
treatment and care services from a single point of care. At the start of the study (April 2010), 
over 91,985 individuals were registered by UNHCR as refugees and asylum seekers in 
Malaysia, most having fled the protracted conflict between the Burmese junta and rebel groups 
from the ethnic periphery. At the end of 2009, the average length of a stay for an HIV-positive 
refugee in Malaysia was 3.7 years. Of this group, 32% were resettled to high-income countries 
after an average of 2.9 years (UNHCR Malaysia, Pers. Comm.). The Malaysian government has 
not signed the 1951 Refugee Convention and its 1967 Protocol; however, the Ministry of Health 
issued a circular in 2006 that permitted refugees to access public health services, including 
antiretroviral therapy (ART) as part of the national HIV treatment and program. The National 
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HIV/AIDS Strategic Plan 2006-2010. referred to refugees as a "vulnerable group" but no 
specific strategies were formulated [to). Refugees were formally included in the 2011-2015 
Strategic Plan [11]. The Malaysian host community is composed primarily of Malay. Chinese. 
and Tamil ethnic groups. For Malaysians, the national treatment program fully subsidises first-
line treatment and a range of services including virological monitoring; second-line treatment is 
partially subsidised. For refugees, the national program fully subsidises first-line fixed-dose 
treatments. however, more expensive first and second-line drugs (e.g. efavirenz; 
lopinavir/ritonavir) and virological monitoring are supported by UNHCR so that refugees may 
receive all treatment for free. In relation to treatment decisions. UNHCR defers to national 
guidelines and their implementation by local clinicians. At the start of the study, there were 315 
HIV -positive refugees known to UNHCR, 171 on HAART. over 98% of whom were from 
Burma. Only refugees, meaning those who possessed documented approval of their refugee 
status. received subsidised treatment and support. HIV -positive asylum seekers in need of 
HAART are expedited through the Refugee Status Determination process in order to facilitate 
timely access to treatment. The usual pathway to treatment for refugees was diagnosis at a free 
clinic run by a non-governmental organisation (NGO) and subsequent referral to the reference 
hospital; the host community was either referred to the reference hospital from elsewhere. or 
diagnosed and treated on site. Sungai Buloh Hospital is the national reference hospital for HIV 
and was the first hospital to offer ARTs in Malaysia. HIV -positive refugees and host nationals 
received routine counselling from hospital nurses and more frequent individual and group-based 
support from NGO adherence support counsellors. Counsellors serving refugees were recruited 
from among their communities and assisted with routine counselling on disease and treatment, 
and refugee-specific challenges such as overcoming language barriers, arranging transport to the 
clinic, and preparing for eventualities such as arrest or detention. Malaysian counsellors fulfilled 
similar functions for the host community. For the most vulnerable refugees, financial assistance 
was provided for travel to the clinic and pharmacy. Immunological and virological tests were 
routinely administered to all clients upon enrolment. Up until and during the study period, if 
CD4 was <250 cells/JAL, clients were counselled. prescribed multivitamins and cotrimoxazole, 
and started on first-line HAART. 
Study design 
We conducted a IS-week (March-July 2010) cross-sectional survey at Sungai Buloh Hospital 
that aimed to recruit an refugees identified by UNHCR as recipients of HAART and a similar 
number of serially-recruited host community clients attending the same outpatient clinic. Clients 
~18 years and on regular HAART for at least 30 days were systematically recruited at the time 
of their regular clinic appointment. Refugees who did not attend during the study period or who 
could not be seen by the research team on an appointment day were contacted through an active 
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recruitment protocol implemented by research staff. Efforts were made to contact all known. 
eligible refugee clients on HAART who met the inclusion criteria. Host community clients were 
recruited serially at the time of clinic appointment and were not actively sought if they failed to 
attend. To assess representativeness of the recruited host community sample. a sampling frame 
was constructed and basic demographic data were collected on a randomly selected comparison 
sample of 150 clients. We focused our recruitment efforts on refugees during the designated 
refugee clinic day (once per week) and matched this with one designated host community 
recruitment day per week. 
Data sources 
Data sources included a structured questionnaire with self-reported adherence measures. a 
pharmacy-based measure of HAART prescription (Rx) refills. and HIV viral loads. The primary 
outcome was unsuppressed viral load (cut-off <40 copies/mL). The questionnaire was translated 
into Bahasa Malaysia. Tamil. Mandarin. Burmese. and Falam (Chin dialect), and then 
backwards translated into English. The original and backwards-translated English versions were 
reconciled prior to pre-testing and pilot-testing. Key self-reported adherence measures included 
a retrospective four-day dose-by-dose recall [12] and a retrospective one-month general recall 
measured on a visual analogue scale (VAS) [13]. Adherence to pharmacy refill schedule was 
assessed using a pharmacy-based measure of HAART prescription refills and calculated as the 
proportion of prescribed refills collected divided by the total required refills up to 24 months 
prior to the interview date. A successful refill was determined by dividing the number of tablets 
claimed into the number of tablets required to avoid a personal stock-out, allowing a 14-day 
grace period for each collection. The pharmacy data were extracted from a confidential 
electronic pharmacy database by the hospital pharmacists. For all adherence measures, ~95% of 
doses taken as prescribed was used to signify "optimal adherence". HIV viral loads were 
collected using routine hospital phlebotomy procedures and analysed at a private laboratory 
using the COBAS Amplipreprraqman platform (Roche Diagnostics Systems, Branchburg, New 
Jersey. USA). 
Statistical methods 
Socio-demographic characteristics were compared between host and refugee groups using 
Mann-Whitney tests for continuous variables, Chi-square or Fisher's exact test for categorical 
variables, and Chi-square test for trend for ordered categorical variables. Risk factors for 
unsuppressed viral load were evaluated using unconditional logistic regression; effect estimates 
were odds ratios (OR) and corresponding 95% confidence intervals (CI). The order of entry of 
factors into the model was determined using a three-level, forwards. step-wise modelling 
approach. Drawing on social action theory [14], factors were grouped into levels representing 
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treatment contexts such as socio-demographic. displacement-related. and treatment factors; self-
change processes such as knowledge scores. self-efficacy. and reported serostatus disclosure; 
and action state factors incorporating adherence measures (Figure 1). First. associations between 
unsuppressed viral load and factors from all levels were evaluated in univariable analyses using 
log-likelihood ratio tests. A "treatment context model" was then fitted by adjusting for treatment 
context factors with p<O.1 in univariable analyses. A "self-change processes model" was fitted 
by adjusting each new factor by all retained treatment context factors. then adjusting again for 
any additional factors with p<O.l. A model evaluating the effect of "action state (adherence) 
factors" was fitted in a similar fashion. As these adherence measures were collinear. the "action 
state" model restricted adjustment to factors from previous levels only. The final multi variable 
logistic regression model was obtained by excluding the factor with the highest p-value one at a 
time. until all remaining factors had p<O.05. Covariates of interest retained throughout the 
modelling process included refugee status. age. and time on HAART. Adherence factors were 
not included in final model building to avoid over-adjustment bias [15.16.17] due to their 
putative role as mediators. Therefore. any adherence factor with an adjusted OR of p<O.05 in the 
"action state model" was presented in the final model and adjusted for other factors. however. 
other factors were not adjusted for adherence factors. 
Ethical approval 
Ethical approval was received by the Clinical Research Centre and the Medical Research Ethics 
Committee. Malaysia (Approval 3275) and the London School of Hygiene and Tropical 
Medicine Research Ethics Committee (Approval 5547). 
[*** Figure 1. p.n. near here ***] 
REsULTS 
Study population 
We recruited 153 refugees and 148 Malaysians adults reflecting 90% and 81 % participation 
rates (eligible clients who were seen or contacted and agreed to participate). respectively. The 
serially-recruited Malaysian group comprised 6% of the target population of eligible clients 
(N=2.870) and was similar on key socio-demographic indicators to a randomly sampled host 
comparison group (Supp. Table i). with the exception of ethnicity (p<O.OO 1). Almost all (95%) 
HIV -positive refugees accessing services from the study clinic were Burmese while the host 
community group was 61 % Chinese. 25% Malay. and 15% Tamil or other ethnic groups. The 
recruited refugee and host community groups were statistically different on a variety of other 
indicators (Table 1). The refugee group was younger (median age 35y v. 4Oy. p<O.OOI) and had 
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a higher proportion of females (36% v. 22%, p=O.OO6). The refugee group had a considerably 
shorter median time on HAART (61 v. 153 weeks, p<O.OOl), median time since HIV diagnosis 
(113 v. 315 weeks, p<o.OO I), and a lower most recent routine CD4 count (278 v. 350 cellslfJL, 
p=O.03). There was no difference between the two groups with respect to current pharmacy 
defaulters (7% v. II %, p=O.19). Among refugees, the median time of residence in asylum was 
3.6 years (IQR 2.0, 6.2) compared with a median time since having received formal refugee 
recognition of 1.8 years (lQR 1.0, 2.9). 
[--- Table 1. p.73, near here ---] 
Virological and adherence outcomes 
Viral load results indicated that 76% (224/296) of clients had achieved viral suppression «40 
copieslmL). There were no statistical differences between the proportions of refugees and host 
community clients who achieved viral suppression overall (74% v. 78%, p=O.4l), or when 
restricting analyses to clients on treatment for ~25 weeks (81 % v. 84%, p=O.54; Table 2). On 
key measures of self-reported adherence among all surveyed clients, refugee and host 
community clients performed similarly (Table 3). The four-day recall showed that a high 
proportion of both refugee and host clients self-reported optimal adherence (92% v. 96%, 
p=O.20), whereas the proportions who self-reported optimal adherence on the one-month V AS 
were lower but similar in both groups (72% v. 70%, p=O.79). The Rx results were also lower but 
similar in both groups (74% v. 66%, p=O.15). Within each group, there was evidence for 
ordered trends, among clients on treatment for ~25 weeks, between the self-reported measures 
of adherence and the proportions who fully suppressed viral load (four-day recall: p=O.07 v. 
p=O.06; VAS: p=O.06 v. p=O.OO2). On the Rx measure, there was strong evidence for this trend 
among refugees (p=O.OO4), but this did not hold for the host community (p=O.lO) (see SUpp. 
Table ii). 
l--- Table 2, p.73, and Table 3, p.74, near here ***] 
Risk factors for unsuppressed virological outcomes 
Unsuppressed viral load was defined as ~40 copieslmL. In initial analyses of contextual factors 
(Table 4), among clients on HAART for ~ly, 17% were not suppressed. The proportion not 
suppressed was 15% among those on HAART for <Iy. There was no significant relationship 
between increasing time on treatment above one year and virological outcomes (ORldj= 1.17, 
95%CI 0.69, 1.96; p=O.56). 
[*** Table 4, p.75-6, near here .. *] 
There were no statistically significant associations between self-change process factors and the 
outcome (Table 5). Among exposures modelled in the action state level (Table 6), there was 
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strong evidence for a protective effect of adherence to pharmacy refill schedule modelled as a 
linear effect (OR...J=O.47. 95%CI 0.27.0.83; p=O.OO9). and a harmful effect of having reported 
any treatment interruption in the past month (ORadj=2.77. 95%CI 0.91.8.43; p=O.08). These 
associations were adjusted for age group. time on HAART. refugee status. sex, temporary travel 
in past year. time to clinic. time from diagnosis to HAART start. and previous regimen switch. 
[ ... Table 5. p.77. and Table 6. p78. near here ••• ] 
The final multi variable model (Table 7) identified female sex (ORadj=O.39, 95% CI 0.14, 1.05; 
p=O.05). increasing time between diagnosis and treatment start (OR...j=O.64, 95%CI 0.41. 0.99; 
p=O.04). and adherence to pharmacy claim schedule (ORadj=O.47. 95%CI 0.27,0.81; p=O.OO7) 
as protective. while temporary migration of~1 month in the past year (ORadj=4.l2, 95%CI 1.70, 
9.99; p=O.OO2) and average travel time to clinic of ~ I hour (ORadj=3.05, 95%CI 1.09, 8.49; 
p=O.02) were independent risk factors that increased the odds of unsuppressed viral load. There 
was no evidence for an association between refugee status and unsuppressed viral load 
(ORad)= 1.28, 95%CI 0.52. 3.14; p=O.6O). The final multi variable model was adjusted for age 
group, refugee status, time on HAART. sex. temporary migration in the past year, average time 
to clinic. and time from HIV diagnosis to HAART start. Age. refugee status, and time on 
HAART were retained in the final model as a priori factors of interest, despite showing no 
evidence of associations at previous modelling levels. 
[ ... Table 7, p.79. near here ... ] 
DISCUSSION 
In this study, the first we are aware of to investigate both adherence and treatment outcomes 
among both refugee and a host community in an asylum setting. the majority of both refugee 
(74%) and host community clients (78%) achieved viral suppression. As expected, the 
proportion who had achieved suppression was higher in those who had been on HAART for at 
least 2S weeks, increasing to .81 % of refugees and 84% of host community clients. Despite some 
differences on socio-demographic measures and time on treatment. there were only minor 
differences. none statistically significant. between the refugee and host community groups on 
virological and adherence measures. Adherence and treatment outcomes in the present study 
were acceptable insofar as they were similar to reported results from other Asian HIV clinics. 
Oyomopito and colleagues observed 83% suppression after 12 months on HAART in a 
muhicentre prospective cohort of 17 Asian settings [18]. In a multicohort study of second-line 
treatment failure in 27 Asian and African settings. the observed rate of failure was 16 (9. 30) per 
1000 person-years. while the rate of optimal adherence was 176 (124. 249) per 1000 person-
years (19). 
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Although there are currently no other reports of virological outcomes among refugees or other 
conflict-affected persons residing in active- or post-conflict areas, the data that has been 
collected among these groups has shown acceptable adherence and treatment outcomes, 
consistent with the present study. For example, in conflict-affected northern Uganda, Kiboneka 
and colleagues [20] found optimal adherence ~95%) in 92% of internally-displaced persons 
(IDP), as measured by a composite score including a pharmacy-monitored drug possession ratio, 
phannacy refill records. and a three day recall by patients or caregivers. Among clients with 
sub-optimal adherence, 9.3% died compared with 1.2% of those sustaining optimal adherence. 
In a separate cross-sectional study of lOPs in Uganda. mean self-reported adherence was 99.5% 
[7]. In the western Equatorial province of Sudan, 88% of refugees and lOPs on HAART for ~6 
months self-reported ~95% adherence [21]. Similarly, during active conflict in the Democratic 
Republic of the Congo, optimal adherence. measured by pill counts, was found in 99% of 
clients. In this study, CD4 gain at 6 months was similar to other stable cohorts, although the 12-
month mortality of 7.9% was elevated in comparison to stable resource-limited settings [6]. 
These studies provided further evidence that refugees and other conflict-affected persons are 
able to sustain adherence to HAART and benefit from good treatment outcomes. 
Multivariable analyses confirmed the lack of an association between refugee status and failure 
to suppress viral load after adjusting for age, sex, time on HAART, time from diagnosis to 
HAART start. temporary migration in the past year, and time to clinic. Given the potential 
vulnerabilities connected with cross-border displacement that may increase the vulnerability of 
refugees to inferior outcomes. it was reassuring that the study showed that a high proportion of 
refugees were achieving excellent viral suppression. This has important equity and policy 
implications. In addition to refugee status, we assessed other migration-related factors. 
Temporary migration outside of current residence for at least one month in the past year resulted 
in a fourfold increase in the odds of unsuppressed viral load. a result that may be explained by 
difficulties accessing medications when personal stocks were depleted in the absence of any 
back-up source or contingency plan for replenishment. This finding was consistent with 
evidence from a Canadian setting also showing an adverse impact of temporary migration [22]. 
A longer travel time to clinic ~ I hour) was linked to a threefold increase in the odds of failing 
to suppress viral load. consistent with similar evidence concerning the harmful effects of longer 
travel times on outcomes in a variety of settings [23,24,25]. A longer time between diagnosis 
and HAART start was protective, a surprising result given that starting HAART at a higher CD4 
counts is known to reduce mortality [26]. Clients with longer lead-in times to routine treatment 
may have been better prepared for the adherence requirements of HAART. The expected 
negative effect of delaying treatment may have been confounded by longer delays between 
seroconversion and diagnosis. Motivation may. therefore, have been an issue; if diagnoses were 
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delayed. clients may have started HAART during periods of acute illness when the will to 
recover may have encouraged excellent adherence. With respect to CD4 measurement. it was 
not possible to identify if clients were HAART naive at the time of the first routinely-reported 
CD4. so we did not include these data in analyses. 
The strong evidence for a protective effect of female sex in the final adjusted analysis was a 
notable sex difference and may be related to differences in the proportions of men and women 
who reported disclosing their status to their partners (49% of males vs. 66% of females. p=O.05) 
and in the proportions with children (40% of males vs. 61 % of females. p=O.OO4). These factors 
may operate on adherence and virological outcomes through non-disclosure of HIV status [27]. 
and through encouraging earlier pathways to HIV services by way of antenatal screening. 
respectively [28]. This sex difference was also consistent with a protective effect observed in a 
Chinese study [29] and evidence from South Africa showing that men who present for ART are 
typically sicker than women [30]. However. most previous studies have either not found any 
evidence of sex differences in HAART clients or have been insufficiently powered to detect 
them. a gap that should be addressed in future research [31]. 
Consistent with other findings showing that phannacy-based adherence is an effective indicator 
of immunological and virological status [32.33]. there was strong evidence for a protective 
effect of phannacy refill adherence on unsuppressed viral load. These findings support the 
usefulness of this measure for routine monitoring of adherence and treatment outcomes in this 
setting. Self-reported treatment interruptions of one da~ or more in the past month were weakly 
associated with the outcome (p=O.08) in the action state level and was not included in the final 
model. Similarly. the other self-reported adherence measures were strongly associated with 
virological outcomes in crude analyses. but failed to reach statistical significance in adjusted 
analyses. The slightly lower proportion of Malaysians adhering optimally to the phannacy claim 
schedule may have been a consequence of a system that allowed the host community to collect 
their medications from external phannacies on an occasional or supplementary basis. One-sixth 
of host community clients reported collecting drugs in this manner within the assessed 
phannacy refill period lending support to the principle that multiple routine proxy measures are 
needed to identify patterns of adherence over time and to make up for deficits in any single 
measure [34]. 
The findings suggested that many of the "typical" obstacles thought to negatively affect 
treatment outcomes among refugees such as language barriers. unemployment. deficiency in 
support networks, and overall stability were either not linked to outcomes or were not unique to 
refugees. There was no evidence for any harmful effect of unemployment or mother tongue. We 
did not directly study deficiencies in support networks: however satisfaction with primary 
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providers was high among both refugee and host community clients (see Supp. Table v). 
Moreover, there was no association between disclosure of HN status to partners or family and 
outcomes. Refugees often build strong networks among their families and ethnic communities 
while in asylum and for those who find themselves isolated, linkage to treatment and care may 
provide a natural network of peer- and counsellor-based support upon which they can rely. 
Language barriers in medical contexts are clearly important, but may be overcome by judicious 
clinicians who use interpreters effectively and by employing support counsellors from among 
refugee communities. We did not study onwards displacement directly; however the average 
length of stay for an HIV-positive refugee of 3.7 years was generally indicative of stability. The 
finding that temporary migration (for ~ 1 continuous month in the past year) was a risk factor 
after adjusting for refugee status suggested that this was common to the full study group. The 
absence of a link between the number of reported barriers to adherence and failure to suppress 
viral load was suggestive that both groups of clients were resilient and may have identified 
adherence barriers in order to formulate practical solutions. 
Although the proportion who did not suppress HIV viral load decreased with better self-reported 
or pharmacy claim adherence, suppression appeared to be relatively tolerant of deviations from 
ideal adherence using multiple indicators, in both population groups. A level of routine 
adherence of at least 95% is generally considered to be optimal for achieving and sustaining 
viral suppression [35,36] but this threshold may be pliable in relation to regimen-specific 
genetic barriers to resistance. For example. NNRTI-based (non-nucleoside reverse transcriptase 
inhibitor) therapy. received by 96% of clients in the present study. may facilitate viral 
suppression at adherence levels below 95% [37.38]. In this study there were insufficient 
numbers of HAART naive clients on protease-inhibitors to enable analyses on interaction 
effects between regimen type and adherence. In spite of the fact that viral outcomes were 
tolerant of sub-optimal adherence. these results suggested opportunities for further improvement 
in viral suppression by working to shift moderate adherers to optimal levels. To this end. 
interventions targeting poor adherers or defaulters ought to be mindful of the fact that the 
minimum levels of NNRTI adherence needed for optimal levels of viral suppression are unclear 
[39.40.41] and that. in comparison to negligible levels of drug pressure. moderate but sub-
optimal ART plasma concentrations may increase the likelihood of secondary resistance [42]. 
To avoid scenarios where marginal improvements in adherence actually increase the likelihood 
of resistance. close monitoring of adherence interventions outside of trials is critical. especially 
among clients with past episodes of poor a,dherence and at high risk of future difficulties. 
Caution must be used in generalising these findings to other refugee populations given that only 
one setting was studied and HAART delivery systems are often specific to country and clinic 
setting. However. contingent generalisations may be made to refugee groups elsewhere upon 
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careful comparison of settings. The refugee caseload overall. and the HIV -positive case load 
among refugees. were both considerably higher in Malaysia when compared with other major 
programs in the region. Bangkok and New Delhi have only 10 identified cases each. Moreover. 
there are many differences between urban and camp or ruraVdispersed refugee groups with 
respect to demographic and epidemiological profiles and service-provision challenges [43]. 
Socioeconomic differences between different refugee settings such as high unemployment may 
at least be partially mitigated by the fact that the direct financial assistance provided by UNHCR 
is assessed at the country-level and partly determined by local socioeconomic considerations. 
As with other studies that have compared different clinical settings within one national program 
[44]. the clinic setting itself may be the crucial consideration when evaluating generalisability. 
In the present setting. refugees accessed HIV services from a leading reference hospital. These 
conditions may be found in other urban refugee populations where UNHCR and Ministries of 
Health have cultivated close links. but are unlikely to be replicated among ruraUdispersed or 
camp-based refugee groups where top reference facilities are unavailable. In addition to the 
quality of the facility. the attitude of providers to refugees is critical for delivering equitable 
care. In the current setting. refugees also benefitted from routine laboratory monitoring. 
including viral load testing. As laboratory monitoring for refugees is implemented in line with 
national protocols. any differences between refugee groups attributable to levels of monitoring 
would be expected to track national differences. 
Factors identified from these data will help to locate those who might benefit from targeted 
interventions. To this end. additional counselling for men on HAART. support for those 
HAART clients who spend lengthy periods in transit to access routine care. and those who do 
not consistently refill their HAART prescriptions as monitored by the pharmacy. might be 
beneficial. Risk assessments for clients who may travel for extended periods could be 
implemented to ensure that consistent medication supply is available and contingency plans are 
in place in the event that medication is exhausted; this applies to refugees and host communities. 
Use of mobile phones. either through training in using personal alarms. or more actively through 
a text-message intervention may help to mitigate some of these challenges [45,46]. 
Notably, this study only included refugees and host communities, yet HIV-positive asylum-
seekers who have been receiving HAART in their country of origin may be particularly 
vulnerable to poor outcomes given the possibility that their HAART supplies were exhausted 
prior to obtaining formal refugee status. UNHCR actively attempts to expedite these cases, and 
programs should continue to facilitate pathways to treatment and care for vulnerable asylum 
seekers. Given the importance of the pharmacy-based adherence assessment, this measure 
should be formalised as a routine adherence indicator. be linked to medical records, and 
monitored. When the reported result is poor. this should alert providers and trigger more 
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advanced and expensive testing (e.g. viral loads). Host community clients who collect 
medications from elsewhere on an occasional or supplementary basis should be identified to 
ensure that they are not missed by monitoring programs. If a means of tracking external refills 
cannot be found. an alternative monitoring measure such as pill counts ought to be implemented 
for these clients. 
This study had important limitations. As only a single study viral load sample was collected. 
outcomes may have been subject to sporadic viral escape. or "viral blips" leading to 
misc1assification of the outcome. Such episodes may be classified as low-level viraemia, 
typically caused by random biological or statistical variation around mean HIV-levels (e.g. 
release of virus from latent reservoirs) and high-level viraemia, usually of longer duration and 
possibly indicative of treatment failure andlor inadequate adherence [47,48,49]. Given that 
~500 copieslmL is an indicator of viral rebound [50], the area of concern for misclassification 
bias due to viral blips is in the range of 40-499 copies/mL. Moreover, viral blips are only 
relevant for patients who were recently virologically suppressed. Among clients for whom the 
most recent routine viral load prior to the study fell in the suppression range of <40 copieslmL. 
5% (7/147) tested in the range of 40-499 copieslmL for the study, suggesting that viral blips 
contributed a minimal amount of bias by misclassifying suppressed clients as unsuppressed. 
Selection bias in the host community group may also have affected our findings. Although the 
response rates of the interviewed samples were high in both groups, the lower rate in the host 
community could have introduced some differential bias. The serially-recruited host community 
study sample represented 6% of the target population and those not included may have been 
sicker or possessed other characteristics leading to bias. To examine this limitation, we 
extracted and compared routine socio-demographic data from a simple random sample of 150 
host community clients to interviewed host community clients. The random sample was 
statistically similar to the study sample on all key socio..<Jemographic indicators with the 
exception that ethnic Chinese clients were over-represented in the study sample. This difference 
may have introduced bias linked to socioeconomic status: the ethnic Chinese community in 
Malaysia typically has a lower incidence of poverty and the highest mean monthly gross 
household income when compared with other ethnic groups [51]. Also, the study groups were 
ethnically and linguistically diverse. To minimise the effects of this, the questionnaire was 
translated and independently back-translated and the study used local research staff in order to 
increase confidence in the technical and semantic equivalence of our questionnaires [52]. 
Finally, the cross-sectional design of the study limited our ability to draw any firm causal 
conclusions, and to accurately measure and classify longer-term viral suppression and adherence 
[53]. In multivariable analysis, the n for each strata was often small, which limited our ability to 
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conduct sub-group analyses and the power available for detecting the true effects of independent 
risk factors. 
Strengths of the study included detailed adherence assessment using self-report and pharmacy 
claim measures in accordance with recent best-practice guidelines [34]. collection of blood 
samples by using the routine phlebotomy service. analysis of samples conducted in a private 
laboratory with a good quantitative platform and effective quality control. translated and back-
translated questionnaires. and the use of well-trained local research staff. 
In summary. it was encouraging that a high proportion of both host and refugee clients attending 
this public sector clinic had achieved viral suppression at <40 copieslmL (83% at 2:25 weeks). 
Prevalence of 2:95% self-reported adherence was similar in host and refugee clients. and 
although adherence to pharmacy claim schedule was slightly higher in refugees compared with 
host clients. this may have been due to host clients having occasional, undocumented access to 
HAART medications at alternative pharmacies. Overall, our findings support the feasibility of 
providing HAART on an equitable basis to both refugees and host communities in this urban 
setting. The results also suggest that interventions among men. clients who travel or migrate for 
extended periods, clients who have excessive transit times to access HIV services, and those 
who have inconsistent pharmacy refill schedules. may improve outcomes. Formalised 
approaches to adherence monitoring may assist in this regard. 
Some Governments are concerned that equitable provision of HAART will constitute a pull 
factor for refugees to come to their country and a possible impediment for their return if 
HAART is unavailable in their country of origin. This places ever more emphasis on 
demonstrating the public health benefits of HAART in a range of settings and underscores the 
need for research on the effects of potential "pull" factors, if any, on the provision of HAART to 
refugees in countries of asylum as well as the potential of delaying repatriation if HAART is 
unavailable in the areas from where they have come. Future studies should also consider 
prospective designs that may assess causal differences between refugee and host community 
groups over time. 
Importantly, the future sustainability of HAART to refugees needs to be critically evaluated. 
Currently. the national program fully subsidises first-line fixed-dose treatments for refugees. 
however, efavirenz, second-line treatments, and virological monitoring are paid for by UNHCR. 
Given the current global reduction of funding for HIV, we are concerned that in the future, 
national programs that currently include refugees may begin excluding them as funding 
continues to decline. Our findings reinforce the imperatives of refugee protection over the full 
duration of asylum, as codified in international humanitarian law, by showing that effective 
provision of HAART treatment and support results in tangible public health benefits. If we are 
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to reach to the goal of universal access, then refugees, asylum seekers and other persons 
affected by conflict must be included in country and regional proposals and planning for HIV to 
the fullest extent possible. 
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TABLES AND FIGURES 
Figure 1: Hierarchical conceptual framework 
.' . ACTION CONTEXTS ("LEVEl 1") 
Food insecurity Displacement Clinic setting Sociodemographic Treatment contexts 
• , SELF-CHANGE PROCESSES ("lEVEl 2") 
Motivation Knowledge Problem-solving skills Social interaction 
ACTION STATES ("LEVEl3") 
Self-reported adherence Pharmacy claim adherence Treatment interruptions 
• VIROLOGICAL OUTCOME 
. Viral load (coples/mL) 
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Table 1: Baseline soclo-demo .... phlc and treabnent factors among host community (nl=148) and 
refugee (nz=153) dlents 
Factor 
Femaleltrallllfader, a (%) 
AIf, medlaa yean (IQR) 
Uaemployed, a (% ) 
Educational status. a (% ) 
None 
Any primary 
Any secondary or above 
Marital.tatus, a ( %) 
Single 
Married 
Natloaallty 
Malaysian 
Bunnese 
Other 
Curreat defaulten, a (%). 
Viral load, copiesImL (%) 
Suppressed <40 
NO! suppressed 2:40 
Most receat routlae CD4, medlaa celis/ilL (IQR) * 
Time oa HAART, medlaa weeks (lQR) U 
Time liace HIV ell ..... median weeks (lQR)*U 
Time liace eatry to holt couatry, medlaa weeks (lQR) 
Time liace refuaee status approval, medlaa weeks 
(IQR)**U 
tChi-squarc test ttMann-Whitncy test tttfisher's exact test 
.1-5 consecutive months without pharmacy refill 
Host 
33/148 (22) 
40 (35, 48) 
501148 (34) 
31148 ( 2) 
161148 (II) 
1291148 (87) 
901148 (61) 
581148 (39) 
148/148 (100) 
0/148 ( 0) 
0/148 ( 0) 
161148 ( II) 
1121144 (78) 
321144 (22) 
350 (202, 486) 
153 ( 63,298) 
315 (152, 571) 
NA 
NA 
Refugeef 
551153 (36) 
35 (31, 39) 
91/152 (60) 
8/153 ( 5) 
601153 (39) 
851153 (56) 
61/153 (40) 
921153 (60) 
01151 ( 0) 
1461151 (97) 
51151 ( 3) 
101153 ( 7) 
1121152 (74) 
401152 (26) 
278 (182,423) 
61 ( 35,108) 
113 ( 66,170) 
186 (105,324) 
91 (54, 149) 
p-value 
O.OO6t 
<O.OOltt 
<O.OOlttt 
<0.00 It 
<O.OOlt 
<O.OOlt 
0.19ttt 
0.41ttt 
0.03tt 
<O.OOltt 
<O.OOltt 
NA 
NA 
tThree refugees were traced to the inpatient and TB wards and were retained in analyses (two had suppressed viral load) 
*n.-14O, n,-141; Un.'"'147, n, .. 150; ***n.=146, n,=153; UUn, .. 152 
Table 2: Comparison ofvlrologtcal outcomes In host community and refugee clients 
Time oa HAART Group <40 copleslmL. n (%) Total. a (%) p-valuet (weeks) 
AU Host 112 (78) 144 (100) 0.41 
Refugee 112 (74) 152 (100) 
<15 Host 6 (33) 18 (100) 1.00 
Refugee 12 (41) 29 (100) 
2:15 Host 105 (84) 125 (100) 0.54 
Refugee 98 (81) 121 (100) 
tChi-squarc test 
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Table 3: Adberence in bost community and refugee clients 
Adherence measure 
Dose-by-dosc: self-report (4 days) 
0+ 
80+ 
95+ 
Visual analogue scale self-report (I month) 
0+ 
80+ 
95+ 
Phannacy claim adherence (24 months)§ 
0+ 
80+ 
95+ 
Host, D (%) 
(n=148) 
6( 4) 
o ( 0) 
142 (96) 
(n=148) 
11 ( 7) 
33 (22) 
104 (70) 
(n=143) 
14 (10) 
34 (24) 
95 (66) 
Refugee. D (%) 
(n=153) 
II (7) 
1 ( I) 
141 (92) 
(n=153) 
II ( 7) 
32 (21) 
110 (72) 
(n=136) 
9 ( 7) 
26 (19) 
101 (74) 
t Chi-square test for trend (Cochran-Annitage test) §Since started on HAART to a mallimum of 24 months. 
p-valuet 
0.20 
0.79 
0.15 
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Table 4: Association of contextual factors with unsuppressed viral load among refugees and local host 
community on HAART for iitZS weeks In Kuala Lumpur, Malaysia (N=ZZZ*) 
Prevalence ~ copleslmL, p-value, crude odds p-value, adjusted Factor 
nIN (~)tt ratio (95 ~ CI) odds ratio (95% CI)ttt 
AKe IrouP (yean)t p=O.69 p=O.68 
18- 5125 (20) I I 
30- 18/114 (16) 0.90 (0.52. 1.55) 1.15 (0.60. 2.20) 
40+ 13/83 (16) 
Refu&ee status p=O.19 p=O.6O 
Hosl 151114 (l3) I I 
Refugee 211108 (19) 1.59 (0.77. 3.28) 1.28 (0.52. 3.14) 
Time on HAART (yean)t p=O.79 p=O.56 
0- 7/46 (IS) I I 
1- 9157 (16) 1.06 (0.68. 1.67) 1.17 (0.69. 1.96) 
2+ 201119 (17) 
Sex p=O.04 p=O.05 
Male 301155 (19) I I 
FemalefTransgender 6167 (9) 0.41 (0.16. 1.04) 0.39 (0.14. 1.05) 
Thnf rrom dlalnOlis to start (weeks)t p=O.07 p=O.04 
0- 19/98 (l9) I I 
25- 8130 (27) 0.69 (0.47. 1.03) 0.64 (0.41. 0.99) 
50+ 9194 (10) 
HAART realmea, dOllnl p=O.32 p=O.13 
EfV-bascd.lwicc-daily 211140 (15) I I 
NVP-bascd. twice-daily 12174 (16) 1.10 (0.51.2.38) 1.03 (0.44. 2.43) 
Other 318 (38) 3.40(0.76.15.31) 6.00 (1.14. 31.74) 
Current employment p=O.23 p=O.21 
No 13/101 (13) I I 
Yes 231121 (19) 1.59 (0.76. 3.32) 1.70 (0.74. 3.95) 
Molber tonaue p=O.t9 p=O.26 
Bahasa Malaysia (Malay) 5139 (13) I I 
Tamil 5126 (19) 1.62 (0.42. 6.27) 1.56 (0.36. 6.73) 
Chinese dialects 3/46 ( 7) 0.47 (0.11. 2. \3) 0.47 (0.09. 2.32) 
Chin dialects 13/S4 (24) 2.16 (0.70, 6.66) 6.21 (0.57.67.53) 
Burmese 3124 (13) 0.97 (0.21. 4.49) 2.52 (0.17. 38.58) 
Other 7133 (21) 1.83 (0.52. 6.43) 3.20 (0.30, 34.63) 
Household lbet p=O.73 p=O.97 
1- 9/56 (15) I I 
3- 171112(15) 1.09 (0.66. 1.82) 1.01 (0.59. 1.73) 
7+ 10IS4 (19) 
No. dependent mloon In bouHhold p=O.59 p=O.98 
0 231133 (17) I I 
1+ 13/89 (1.5) 0.82 (0.39. 1.72) 1.01 (0.44.2.33) 
Temponry mllntion (~I continuoul 
IDOIItb 18 put year) p<o.OOI p=O.002 
No 23/187 (12) I I 
Yes 13/3.5 (37) 4.21 (1.87,9 . .50) 4.12 (1.70. 9.99) 
Patbway to dlapOlil p=O.50 p=O.65 
Voluntary Icst 7/43 (16) I I 
Mancialory lesl 8/40 (20) 1.29 (0.42, 3.94) 2.01 (0.56,7.18) 
DlncsllhOlpilalisalion 16188 (\8) 1.14 (0.43, 3.03) 1.00 (0.34, 2.93) 
Other .5/51 (10) 0.56(0.16.1.91) 1.07 (0.27. 4.2.5) 
Avenle time to dlnlc: (boun) p=O.OI ".0.02 
0- 6n4( 8) I 
1+ 301148 (20) 2.88 (1.14. 7.27) 3.05 (1.09. 8.49) 
Realmen 1WI1dI, ever p=O.20 p=O.07 
No 161120 (13) I I 
Yes 201102 (20) 1.59 (0.77. 3.2.5) 2.14 (0.94. 4.8.5) 
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Table 4: Association of contextual factors with unsuppressed viral load among refugees and local host 
community on HAART for ilZS weeks In Kuala Lumpur, Malaysia (N=222·) 
Factor 
Unable to refill prescription, palt 3 
moDths 
No 
Yes 
ADY symptom or lide-elrect, past 4 weeks 
No 
Yes 
Prevalence ~ copleslmL, 
nIN (~)tt 
35/210 (17) 
1/12 ( 8) 
6154 (11) 
30/168 (18) 
p-value, crude odds 
ratio (95 ~ CI) 
p=O.41 
0.45 (0.06. 3.64) 
p=O.23 
I 
1.74 (0.68. 4.44) 
p=O.17 
Secure I 0184 (12) I 
Insecure 261138 (19) 1.72 (0.78. 3.77) 
p-value, adjusted 
odds ratio (95 % 
CI)ttt 
p=O.44 
0.45 (0.05.4.08) 
p..o.41 
I 
1.5 I (0.55. 4.19) 
p=O.23 
I 
1.83 (0.67. 5.00) 
SatlvldlfKtioD with prl~ry health care Mean= 4.21; SO=O.70 p=O.85; 0.95 (0
1
'5597). p=O.64; 0.88 (0.5 I. 1.51) 
pro er, _D iICOre++ • 
·32 clients with incomplete dati excluded (5 missing viral loads; 13 missing phannacy claim records); respondents with missing 
data were nOl significantly different (p>O.05) from those relained for analyses on age. sex. refugee slatus. and time on HAART 
tfaclor modelled as a linear effect (common odds ratios presented) 
ttUnless OIherwise nOled 
tttAdjusted for age group. sex. refugee status. travel in past year. time to clinic. time on HAART. and time from HIV diagnosis to 
HAARTstan 
*Item constructed from 3 questions. each measured on a 3-point Likert scale. An endorsement of "some of the time" or" all of the 
time" on any of the three questions was scored as "insecure" 
Ultem constructed from 2 questions. each measured on a S-point Likert scale; ascending score was consistent with greater 
satisfaction 
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Table 5: Assodation of self-change factors with unsuppressed viral load among refugees and local host 
community on HAART for ~ZS weeks In Kuala Lumpur, Malaysia (N=2ZZ*) 
Faclor 
Adherence eeII-elDc:aey (self-rated ability 
10 I8I1e ~kalioDl as prescribed over 
prem .. month)t 
Excellent 
GoodIvery ,ood 
Very poor/poor/fair 
Serostat .. dl.dosure 10 partner 
No 
Yes 
No partner 
Serostat .. dilc:1osure to ramllytrrlends 
No 
Yes 
Alcohol use., ... t moDth 
Never 
One or more limes 
Use or lUepllharmful substaDc:tI, put 6 
moaths 
No 
Yes 
Use or traditlo .. 1 medlclaa, past 6 
moDths 
No 
Yes 
No. or reported berrien 10 adherencet 
o 
1+ 
3+ 
5+ 
KDowledae f1l HIV aDd AIDS ('III correct 
or 4 quettlolll) 
0+ 
50+ 
Prevalence ~ 
copieslmL, nIN (% ) 
16199 (16) 
141105 (13) 
6118 (33) 
4122 (18) 
171120 (14) 
IS/SO (19) 
10181 (12) 
261141 (18) 
241164 (IS) 
12158 (21) 
321208 (IS) 
4114 (29) 
291188 (IS) 
7/34 (21) 
13/82 (16) 
8/67 (12) 
8/36 (22) 
7137 (19) 
1118(6) 
35/204 (17) 
p-value, crude odds 
ratio (95% CI) 
p=O.37 
1.30 (0.74, 2.26) 
p=O.67 
I 
0.74 (0.22. 2.46) 
1.04 (0.31. 3.52) 
p=O.23 
I 
1.61 <0.73.3.53) 
p=O.29 
I 
1.52 (0.71. 3.28) 
p=O.23 
I 
2.20 (0.65. 7.45) 
p=O.46 
I 
1.48 (0.57.3.57) 
p=O.46 
I 
1.13 (0.82. 1.56) 
p=O.IS 
I 
3.52 (0.45. 27.33) 
p-value, adjusted odcb 
ratio (95% Cl)tt 
p=O.95 
I 
1.02 (0.56. 1.86) 
p=O.77 
I 
1.11 (0.29.4.23) 
1.45 (0.38. 5.53) 
p=O.49 
I 
1.37 (0.56. 3.34) 
p=O.69 
I 
0.83 (0.33. 2.06) 
p=O.83 
I 
1.18 (0.27, 5.31) 
p=O.7S 
I 
1.31 (0.47.3.70) 
p=O.89 
I 
1.03 (0.71.1.49) 
p=O.23 
3.21 (0.37.28.05) 
°32 c:lienl5 with incomplete data excluded (5 mislin, viral loads; 13 missing phannacy claim records); respondents with missing 
dlta were nOllilnificlnlly different (p>O.05) from those retained for analyses on age. sell. refugee status. and time on HAART 
tFactor modelled as a linear effect (common odds ratios presented) 
tt Adjusted for Ige IrouP. sell. refuS" stltuS. travel in past year. time to clinic. time on HAART. time from HIV diagnosis to 
HAART stan. and previous reaimen switch 
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Table 6: Assodatlon of action state (adherence) factors with unsuppressed viral load among refugees 
and local host community on HAART for il:Z5 weeks In Kuala Lumpur, Malaysia (N=2ZZ-) 
Faclor Prevalence ~ p-value. crude odds p-value. adjusted odds 
copleslmL, DIN (% ) ratio (95 % CI) ratio (95% Cl)tt 
Adherence 10 medication schedule. self-
reported p=O.44 p=O.SI 
Never. somelimes. half of Ihe time. mosl of Ihe 
lime 12162 (\9) 
All of Ihe lime 24/160 (15) 0.74 (0.34, 1.5S) 0.90 (0.39. 2.0S) 
Adherence, visual Inalope scale self-report, 
put month (% It p=O.OI p=O.17 
0- 5/13 (39) I I 
SO- 10146 (22) 0.50 (0.29, 0.86) 0.65 (0.35, 1.19) 
95+ 211163 (13) 
Adherence, dose-by-dose seU'-report, past 4 
daYI(%) p=O.04 p=O.30 
0- 419 (44) 1 I 
95+ 321213 (IS) 0.22 (0.06, 0.87) 0.32 (0.06, 1.76) 
Adherence, pharmacy renO schedule, HAART 
start or 14 monthst p=O.OO2 p=O.OO9 
0- 8m (36) I 
SO- 12153 (23) 0.45 (0.2S, 0.73) 0.47 (0.27. 0.83) 
95+ 161147 (II) 
Treatment Interruptions of 2:1 day, self-report, 
put month p=O.OO3 p=O.OS 
None 271200 (14) I I 
Any 9n2(41) 4.44 (1.73, 11.38) 2.77 (0.91, 8.43) 
Unintentional underdosinl p=O.32 p=O.30 
No 271180 (15) I I 
Yes 9/42 (21) 1.55 (0.67, 3.S9) 1.66 (0.65, 4.24) 
-32 clients with incomplete dala ellcluded (5 missing viral loads; 13 missing pharmacy claim records); respondents with missing 
dala were not significantly different (p>O.OS) from Ihose relained for analyses on age, sex, refugee slalus. and time on HAART 
tFaclor modelled as a linear effect (single common odds ratio presented) 
tt Adjusted for age group, sex, refugee stalus, travel in paSI year, lime 10 clinic. lime on HAART. lime from diagnosis 10 HAART 
start, and previous regi men swilch 
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Table 7: Final multivariate model for factors associated with unsuppressed viral load among refugees 
and local host community on HAART for itZS weeks In Kuala Lumpur, Malaysia (N=222*) 
Age group (yean)t 
18· 
3o. 
40+ 
Refugee status 
Hosl 
Refugee 
Sex 
Male 
Female 
Factor 
TbM on HAART (yean)t 
0-
I· 
2+ 
Time from dlapOlis to start (weeks) 
o. 
25· 
50+ 
Temporary migration (~l continuous month In 
past year) 
No 
Yes 
Average time to clinic (houn) 
0-
1+ 
Adherence, pharmacy reno schedule, HAART 
start or l4 monthstl 
o. 
8o. 
95+ 
p-value, 
crude odds ratio (9S% CI) 
p=O.69 
I 
0.90 (0.52. 1.55) 
p=O.19 
I 
1.59 (0.77. 3.28) 
p=O.04 
I 
0.41 (0.16. 1.04) 
p=O.79 
I 
1.06 (0.68. 1.67) 
p=O.03 
I 
0.61 (0.39. 0.95) 
p<O.OOI 
I 
4.21 (1.87. 9.50) 
p=O.OI 
I 
2.88 (1.I4. 7.27) 
p=O.002 
I 
0.45 (0.28. 0.73) 
p.value, 
adjusted odds ratio (95% Cl)tt 
p=O.68 
I 
1.15 (0.60. 2.20) 
p=O.60 
I 
1.28 (0.52. 3.14) 
p=O.05 
I 
0.39 (0.14. 1.05) 
p=O.53 
I 
1.17 (0.69. 1.96) 
p=O.04 
I 
0.64 (0.41. 0.99) 
p=O.002 
I 
4.12 (1.70. 9.99) 
p=O.02 
I 
3.05 (1.09. 8.49) 
p=O.007 
I 
0.47 (0.27. 0.81) 
·32 c1ienls wilh incomplele dala excluded (5 miSsing viral loads; I J missing pharmacy claim records); respondenls wilh missing 
dala were not significanlly differenl (p>O.05) from Ihose relained for analyses on age. sex. refugee Slalus. and lime on HAART 
tFaclor modelled as a linear effecl (single common odds ralio presented) 
ttAdjusled for all faclors in lable excepllhose denoted by §. A priori faclors relained: age group. refugee slatus. and lime on 
HAART. Factors excluded after one iteralion: previous regimen switch 
IFaclor not included in the final model process due to presumptive role as medialor; other final model factors were not adjusted for 
these designaled faclors 
79 
SUPPLEMENTARY MATERIAL 
Table I: Comparison of Interviewed and randomly sampled host community clients using data from 
electronic medical records· 
Factor 
Femaleltrall5leoder, 0 ('II» 
Ale In yean, medlao (lQR) (n.=I48; n,=150) 
Marital status. 0 ('II» 
Single 
Married 
Divorced/widowed 
Etbnidty, n ('II» 
Chinese 
Malay 
TamilJOlher 
Most recent routine viral load, copleslmL ('II» 
Suppressed <40 
Nol suppressed ~40 
Recent routine CD4, median c:ellslpL (lQR) (n.=I44; 
0,=149) 
Time on HAART, median weeks (IQR) (D.=I40; D,=130) 
tFisher's exacilesl ttChi·squared les! iMann-Whilney!es! 
Interviewed 
sample (n.) 
33/144 (23) 
42(34,49) 
63/141 (45) 
681141 (48) 
10/141 ( 7) 
881145 (61) 
361145 (25) 
211145 (15) 
I I 1/146 (76) 
351146 (24) 
376 (248, 598) 
184 (59, 324) 
Random sample 
(0,) 
321150 (21) 
39 (35, 48) 
521115 (45) 
611115 (53) 
21115 ( 2) 
50/140 (36) 
561140 (40) 
34/140 (24) 
1051139 (76) 
341139 (25) 
350 (202, 486) 
134 (66, 259) 
p.value 
0.74tt 
0.35i 
0.14t 
<O.OOltt 
0.92tt 
O.On 
0.09; 
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Figure I: Scanerplot of viral load (Jogl0 copies/mL) by time on treatment (weeks) and by refugee 
status 
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A catterplot of viral load (Iog1 0 copies/mL) by time on treatment showed little evidence for a 
linear relation hip between viral load and time on treatment in either the refugee (R2=O.009 , 
p=O.51) or host community (R2=O.03, p=O.26) groups. Fitting a third order polynomial curve to 
the data yielded a slightly stronger (but still weak) relationship between viral load and time on 
treatment for both the refugee (R2=O.1) and host community (R2=O.l) groups. In the host group, 
the hallow U-shaped curve suggested the possibility of some acquired resistance to HAART 
over time. However, the best-fitted polynomial curve for the refugee population was not U-
haped, uggesting that this may not have been the case in that group. 
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Table II: Viral suppression by type of adherence measurement, stratified by refugee status (~2S weeks 
on treatment) 
Adherence measurement <40 copleslmL. n Total p-valuet 
(%) 
Host 
Dose-by-dose self-repon (4 days); n=125 
0+ 2 (50) 4 (100) 0.06 
80+ o ( 0) O( 0) 
95+ 103 (85) 121 (100) 
Visual analogue scale self-report (I month); n= 125 
0+ 6 (55) II (100) 0.002 
80+ 21 (78) 27 (100) 
95+ 78 (90) 87 (100) 
Pharmacy claim adherence (24 months); n=121 
0+ 9 (69) 13 (100) 0.10 
80+ 27 (84) 32 (100) 
95+ 67 (88) 76 (100) 
Refugee 
Dose-by-dose self-report (4 days); n=152 
0+ 3 ( 50) 6 (100) 0.07 
80+ 1 (100) 1 (100) 
95+ 94( 83) 1\4 (100) 
Visual analogue scale self-report (I month); n=\2\ 
0+ 4 (57) 7 (100) 0.06 
80+ 18 (75) 24 (100) 
95+ 76 (84) 90 (100) 
Pharmacy claim adherence (24 months); n=113 
0+ 5 (56) 9 (100) 0.004 
80+ 17 (68) 25 (100) 
95+ 69 (87) 79 (100) 
tChi-squared test for trend (Cochran-Armitage test) 
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Table Iii: Proportions of clients reporting specific barriers to adherence 
Barrier Rerugee Host Total 
Never / Sometimes Never / Sometimes Never / Sometimes 
Rarely IOrten Rarely IOrten Rarely IOrten 
... Away from home 141 (94%) 9(6%) 130 (88%) 17 (12%) 271 (91%) 26(9%) 
... Busy with other things 139 (93%) II (7%) 124 (84%) 24 (l6%)~ 263 (88%) 35 (12%). 
... Simply forgOl 141 (94%) 9(6%) 140 (95%) 8(5%) 281 (94%) 17(6%) 
... Have too many pills to take 149 (99%) 1(1%) 140(95%) 8 (5%) 289 (97%) 9(3%) 
... Wantto avoid side-effects 149 (99%) 1(1%) 139 (94%) 9(6%) 288 (97%) 10(3%) 
... Not want others to notice 142 (95%) 8(5%) 138 (93%) 10(7%) 280 (94%) 18(6%) you taking your meds 
... Have a change in daily 145 (97%) 5 (3%) 139 (94%) 9(6%) 284 (95%) 14(5%) 
routine 
... Feellike the drug is ISO (100%) 0(0%) 138 (93%) 10 (7%) 288 (97%) 10(3%) toxiclharmful 
... Fall asleep/slept through 142 (95%) 8(5%) 134 (91%) 14 (9%) 276 (93%) 22 (7%) dose lime 
... Feel sick or ill 149 (99%) 1(1%) 142 (96%) 6(4%) 291 (98%) 7 (2%) 
.. ' Feel depressed/overwhelmed 148 (99%) 2(1%) 137 (93%) II (7%) 285 (96%) 13 (4%) 
... Have problems taking pills 142 (95%) 7 (5%) 138 (94%) 9 (6%) 280 (95%) 16(5%) 
at spc~ified times 
... Run out of pills 141 (94%) 10(7%) 139 (94%) 9(6%) 280 (94%) 19(6%) 
... Detained or incarcerated by 139 (94%) 9(6%) 120(96%) 5 (4%) 259 (95%) 14(5%) the authorities 
... Difficulty concentrating 144(96%) 6(4%) 136 (93%) 10(7%) 280 (95%) 16(5%) 
... Feeling irritable/angry 145 (97%) 4(3%) 135 (91%) 13 (9%) 280 (94%) 17 (6%) 
... Less interesl in daily 139 (93%) 10 (7%) 139 (94%) 9 (6%) 278 (94%) 19(6%) 
activities 
... Feeling that you have leas 134 (90%) IS (I0%)t 135 (91%) 13 (9%) 269(91%) 28 (9%) 
skills than you had before 
... Having difficullY dealing 139 (93%) II (7%) 139 (94%) 9 (6%) 278 (93%) 20 (7%) 
with new situalions 
... Feeling unable 10 make daily 143 (95%) 7 (5%) 140(95%) 8 (5%) 283 (95%) 15(5%) plans 
... Worrying too much about 138 (93%) II (7%) 134 (91%) 14(9%) 272 (92%) 25 (8%) 
things 
... Feeling hopeless aboulthe 139 (93%) 11(7%) 132 (90%) IS (10%) 271 (91%) 26(9%) future 
Other reason. cited (HOlts): 
Ramadan period (fasl). resislant 10 presenl medication. admitted 10 hospital. allend wedding dinner (got drunk). centre forgollo give 
client. family was annoying. forgot 10 bring medications out. forgot 10 lake along medication. fiustration from children. gOl stolen. 
high on drugs. left mcds al home. need 10 stay clear/alert. no confidence in mcds. 100 slreSsedlhappy aboul other things. look beer. 
travelling. unstable emotion. work pressure. working in PcraIc. confused with panadol. financial problems 
Other reason. cited (Reruaees): 
Did nOl know had 10 take sioerin. doetor stopped medication. drunk. forget to take while going out. forgOl phone alarm, missed at 
beginning of HAART. no money for Iransportation. phone alarm not working well. rain dissolved medications. warded in hospital 
t Most reported barrier for refugees 
*Most reported barrier for host community 
.Most reported barrier overall 
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Table Iv: Proportions of clients reporting on food Insecurity 
Refugee Host Total 
To what extent are the Not true Sometimes! Not true Sometimes! Not true Sometimes! 
rollowlng statements true ... orten true Orten true Often true 
.. .1 can 'I afford 10 cal properly. 4S(31%) 105 (69%) 102 (69%) 46(31%) 150 (50%) 151 (50%) 
... 1 am often hungry bUI I don 'I 
eal because I can'l afford 44 (29%) 109(71%) 117 (79%) 31 (21%) 161 (53%) 140 (47%) 
enough food . 
.. .1 cal less Ihan Ilhink I 
should because I don'l have 50 (33%) 102 (67%) lOS (73%) 40(27%) 158 (53%) 142 (47%) 
enough money for food . 
... 1 cannOI give my child(ren) I 
dependenls a balanced meal 15 (23%) 49 (77%) 43 (SI%) 10(19%) 58 (50%) 59 (50%) 
because I can 'I afford lhal. 
Table v: Proportions of clients reporting satisfaction with doctor-patient relationship 
Refu&ee Host Total 
Thinking about the doctor that prescribes your medication ... 
Strongly Agree! Strongly Agree! Strongly Agree! 
disagree! stroBlly disagree! stroBlly disagree! strongly 
disagree! agree disagree! agree disagree! agree 
uncertain uncertain uncertain 
... He/she offers Ihe besl 27 (18%) 126 (82%) 17(11%) 131 (89%) 44 (15%) 257 (85%) 
medical care Ihey can provide 
... He/she pUIS your health 31 (20%) 122 (SO%) 16 (II %) 132 (89%) 47 (16%) 254 (84%) 
above everything else 
Thinking the provider that you Interact with most orten (If not your doctor) ... 
... He/she offers the best 13 (17%) 63 (83%) 4(13%) 28 (88%) 17 (16%) 91 (84%) 
medical care they can provide 
... He/she pUIS your health 17 (22%) 59 (78%) 2(6%) 31 (94%) 19 (17%) 90(83%) 
above everything else 
Table vi: Proportions of clients reporting on wait-time, obstacles to refill, and costs 
Refu&ee Hon 
No Yel No Yel 
... Left clinic due to waiting 148 (99%) 2 (1%) 137 (93%) 
time in pastlhree months 
... Unable 10 refill HAART 
prescription in past three 138 (93%) II (7%)t 141 (95%) 
months· 
... lncur costs relaled 10 liking 21 (14%) 132 (86%) 2S (17%) 
HAART 
ts/II (46%) reported stock-oul: 2111 (18%) reponed coslsIIack of money for transpon 
*217 (29%) reponed slock-out 
10 (7%) 
7(5%)* 
123 (83%) 
Total 
No Yel 
285 (96%) 12(4%) 
279(94%) 18 (6%) 
46(15%) 255 (85%) 
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Dear Editor: 
We are delighted to submit our manuscript entitled: "Adherence to HAART in refugees and 
host communities in a refugee camp setting: is forced displacement a barrier to adherence?" 
We believe that this work is germane to The Lancet and is relevant to its general audience for 
three main reasons: 
• It is highly relevant to The Lancet expressed interest in global health research. 
• We believe that your general readership will be interested in the subject matter given 
recent public interest in the ongoing famine and mass displacement in Somalia and 
eastern Kenya and recent debates about a broad approach to HIV treatment as 
prevention. 
• It is the first work that we are aware of that systematically studies adherence in asylum-
based refugees in a refugee camp, therefore its contribution is novel. 
• We report extremely worrying clinical outcomes in this setting. 
In the event that we are fortunate enough to have the manuscript published in the Lancet, if 
the editors must shorten the paper for print publication, we suggest that Tables 1-3 and 5 are 
retained and the remainder of tables and figures published as web extra material. 
Sincerely 
Joshua Mendelsohn (on behalf of co-authors) 
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ABSTRACT 
Background. Given the near absence of data on treatment outcomes among refugees, our 
objective was to evaluate if refugees and the local host community attending a remote refugee 
camp clinic were achieving acceptable adherence and virological outcomes. 
Methods. We conducted a cross-sectional survey among HAART clients (~18 years) in 
Kakuma, Kenya. Data sources included structured questionnaires, a pharmacy-based measure of 
HAART prescription refills over 24 months prior to the study interview (Rx), and HIV viral 
loads. The primary outcome was unsuppressed viral load (~IOOO copieslmL). 
Findings. In refugees and host clients, 86% (n=73) and 84% (n=86) of all clients not lost to 
follow-up participated. Compared with the host community, refugees were older (median age 
36y (IQR 31, 41) v. 32y (IQR 27, 38); p=0.02), but similar with respect to the proportion of 
women (67% v. 66%,p=0.91) and median time on HAART (147 weeks (lQR 38,264) v. 139 
(IQR 39,225); p=O.65). Median time spent by refugees in the host country was 9.8 years (IQR 
4.5,15.7). Proportions optimally adherent to Rx were 85% among refugees vs. 74% among the 
host community (p=O.09). Similar proportions in both groups on treatment for ~25 weeks had an 
unsuppressed viral load (88% v. 89%, p=O.89). In multi variable analyses, refugee status was not 
associated with the outcome (ORadj=O.64, 95%CI 0.20,2.08; p=O.46). Larger household sizes 
(ORadj=0.26, 95%CI 0.11,0.61; p<O.OO I) were protective and there was weak evidence that 
underdosing (ORadj=7.48, 95%CI 0.74,27.22; p=O.07) was independently associated with lack of 
viral suppression. 
Interpretation. Virological measures were valuable for monitoring program effectiveness. The 
unacceptable levels of viral suppression may have resulted from previous unmeasured treatment 
interruptions or adherence lapses. Remedial interventions are urgently required to improve 
outcomes in this setting. 
Funding. Funding for this work was provided by the Canadian Institutes for Health Research, 
UNHCR, and the Parkes Foundation. 
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INTRODUCTION 
Previous studies among conflict-affected populations has reported good adherence and 
treatment outcomes (1-3). As a result, international guidelines now recommend provision of 
highly active antiretroviral therapy (HAART) to conflict-affected populations (4). However, 
among these groups. refugees are unique insofar as they have crossed an international border 
and are normally entitled to a level of health care equivalent to the standard of care for host 
nationals. In Kenya. where most refugees reside in remote camp settings. supporting clients on a 
complex chronic therapy such as HAART may be facilitated by the ability to follow them up in 
the relatively small area of the refugee camp. Even in urban settings. recent findings 
demonstrated that good. equitable adherence and virological outcomes are achievable (5). Yet, 
in times of financial uncertainty when allocating scarce resources to non-nationals may be 
contested. refugees may face questions pertaining to their ability to sustain treatment. In this 
context. high unemployment. lack of disposable income. and fractured support networks may be 
used to argue that optimal adherence and treatment outcomes will be difficult to achieve (6). 
The lack of data on adherence and treatment outcomes among refugees unwittingly fuels these 
assertions. in addition to stifling the ability of providers to assess and improve program delivery. 
In response to these concerns. we conducted a study of adherence and treatment outcomes with 
refugee and host community clients accessing HAART in Kakuma Refugee Camp, Kenya. 
METHODS 
Study setting 
The Comprehensive Care Clinic. Kakuma (CCCK). was chosen as it presented an opportunity to 
study a refugee camp setting in sub-Saharan Africa with sufficient numbers of clients accessing 
treatment. At the time of study start (February 2011). 446.946 refugees from the Hom of Africa 
were registered by UNHCR in Kenya; the population of Kakuma Refugee Camp was 82,409. 
The Kenyan government has signed the 1951 Refugee Convention and its 1967 Protocol. and 
the National HIV I AIDS Strategic Plans included refugees. Access to first and second-line 
HAART is provided by the national program. The comparison group (local host community) 
was comprised primarily of the Turkana. a nomadic-pastoralist ethnic group. Although 
traditionally nomadic. many Turkana opt for a non-nomadic way of life. living in more 
permanent dwellings around established towns or settlements. The CCCK is managed by the 
International Rescue Committee (IRC). Biomarker testing. nutritional. and counselling services 
were routinely provided to all clients. At the start of the study in February 2011. 389 HIV-
positive refugee and host community clients had been enrolled since the start of the HAART 
program. If diagnosed HIV -positive. clients were routinely counselled and started on 
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multivitamins and cotrimoxazole. A two week trial regimen of nevirapine-based HAART, dosed 
once-daily, was routinely initiated when indicated by national guidelines. Depending on 
tolerance, this regimen was either continued twice-daily or substituted with an efavirenz-based 
therapy. 
Study design 
A five-week cross-sectional survey was conducted at the Comprehensive Care Clinic in 
Kakuma Refugee Camp with a serially-recruited sample of refugee and Kenyan adults. Clients 
who were ~ 18y, on HAART for ~30 days, not lost to follow-up (defined as having missed six or 
more consecutive monthly pharmacy refills), and not exclusively on ART for prevention of 
mother-to-child transmission (PMTCT), were systematically recruited at the time of their 
regular clinic appointment or through an active recruitment protocol implemented by home-
based care workers. Efforts were made to contact all known eligible HAART clients meeting 
the inclusion criteria at least three times by either telephone or home visit. Clients self-identified 
as a refugee or host community national. 
Data sources 
Data sources included a structured questionnaire with self-reported adherence measures, a 
pharmacy-based prescription refill measure, and HN viral loads. The primary outcome was 
unsuppressed viral load (cut-off <1000 copieslmL). The questionnaire was translated into 
Kiswahili, Nga'turkana, French, Amharic, and Somali, and backwards translated into English. 
The back-translated and original English versions were reconciled prior to pre-testing and pilot-
testing. Adherence to pharmacy refill schedule (Rx) was measured using a pharmacy-based 
measure of HAART prescription refills, calculated as the proportion of refills collected over the 
total prescribed up to 24 months prior to the interview date. Self-reported adherence was 
measured using both a four-day dose-by-dose recall and a general one-month visual analogue 
scale (V AS). HN viral loads were collected as dried blood spots on Whatman 903 filter paper, 
dried and frozen at -20°C. Samples were shipped on dry ice to the Kenya Medical Research 
Institute HN Laboratory in Kisumu, Kenya and analysed using the COBAS Amplipreprraqman 
platform (Roche Diagnostics Systems, Branchburg, New Jersey, USA). 
Statistical methods 
Socio-demographic characteristics were compared between host and refugee groups using 
Mann-Whitney tests for continuous variables, Chi-square or Fisher's exact test for categorical 
variables, and Chi-square test for trend for ordered categorical variables. The primary outcome 
was unsuppressed viral load (::!IOOO copieslmL). Risk factors for unsuppressed viral load were 
evaluated using unconditional logistic regression; effect estimates were odds ratios and 
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corresponding 95% confidence intervals (CI). A three-level forwards, step-wise modelling 
approach was used to classify and order the entry of factors into the model. Drawing on social 
action theory (7), factors were grouped into levels representing treatment contexts such as socio-
demographic, displacement-related, and treatment factors; self-change processes such as disease 
and medication knowledge, self-efficacy, and serostatus disclosure; and action state factors 
including adherence measures. Associations between unsuppressed viral load and factors from 
all levels were first evaluated in univariable analyses using log-likelihood ratio tests. A 
"treatment context model" was then fitted by adjusting for treatment context factors with p<O.1 
in univariable analyses. A "self-change processes model" was fitted by adjusting each new 
factor by all retained treatment context factors, then adjusting again for any additional factors 
with p<0.1. A model evaluating the effect of "action state (adherence) factors" was adjusted for 
factors from previous levels only due to collinearity between adherence measures. The final 
multi variable logistic regression model was obtained by excluding each retained factor with the 
highest p-value, one at a time, until all remaining factors had p<0.05. Refugee status, age, and 
time on HAART were retained throughout all modelling. Due to their role as mediators in the 
causal mechanism between distal factors and treatment outcomes, factors were not adjusted for 
adherence in the final model to avoid over-adjustment bias (8). 
Ethical approval 
Ethical approval was received by the Kenya Medical Research Institute (Approval 1884) and 
the London School of Hygiene and Tropical Medicine Research Ethics Committee (Approval 
5547). 
Role of funding source 
UNHCR supported this study and its representatives assisted with study design, interpretation of 
data, and writing of the manuscript, and approved the protocol in advance of data collection. 
The corresponding author had full access to all the study data and took the final decision to 
submit the work for publication. 
RESULTS 
Study population 
Among those eligible, we recruited 73/85 (86%) refugees and 861102 (84%) of the Kenyan 
adults. Among those not participating, nine refugees (75%) declined and 3 (25%) were not 
found, while 6 (38%) host community clients declined and 10 (62%) were not found. The HIV-
positive clients at the Kakuma clinic from the refugee and host communities were similar in 
relation to the proportions of females (67% v. 66%, p=O.91) and median time on HAART (147 
94 
v. 139 weeks, p=0.65). Although not statistically significant, current defaulters were more 
prevalent among the host community (1 % v. 7%, p=0.13). The refugee group was older (median 
age 36y v. 32y. p=O.02). had a median time in the host country of 9.8 years (IQR 4.5, 15.7), and 
median since registration with UNHCR of 8.5 years (lQR 2.8. 14.9) (Table 1). 
[*U Table I, p.l 04, near here U*] 
Virological and adherence outcomes 
U sing a threshold of < I 000 copieslmL to signify viral suppression. 11% (18/159) of surveyed 
clients were virologically suppressed. The proportions suppressing viral load were similarly low 
in both refugee 10% (7n3) and host clients 13% (11/86) (p=O.53). Even after restricting 
analyses to clients who had been on treatment for a minimum of 25 weeks, only 12% (7/59) of 
refugees and II % (8n2) of host community clients had a suppressed viral load (p=O.89) (Table 
2). 
Among all clients, the four-day dose-by-dose adherence recall showed that a high proportion of 
refugee and host clients self-reported optimal adherence over the previous four days (86% vs. 
88%, p=O.92). There was weak evidence for a difference between the groups on adherence to 
Rx (85% v. 74%, p=O.09). The proportions self-reporting optimal adherence on the one-month 
(VAS) were still lower. and a comparatively higher proportion of refugees reported optimal 
adherence (62% v. 28%, p=O.002). Among clients on HAART for ~25 weeks, within each 
group, there was no evidence for ordered trends between proportions not suppressing viral load 
and adherence measured by the four-day recall (p=O.81,p=1.00) and Rx (p=O.74, p=O.91). On 
the V AS, there was strong evidence for a trend (p=O.02) among host nationals but not among 
refugees (p=O.91) (see Supp. Table ii). 
[u* Table 2, p.104 and Table 3, p.105, near here ***] 
Risk factors for unsuppressed virological outcomes 
Unsuppressed viral load was defined as ~1000 copieS/mL. In initial analyses of contextual 
factors (Table 4). there was strong evidence for a protective effect of increasing household size 
(ORadj=O.25. 95%CI 0.10, 0.62; p=O.OO 1). Longer time between HIV diagnosis and HAART 
start (ORadj=2.23. 95%CI 0.83. 5.98; p=0.07) increased the odds of unsuppressed viral load. 
There was no association between lack of viral suppression and refugee status (ORadj=O.70. 
95%CI 0.21. 2.34; p=0.56) after adjusting for age grouP. time on HAART. refugee status. 
household size. and time from HIV diagnosis to HAART start. 
[*U Table 4. p.l06-107. near here ***] 
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Among self-change process factors (Table 5). more reported adherence barriers resulted in more 
protection (ORadj=0.56. 95%CI 0.30. 1.03; p=O.05). Among exposures in the action state level 
(Table 6). there was strong evidence that clients reporting unintentional underdosing 
(determined by comparing self-reported dosing schedules to commonly recommended dosing 
schedules) (9) were more likely to have an unsuppressed viral load (ORadj=7.49. 95%CI 1.02. 
55.33; p=O.03). and weak evidence for a protective effect of perfect self-reported adherence to 
medication schedule (ORldj=O.21. 95%CI 0.02. 1.79; p=O.09). These associations were adjusted 
for age group. time on HAART. refugee status. household size. time from diagnosis to HAART 
start. and number of reported adherence barriers. 
[*** Table 5. p.108 and Table 6. p.109. near here ***] 
The final multi variable model (Table 7) identified strong evidence for a protective effect of 
increasing household size (O~j=0.26. 95%CI 0.11. 0.61; p<o.OO I). There was weak evidence 
for an association between lack of viral suppression and underdosing (ORldj=7.48. 95%CI 0.74. 
27.22; p=O.07). Pharmacy refill schedule was tested in the final model but no association with 
lack of viral suppression was found (ORadj=O.96. 95%CI 0041.2.24; p=O.74). Refugee status 
was not associated with failure to suppress viral load (ORadj=O.64. 95%CI 0.20. 2.08; p=OA6) 
after adjusting for age group. time on HAART. refugee status. and household size. Among 
clients on HAART for 1-3y. 83% were not suppressed. rising to 91% among those on HAART 
for ~3y but no association between increasing time on treatment and outcomes was found 
(ORldj= 1.25. 95%CI 0.59. 2.64; p=O.57). 
[*** Table 7. p.1IO. near here ***] 
DISCUSSION 
Few clients on HAART attending the CCCK achieved viral suppression. a very worrying result 
that is inconsistent with the effectiveness of HAART. There were only minor differences. none 
statistically significant, in terms of pharmacy refill adherence and virological outcomes between 
the refugee and host community groups. Self-reported one-month adherence was worse among 
the host community (p=0.OO2) and at poor levels in both groups. Although virological data are 
unavailable for other non-refugee. conflict-affected groups. good treatment outcomes as 
measured by CD4 gains and survival have been reported (10. 11). In studies of refugees who 
have been resettled. virological outcomes were also good (12-16). In sub-Saharan African HIV 
treatment programmes as a whole. a meta-analysis of 89 studies found that 76% of clients had 
achieved viral suppression after six months. and 67% after 12 months on treatment (17). 
Although viral suppression decreased slightly between 12 and 24 months, suppression remained 
high at 24 months. a finding that was not replicated in the present study setting. However. other 
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studies have found virological failure in the presence of good self-reported and phannacy refill 
adherence (18, 19), a phenomenon that may be due to the sensitivity of virological outcomes to 
the dynamic, time-dependent features of adherence. The adherence outcomes in the refugee 
group were comparable to previously reported data in conflict-affected groups. In northern 
Uganda, 92% of internally-displaced persons (lDPs) achieved optimal adherence (~95%) as 
measured by a composite score including drug possession ratio, pharmacy refill records, and 
three day recall by patients or caregivers (II). In a different Ugandan study, mean self-reported 
adherence among IDPs was 99.5% (2) and in western Equatorial Province, Sudan, 88% of 
refugees and IDPs on HAART for ~6 months self-reported ~95% adherence (20). During active 
conflict in the Democratic Republic of the Congo, 99% of clients were adhering optimally as 
measured by pill counts (1). 
Some potential explanations for the unacceptable levels of viral suppression include: poor 
adherence over time due to daily lapses or irregular medication refills, either not captured by the 
adherence proxy measures or occurring before the retrospective period that was covered by the 
study; poor continuity of care due to interruptions in HAART supply or poor client follow-up; 
accumulation of drug resistant mutations over time due to poor adherence and/or treatment 
interruptions; reduced potency of medications due to quality of medications, storage conditions, 
and/or drug-drug interactions; initial transmission of drug resistant virus; severe malnutrition; 
infrequent viraemia (viral "blips"); and high baseline viral load. 
The adherence findings provided few clues as to the reasons for the low levels of suppression. 
Routine adherence of at least 95% of tablets taken as prescribed is the optimal level required for 
achieving and sustaining viral suppression across common triple-therapy regimens including 
NNRTls (21, 22). There was a clear gap between the proportions not suppressing viral load at a 
threshold of < 1 000 copieS/mL (88% and 89% for refugees and hosts on treatment for ~25 
weeks, respectively) and those self-reporting adherence of <80% of doses by four-day recall 
(8% and 12% among refugees and hosts, respectively), by VAS (14% in each group), and also 
within the pharmacy refill data (7% v. 14%, respectively). The prevalence of optimal self-
reported adherence was much lower according to the self-reported one-month V AS when 
compared to the pharmacy refill measure, suggesting that daily adherence may have been more 
problematic than simply collecting the drugs as prescribed. However, the data did not show any 
independent associations between adherence measures and virological outcomes. Unintentional 
underdosing (discrepancies between self-reported dosing and routine dosing schedules), was a 
weak independent risk factor for unsuppressed viral load in the final model, suggesting that 
some of the result may have been due to confusion in dosing schedules. 
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Intermittent continuity of care such as interruptions in HAART supply or poor client follow-up 
may have led to sub-optimal adherence andlor treatment interruptions. Anecdotal reports of 
prescribing and stocking abnormalities during the transition from stavudine as a routine first-
line drug was suggestive of difficulties that may have contributed to past adherence lapses. Of 
the 13% (201157) of clients who reported an inability to refill their medications in the past three 
months, one-third (7120) reported that the reason was a pharmacy stock-out. The fact that many 
host clients lived considerable distances away from the clinic or lead traditional nomadic 
lifestyles may also have contributed to irregular clinic or pharmacy attendance. However, in 
terms of displacement-related factors, neither travel time to clinic, previous travel in the past 
year, nor refugee status, were associated with virological outcomes. Only 54% of surveyed 
clients indicated that they either rarely or never used specific reminders to assist with daily 
adherence, a result that suggested intervention opportunities by using mobile phones to engage 
clients with adherence support (23). 
The possibility that the poor viral suppression results may have been a consequence of 
underlying resistance patterns was indirectly supported by the lack of independent associations 
between unsuppressed viral load and any measure of adherence in the final model. Non-
nucleoside reverse transcriptase inhibitor (NNRTI) resistance over time appears to be the most 
problematic form of resistance, with mortality rates three times higher than for other regimens 
(24) and the majority (98%) of clients in the present setting received NNRTI-based therapy. it 
was plausible that very high baseline viral loads contributed to the low levels of viral 
suppression. In a previous study, baseline viral loads ~IOO,()()() were shown to lower the 
likelihood of ever achieving viral suppression over the duration of follow-up (25). There is an 
increased likelihood of mortality at these high baseline levels in the presence of poor adherence 
(26, 27). As there had been no previous viral load testing in this population, a baseline measure 
was unavailable. The 36%/year (95% CI 15,45) increase in prevalence of NNRTI resistance 
recently observed in East Africa (28) suggests that resistance was responsible for the high levels 
of viraemia in the present setting. In one rural South African setting, 86% (160/187) of 
virological failures had ~ 1 drug resistance mutations, compromising second-line therapy in 18% 
of clients (29). Thus resistance is on the rise and must be carefully monitored, however, NNRTI 
resistance prevalence in East Africa is still estimated at only 5.1 %, eight years after ART 
rollout, suggesting that this explanation was unlikely in the present setting (28). 
One counter-intuitive finding that emerged from the analysis of risk factors was that increasing 
household numbers protected against poor virological outcomes. Conventional wisdom would 
suggest that adherence might be compromised in crowded living environments due to fear of 
serostatus disclosure (30). By contrast, our findings suggested that larger household sizes may 
have benefitted clients in this context, perhaps through enhanced assistance and support. Half of 
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clients indicated that they received emotional support from family and friends (see Supp. Table 
vii). The extent to which larger households are integrated (e.g. the strength of ties between 
household members), or a greater chance that effective support networks emerge from larger 
households may also be important factors that merit further study. 
This study had important limitations. First, some explanations for the poor outcomes, such as 
drug resistance. drug potency, and malnutrition, were not assessed. Food insecurity was 
assessed but was not associated with the outcome in multi variable analyses. Second, the single 
viral load sample collected invited the possibility that some unsuppressed outcomes were due to 
"viral blips". These fluctuations are caused by random statistical or biological variation around 
mean HIV -levels often as a result of sporadic release of virus from latent reservoirs (31, 32). 
However, given that viral blips usually occur at low levels around the detection limit «400 
copies/mL in the present study), the widespread lack of suppression in the very high ranges 
observed (median=4,840 copieslmL, IQR 1,920-21,100) was a consequence of treatment failure 
or inadequate adherence as opposed to sporadic escape. Moreover, we chose a cut-off of <1000 
copies/mL for the outcome to ensure that small fluctuations around the detection limit would not 
lead to false positives. Third, recall and social desirability biases may have plagued adherence 
measurement. Pharmacy refills are good predictors of treatment outcomes in some settings (33), 
but this measure may not have been sufficiently sensitive to poor daily adherence to serve as a 
good proxy in the present setting (34). Fourth, the cross-sectional design placed limits on the 
study in relation to the attribution of causality and the potential exacerbation of recall biases. 
Lastly, clients who were defaulting for five months or more were considered lost to follow-up. 
Exclusion of these individuals may have introduced survivor bias by overestimating outcomes. 
In relation to generalisability, the comparison group (local host community) was comprised 
primarily of the Turkana, a nomadic-pastoralist ethnic group. Nomadic groups can also be 
expected to face particular adherence challenges in relation to migration and poverty. 
Key study strengths included the high participation rates in both groups, a sampling frame that 
included the entire eligible population and efforts to mitigate recall and social desirability biases 
by conducting face-to-face interviews with trained local researchers. The study also aimed to 
triangulate multiple adherence measurements in an effort to enhance the overall validity of 
findings. 
In summary, the very low proportion of clients who had achieved viral suppression (11% <1000 
copies/mL) is highly concerning and requires immediate remedial programmatic action. 
Importantly, there were no differences observed between refugees and the host community on 
adherence or treatment outcomes. Optimal adherence was not ideal but better than the viral load 
results would predict. Unintentional underdosing by clients, inconsistent maintenance of 
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personal medication supply, poor continuity of care, and occasional daily adherence lapses may 
account for some of the poor clinical outcomes observed. Overall, the severe degree of failure in 
this HAART delivery programme was not fully captured by single or multiple factors. Clinic 
procedures and adherence support have been strengthened by providers since the study by 
enhancing routine follow-up and counselling performed by home-based care staff. These efforts 
will be evaluated by conducting a second round of viral load testing to confirm treatment 
failures and drug resistance testing for those clients. Future work will include a pre-post study to 
verify if these remedial measures were effective. In general, these very poor outcomes serve as a 
stark reminder that programs must regularly evaluate their performance and adapt, if HAART is 
to be scaled-up effectively and universally. 
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TABLES AND FIGURES 
Research in context 
Systematic review 
See Mendelsohn et al. Adherence to highly active antiretroviraltherapy in forcibly displaced populations - a systematic review [if 
published or in print in advance] 
Interpretation 
We report very poor treatment outcomes among both refugees and the local host communities accessing services from a remote 
clinic in Northwestern Kenya. 
Table 1: Baseline sodo-demographlc and treatment factors Interviewed host community (n=86) and 
refugee clients (n=73) 
Factor Host 
Female, n ('lI> ) 57 (66) 
Age In years, median (lQR) 32 (27,38) 
Unemployed, n ('lI» 70 (81) 
Edueational status, n ('lI» 
None 38 (44) 
Any primary 39 (45) 
An y secondary or above 9 (II) 
Marital status, n ('lI» 
Single 47 (55) 
Married/relationship 39 (45) 
Nationality 
Kenyan 86 (100) 
Somali, Ethiopian, Eritrean O( 0) 
Sudanese O( 0) 
Rwandese, Congolese, Burundian O( 0) 
Current deraulters, n ('lI> )1 6( 7) 
Viral load, copleslmL (IQR) 5875 (2120,28500) 
Most recent routine CD4, median celis/pL (lQR)* 308 (192, 439) 
CD4 at HAART prognm start, c:eUs/pLH 198 (119, 289) 
Time on HAART, median weeks (lQR) 139 ( 39,225) 
Time since HIV dlaposls, median weeks (IQR) 182 ( 83,265) 
Time In hOlt country, median weeks (IQR) NA 
Time since refuaee statUi approval, mecllan weeks (IQR) NA 
§ 1-5 consecutive months without pharmacy refill at time of survey interview 
tChi-square test ttMann-Whitney test tttFisher's exact test 
*n,=76, nJS61 **n ,,,,55 , nl"'48 
Rerugee 
49 (67) 
36 (31, 41) 
63 (86) 
28 (38) 
33 (45) 
12 (16) 
44 (60) 
29(40) 
0(0) 
36 (49) 
20 (27) 
17 (23) 
I ( I) 
3580 (1810, 12800) 
254 (141,472) 
196 (136, 320) 
147 ( 38,264) 
212 ( 87,288) 
507 (234, 814) 
440 (143, 774) 
Table 2: Comparison of virological outcomes In host community and refugee clients 
Time on HAART Group ~lOOO c:opieslmL, n Total, n ("') (weeks) ("') 
All Host 75 (87) 86 (100) 
Refugee 66 (90) 73 (100) 
<25 Host II ( 79) 14 (100) 
Refugee 14 (100) 14 (100) 
~25 Host 64 (89) 72 (100) 
Refugee 52 (88) 59 (100) 
tChi-square test ttFisher's exact test 
p-value 
O.91t 
0.02tt 
O.4lt 
O.50t 
O.48tt 
<O.OOlttt 
O.13ttt 
O.l4tt 
0.57tt 
0.28tt 
O.65tt 
0.22tt 
NA 
NA 
,"yalue 
0.53t 
0.22tt 
O.89t 
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Table 3: Adherence In host community and refugee clients 
Adhereac:e measure 
Dose-by-dose self-repon (4 days) 
0+ 
80+ 
95+ 
Visual analogue scale self-report (I month) 
0+ 
80+ 
95+ 
Pharmacy claim adherence (24 months)§ 
0+ 
80+ 
95+ 
Host,n(%) 
(N=86) 
10 (12) 
o ( 0) 
76 (88) 
(N=86) 
12 (14) 
50(58) 
24 (28) 
(N=86) 
12 (14) 
10 (12) 
64 (74) 
Refugee, D (%) 
(N=72) 
6 ( 8) 
4 ( 6) 
62(86) 
(N=73) 
10(14) 
18 (25) 
45 (62) 
(N=73) 
5 ( 7) 
6 ( 8) 
62 (85) 
tchi-square test for trend (Cochran-Annitagc test) §Since stancd on HAART to a maximum of 24 months 
p-vaJuet 
0.92 
0.002 
0.09 
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Table 4: Assodation of contextual factors with unsuppressed viral load among refugees and local host 
community on HAART for ~ZS weeks In Kakuma, Kenya (N=lZS*) 
Factor 
Age group (years)t 
18-
30-
40+ 
Refugee status 
Host 
Refugee 
Time on HAART (years)t 
0-
1-
3+ 
Sex 
Male 
Female 
Travel P-I continuous month In past 
year) 
No 
Yes 
Nationality 
Kenyan 
Somali. Ethiopian. Eritrean 
Sudanese 
Rwandese. Congolese. Burundian 
Household slzet 
I-
s-
9+ 
Living children 
No 
Yes 
Average time to clink: (bours) 
0-
1+ 
Personal Income 
None 
Any income 
Time rrom HIV diagnosis to HAART 
start (weekl)t 
0-
25-
50+ 
HAART rqimen, dOlina 
NVP-bascd. twice-daily 
EFV -based. twice-daily/others 
ADY symptom or slde-ell'ec:t, past 4 weeki 
No 
Yes 
eotrlmoxazole prescription 
No 
Yes 
Rqimea switch, ever 
No 
Yes 
Prevalence ~lOOO 
copleslmL, DIN ('II»t 
28131 (90) 
54163 (86) 
31134 (91) 
63nI (89) 
50157 (88) 
18120 (90) 
34141 (83) 
61/67 (91) 
40/44 (91) 
73/84 (87) 
901102 (88) 
23/26 (89) 
63nI (89) 
27128 (96) 
14118 (78) 
9/11 (82) 
44/45 (98) 
51158 (88) 
18125 (72) 
24125 (96) 
89/103 (86) 
25128 (89) 
881100 (88) 
83/91 (91) 
30137 (81) 
74187 (85) 
13114 (93) 
26/27 (96) 
84197 (87) 
29/31 (94) 
911102 (89) 
22126 (85) 
10111 (91) 
1031117 (88) 
59/69 (86) 
54159 (92) 
p-value. crude odds 
ratio (95 % el) 
p=O.89 
I 
1.05 (0.50. 2.24) 
p=O.86 
I 
0.91 (0.31. 2.67) 
p=O.58 
1.22 (0.60. 2.48) 
p=O.50 
I 
0.66 (0.20. 2.22) 
p=O.97 
I 
1.02 (0.27.3.93) 
p=O.21 
I 
3.43 (0.41. 28.77) 
0.44 ( 0.12. 1.69) 
0.57 ( 0.10. 3.13) 
p=O.OOI 
I 
0.28 (0.12. 0.65) 
p=O.l4 
I 
0.27 (0.03. 2.12) 
p=O.85 
I 
0.88 (0.23. 3.36) 
p=O.12 
I 
0.41 (0.14.1.24) 
p=O.07 
I 
2.16 (0.82. 5.69) 
p=O.27 
I 
2.24 (0.48. 10.55) 
p=O.S3 
I 
0.67 (0.19. 2.29) 
p=O.77 
I 
0.74 (0.09. 6.19) 
p=O.29 
I 
1.83 (0.59. 5.70) 
p-value, adjusted odds 
ratio (95'11> eI)tt 
p=O.66 
I 
1.20 (0.52. 2.77) 
p=O.S6 
I 
0.70 (0.21. 2.34) 
p=O.41 
I 
1.40 (0.64. 3.07) 
p=O.S2 
I 
0.86 (0.23. 3.21) 
p=O.61 
I 
0.67 (0.15. 3.00) 
p=O.33 
I 
2.26 (0.23. 22.12) 
0.47 ( 0.11.2.09) 
0.44 ( 0.07. 2.83) 
p=O.OOI 
I 
0.25 (0.10. 0.62) 
p=O.25 
I 
0.30(0.03.2.93) 
p=O.S3 
I 
0.19 (0.25. 5.65) 
p=O.IS 
I 
0.42 (0.12. 1.48) 
p=O.07 
I 
2.23 (0.83. 5.98) 
p=O.19 
2.78 (0.53. 14.64) 
p=O.45 
I 
0.57 (0.14. 2.35) 
p=O.92 
I 
1.13 (0.09. 13.63) 
p=O.41 
I 
1.69 (0.48. 5.92) 
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Table 4: Association of contextual factors wUh unsuppressed viral load among refugees and local bost 
community on HAART for ~2S weeks In Kakuma. Kenya (N=12S*) 
Factor Prevalence ~lOOO p-value. crude odds p-value. adjusted odds 
copleslmL. DIN (%)t ratio (95% CI) ratio (95% CI)tt 
Unable to renll preseripUon, past 3 
months p=l.00 p=O.95 
No 98/111 (88) 
Yes 15/17(88) 
Food leCurltyt 
Secure 29/32 (91) 
Insecure 84/96 (88) 
Satlsl'acUon with primary health care Mean= 3.66; S&O.05 provider, mean seore** 
-3 clients with incomplete data excluded 
tFactor modelled as a linear effect (common odds ratios presented) 
HUn less otherwise noted 
I I 
1.00 (0.20. 4.85) 0.94 (0.16. 5.59) 
p=O.63 p=O.76 
1 1 
0.72 (0.19. 2.75) 0.80 (0.19. 3.44) 
p=O.38; 0.61 (0.18.2.02) p=O.50; 0.67 (0.19.2.31) 
tttAdjusted for age group. refugee status. time on HAART. household size. time from HN diagnosis to HAART start 
t Item constructed from 3 questions. each measured on a 3-point Likert scale. An endorsement of "some of the time" or .. all of the 
time" on any of the three questions was scored as "insecure" 
Ultem constructed from 2 questions. each measured on a 5-point Likert scale; ascending score was consistent with greater 
satisfaction 
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Table 5: Association of self-change factors with unsuppressed viral load among refugees and local host 
community on HAART for ~2S weeks In Kakuma, Kenya (N=12S*) 
Prevalenc:e ~lOOO p-value, crude odds p-value, adjusted Factor coplesImL, nIN odds ratio (95% 
(%)t ratio (95% CI) CI)tt 
Adbereac:e llelf-emc:acy (lielf-rated abUity to take 
medlc.tloM as prescribed over previous month) p=O.S7 p=O.42 
Excellent/very good 59/68 (87) I I 
GoodIfair/poor/very poor 54160 (90) 1.37 (0.46, 4.11) 1.76 (0.44, 7.02) 
Serostatus disclosure to partner p=O.37 p=O.60 
No 20(25 (80) I I 
Yes 67n5 (89) 2.09 ( 0.62, 7.12) 2.04 ( 0.44,9.40) 
Nopanner 26128 (93) 3.25 (0.57, 18.52) 2.52 (0.31, 20.46) 
Serostatus disclosure to community p=O.37 p:O.16 
No 87/100 (87) I I 
Yes 26128 (93) 1.94 (0.41, 9.17) 3.56 (0.51, 24.77) 
Alcohol use p=O.92 p=O.82 
Never in pasl monlh 99/112 (88) I 
Once or more in pasl monlh 14116 (88) 0.92 (0.19, 4.51) 0.81 (0.13,4.86) 
Use or lIIegaUharmCul substances, past 6 months p=O.86 p=O.69 
No 104/118 (88) I I 
Yes 9/10 (90) 1.21 (0.14, 10.30) 0.60 (0.06, 6.50) 
No, or reported barrlen to adherencet p=O.55 p=O.05 
0 30133 (91) I I 
1+ 31/35 (89) 0.87 (0.54, 1.39) 0.56 (0.30, 1.03) 
3+ 20123 (87) 
5+ 32137 (87) 
KDOwledF or HIV aDd AIDS (% correct or 4 
questions) p=O.78 p=O.62 
0+ 34138 (90) I I 
100+ 79/90 (88) 0.85 (0.25,2.84) 0.70 (0.16,3.02) 
·3 clienls wilh incomplele data excluded 
tFaclor modelled as a linear effecl (common odds ralios presenled) 
tt Adjusled for age group, refugee slalus, lime on HAART, household size, lime from HN diagnosis 10 HAART Slart, and number 
of reported barriers 10 adherence 
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Table 6: Association ofactlon state (adherence) factors with unsuppressed vtralload among refugees 
and local host community on HAART for ~2S weeks In Kakuma, Kenya (N=12S*) 
Prevalence 21000 p-value, crude odds p-value, adjusted Factor odds ratio (95% 
eopleslmL, nIN (%) ratio (95% Cn CI)tt 
Adherence to medication schedule, selC-reported p=O.14 p=O.09 
Less than all of the time 24125 (%) I I 
All of the time 891103 (86) 0.27 (0.03. 2.12) 0.21 (0.02. 1.79) 
Adherence, visual analogue scale seIC-report, past 
month (%) p=O.23 p=O.21 
0- 64170 (91) I I 
95+ 49/58 (85) 0.51 (0.17. 1.53) 0.43 (0.11. 1.63) 
Adherence, dose-by-dose self-report, past 4 days 
(%)t p=O.94 p=O.93 
0- 11112 (92) 1 1 
80- 213 (67) 0.97 (0.38. 2.43) 0.96 (0.35, 2.61) 
95+ 100/1 13 (89) 
All daily dOllH missed, self-report, past 4 days p=O.49 p=O.64 
0 991113 (88) 1 1 
1+ 14/lS (93) 1.98 (0.24. 16.24) 1.68 (0.17. 16.29) 
Adherence, pharllllKY reml schedule, HAART start 
or 14 monthst p=O.91 p=O.74 
0- 13115 (87) I 
80- 14115 (93) 0.96 (0.43. 2.14) 0.86 (0.36. 2.07) 
95+ 86198 (88) 
Treatment Interruptions of ~ days, self-report, past 
6 months p=O.41 p=O.19 
0 88/101 (87) 1 I 
1+ 25127 (93) 1.85 (0.39.8.73) 2.94 (0.51.16.88) 
Unintentional underdosiDa p=O.37 p=O.03 
No 87/100 (87) I I 
Yes 26128 (93) 1.94 (0.41, 9.17) 7.49 (1.02, 55.33) 
• 3 clients with incomplete data ellcluded 
tFactor modelled as a linear effect (single common odds ratio presented) 
ttAdjusted for age group, refugee status, time on HAART. household size. time from HIV diagnosis to HAART start. and number 
of reponed barriers to adherence 
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Table 7: Final multivariate model for factors associated with unsuppressed viral load among refugees 
and local host community on HAART for ~2S weeks In Kakuma, Kenya (N=128*) 
Age group (years)t 
18-
30-
40+ 
Reruaee status 
Hosl 
Refugee 
Fac\ort 
Time on HAART (years)t 
0-
I-
2+ 
Household slzet 
I-
s-
9+ 
Unintentional underdOllng§ 
No 
Yes 
Adherence, pharmacy renO schedule, HAART 
start or 14 monthst§ 
0-
80-
95+ 
'3 clienls wilh incomplele dala e"c1uded 
p-value, 
crude odds ratio (95% CIl 
p=O.89 
I 
1.05 (0.50. 2.24) 
p=O.86 
I 
0.91 (0.31.2.67) 
p=O.58 
I 
1.22 (0.60. 2.48) 
p=O.OOI 
I 
0.28 (0.12, 0.65) 
p=O.37 
I 
1.94 (0.41. 9.17) 
p=O.91 
I 
0.96 (0.43. 2.14) 
tFaclor modelled as a linear effecl (single common odds ralio presenled) 
p-value, 
adjusted odds ratio (95% CI)tt 
p=O.54 
I 
1.30 (0.56. 3.00) 
p=O.46 
I 
0.64 (0.20. 2.08) 
p=O.57 
I 
1.25 (0.59. 264) 
p<o.OOI 
I 
0.26 (0.11. 0.61) 
p=O.07 
I 
7.48 (0.74, 27.22) 
p=O.74 
I 
0.96 (0.41. 2.24) 
ttAdjusled for all factors in table ellcepllhose denoted by §. A priori faclors relained: age group, refugee slalus, time on HAART. 
and adherence 10 pharmacy refill schedule. Factors ellcluded afler two iterations: number of reported barriers 10 adherence; lime 
from HIV diagnosis 10 HAART start 
§Factor not included in the final model process due to presumptive role as medialor; other final model faclors were not adjusled for 
Ihese designated factors 
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SUPPLEMENTARY MATERIAL 
Figure I: Scatterplot ofvtralload (logl0 coples/mL) by time on treatment (weeks) and by refugee 
status 
7 --
6.5 
6 
5.5 
~ • E 
• i 5 -
8 
Q I 4.5 
) 4 
• • 
• 
• 
... .•.. 
• • • • 
Ii ..... 
• • • • • 
• .. __ ._--_._-_ .. .,..._. __ .. _._._._---
• • .. 
............. '. 
• .. . 
• 
• 
• Relu,.o: IOllO(Vl) 
• HO$!: lo,lO(Vl) 
- Rolu .. o: trond line (R'·O.006) 
Relu •• e: polynomial trend (R'.O.ll) 
- Host: trend line (R'.O.OOOl) 
- Host: polynomial trond (R'=O.06) 
• Ira 
• • 
H 
·--::.' ..... n.'-.. ::: ... ~ ___ .&..--..oC~ ___ !-___ . __ 
.~.'.'.".. . • • 
••• 
...... ----..... -.. -~------.. 
• • 
. .. -: •• .1 • • _ .... ___________ _ 
, 
• • • 2.5 _ __I!.... .. ____ .. _~~ __ .. ______ • __ • ____ ~~15Upp,. .... n =de1Ktionlimit· 2.6Io,lOcopies/ml 
2 1 .. 1. .. · ...... · .. · .. · ... ·· .. ·· .... ·_ ........ _, ...... _· .. ··· ...... ·, .... __ .... · .... _ .......... ~-.. -.... -.. -.... -.,-.-.......... -.-~-.. --... - ........ -,.---------··T-·· ........ ---.. - .. ··,--- .... -········ 
o 50 100 150 200 250 300 350 400 450 
TIme on HAART (WHksl 
500 
A scatterplot of viral load (log 10 copies/mL) by time on treatment (see Appendix A, Figure i), 
did not show any evidence of a relationship between viral load and time on treatment in both the 
host community (R2=O.OOOI, p=O.91) and refugee (R2=O.OO6, p=O.47) groups. Fitting a third 
order polynomial curve to the data yielded a slightly stronger relationship between viral load 
and time on treatment for both the host community (R2=O.06) and the refugee groups (R2=O.Il). 
In the refugee group, the V-shaped curve suggested the possibility of some acquired resistance 
to HAART over time. However, the best-fitted polynomial curve for the host population was not 
V-shaped. 
III 
Table I: Virological outcomes by type of adherence measurement, stratified by refugee status 
Adherence measurement ~lOOO copieslmL, n Total p-valuet 
('lI» 
Host 
Dose-by-dose self-repon (4 days) ; n=86 
0+ 9 (90) 10 (100) 0.78 
80+ O( 0) O( 0) 
95+ 66 (87) 76 (100) 
Visual analogue scale self-repon (I month); n=86 
0+ 12 (100) 12 (100) 0.08 
80+ 44 ( 88) 50 (100) 
95+ 19 ( 79) 24 (100) 
Pharmacy claim adherence (24 months) ; n=86 
0+ 10( 83) 12 (100) 0.88 
80+ 10 (100) 10 (100) 
95+ 55 ( 86) 64 (100) 
ReCulee 
Dose-by-dose self-repon (4 days); n=72 
0+ 6 (100) 6 (100) 0.71 
80+ 3 ( 75) 4 (100) 
95+ 56 ( 90) 62 (100) 
Visual analogue scale self-repon (I month); n=73 
0+ JO (100) JO (100) 0.73 
80+ 15 ( 83) 18 (100) 
95+ 41 ( 91) 45 (100) 
Pharmacy claim adherence (24 months); n=73 
0+ 5 (100) 5 (100) 0.70 
80+ 5 ( 83) 6 (100) 
95+ 56 ( 90) 62 (100) 
tChi-squared test for trend (Cochran-Armitage test) 
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Table Ii: Virological outcomes by type ofadherence measurement, stratified by refugee status (~2S 
weeks on treabnent) 
Adherente measurement ~1000 copiesImL, n Total p-valuet 
(%) 
Host 
Dose-by-dose self-report (4 days) ; n=72 
0+ 8 (89) 9 (100) 1.00 
80+ ( 0) O( 0) 
95+ 56 (89) 63 (100) 
Visual analogue scale self-report (I month) ; n=72 
0+ \0 (100) 10 (100) 0.02 
80+ 40 ( 93) 43 (100) 
95+ 14 ( 74) 19 (100) 
Pharmacy claim adherence (24 months) ; n=72 
0+ 10 ( 83) 12 (100) 0.91 
80+ 10 (100) 10 (100) 
95+ 44 ( 88) 50 (100) 
RefUgee 
Dose-by-dose self-report (4 days); n=58 
0+ 4 (100) 4 (100) O.SI 
80+ 2 ( 67) 3 (100) 
95+ 45 ( 88) 5 I (100) 
Visual analogue scale sclf-report (I month); n=59 
0+ 7 (100) 7 (100) 0.91 
SO+ 10 ( 77) 13 (100) 
95+ 35 ( 90) 39 (100) 
Pharmacy claim adherence (24 months); n=59 
0+ 3 (100) 3 (100) 0.74 
SO+ 5 ( 83) 6 (100) 
95+ 44 ( 88) 50 (100) 
tChi-squared test for trend (Cochran-Armitage test) 
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Table Ii: Proportions of clients reporting satisfaction with doctor-patient relationship 
Refugee Host Total 
Thinking about the doctor that prescribes your medication ... 
Not at alII Quite a bill Not at alII Quite a bill Not at alII Quite a bill 
A little Extremely A little Extremely A little Extremely 
... He/she offers the best 1(1%) 85 (99%) 8 (11%) 65 (89%) 9(6%) ISO (94%) 
medical care they can provide 
... He/she puts your health 1(1%) 84 (99%) 8 (11%) 65 (89%) 9(6%) 150 (94%) 
above everything else 
Thlnklugthe provider that you Interad with most often (If not your doctor) ••• 
... He/she offers the best 2 (14%) 12 (86%) 1(6%) 16(94%) 3 (10%) 28 (90%) 
medical care they can provide 
... He/she puts your health 1(7%) 13 (93%) 2 (11%) 15 (89%) 3 (10%) 28 (90%) 
above everything else 
Table III: Proportions of clients reporting on satisfaction clinic and patient autonomy 
Refugee Host Total 
Please tell us how you agree Agree! Uncertain! Agree! Uncertain! Agree! Uncertain! 
with the rollowlng Strongly Disagree! Strongly Disagree! Strongly Disagree! 
statements •.. Strongly Strongly Strongly 
agree disagree agree disagree agree disagree 
... 1 am treated justly and with 
respect during my visits to the 64 (88%) 9(12%) 81 (94%) 5(6%) 145 (91%) 14(9%) 
clinic 
... When I go for medical care. 
they are careful to check 63 (88%) . 9 (12%) 80 (93%) 6(7%) 143 (91%) 15(9%) 
everything when treating and 
examining me 
... Sometimes I wonder if the 
provider's tests and treatments 28 (38%) 45 (62%) 31 (36%) 55 (64%) 59 (37%) 100 (63%) 
are correct 
... 1 was given a choice 
concerning the type of 37 (51%) 36 (49%) 43 (50%) 43 (50%) 80(50%) 79(50%) 
treatment that was prescribed 
to met 
tThe high proportion of clients endorsing this idea may be linked to the validity of the question: clients may have understood the 
question as asking if they believe they are making a choice whether or not to take the medications, as opposed to asking if they felt 
they had a choice of regimens 
Table Iv: Proportions of clients reporting on walt-time, obstacles to refill, and costs 
Refugee Host Total 
No Yes No Yes No Yes 
... Left clinic due to waiting 66(93%) 5 (7%) 77(91%) 8(9%) 143 (92%) 13 (8%) 
time in past three months 
... Unable to refill HAART 
prescription in past three 64(90%) 7 (10%) 73 (85%) 13'<15%) 137 (87%) 20 (13%)* 
months 
... lncur costs related to taking 41 (56%) 32 (44%) 58 (67%) 28 (33%) 99 (63%) 60 (38%) HAARTt 
*7121 (33%) reported reason was stock-out; 6/21 (29%) reported reason was wait time 
t This could be an explanatory factor, but the small sample size placed limitation on sub-group analyses. Costs may have included 
transport or food that clients felt were needed to sustain HAART 
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Table v: Proportions of clients reporting on food Insecurity 
Refugee Host Total 
To what extent are the Not true Sometlmesl Not true Sometlmesl Not true Sometlmesl followlnll statements true ... Often true Often true Often true 
... 1 can't afford to eat properly. \3 (18%) 59 (82%) 17 (20%) 69 (80%) 30(19%) 128 (81%) 
.. .I am often hungry but I don't 
eat because I can't afford 7 (10%) 65 (90%) 5 (6%) 81 (94%) 12 (8%) 146 (92%) 
enough food . 
.. .I eat less than I think I 
should because I don't have 2 (3%) 70 (97%) 1(1%) 85 (99%) 3 (2%) 155( 98%) 
enough money for food . 
.. .I cannot give my child(ren) I 
dependents a balanced meal 2(4%) 55 (96%) g (10%) 74(90%) 10(7%) 129 (93%) 
because I can't afford that. 
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Table vi: Proportions of clients reporting specific barriers to adherence 
Barrier Refugee Host Tola! 
NeverlRarely Sometimes! NeverlRarely Sometimes! NeverlRarely Sometimes! 
Often Often Often 
... Away from home 68 (93%) S (7%) 73 (8S%) 13 (lS%):I: 141 (89%) 18 (11%) 
... Busy with other things 71 (97%) 2(3%) 81 (94%) S(6%) 152(96%) 7 (4%) 
... Simply forgot 67(92%) 6(8%) 85 (99%) 1(1%) 152 (96%) 7 (4%) 
... Have too many pills to take 69 (9S%) 4 (5%) 82 (95%) 4(5%) 151 (95%) 8 (5%) 
... Want to avoid side-effects 71 (97%) 2(3%) 82 (95%) 4 (5%) 153 (96%) 6(4%) 
... Not want others to notice 71 (97%) 2(3%) 80 (93%) 6(7%) 151 (95%) 8 (5%) you taking your meds 
... Fall asleep/slept through 68 (93%) 5 (7%) 82 (95%) 4(5%) 150 (94%) 9(6%) dose time 
... Feel sick or ill 62 (85%) 11 (15%) 82 (9S%) 4(5%) 144 (91%) IS (9%) 
... Feel 59(81%) 14 (l9%)t 82 (9S%) 4(5%) 141 (89%) 18(11%) depressed/overwhelmed 
... Have problems taking pills 66 (90%) 7 (10%) 81 (94%) 5 (6%) 147 (92%) 12(8%) 
at specified times 
I 
... Run out of pills 66 (9O%) 7 (10%) 72 (84%) 14 (16%):1: 138 (87%) 21 (13%)' 
... Detalned or incarcerated by 69 (9S%) 4(5%) 85 (99%) 1(1%) 154 (97%) 5 (3%) 
the authorities 
... Difficulty concentrating 67 (92%) 6(8%) 85 (99%) 1 (1%) 152 (96%) 7(4%) 
... Feeling irritable/angry 60 (82%) 13 (18%) 80(93%) 6(7%) 140 (88%) 19 (l2%) 
... Less interest in daily 66(90%) 7 (10%) 84 (98%) 2(2%) ISO (94%) 9(6%) 
activities 
... Feeling that you have less 67 (92%) 6(8%) 83 (96%) 3 (4%) 150 (94%) 9(6%) 
skills than you had before 
... Having difficulty dealing 66 (90%) 7 (l0%) 82 (95%) 4(5%) 148 (93%) II (7%) 
with new situations 
... Worrying too much about 67 (92%) 6(8%) 82 (95%) 4(5%) 149 (94%) 10 (6%) 
things 
... Feeling hopeless about the 67 (92%) 6(8%) 83 (98%) 2 (2%) 150 (9S%) 8 (5%) 
future 
... Wantto be free of 69 (95%) 4 (S%) 84 (98%) 2 (2%) 153 (96%) 6(4%) 
medicines 
... Financial constraints 56 (77%) 17 (23%)t 81 (94%) 5 (6%) 137 (86%) 22 (l4%)' 
... Other illnesses 58 (79%) 15 (21%)t 84 (98%) 2(2%) 142 (89%) 17(11%) 
... Fell fineJhealthy 65 (89%) 8 (11%) 8S (99%) 1(1%) 150(94%) 9(6%) 
... Decreased quality of life 67 (92%) 6(8%) 84 (98%) 2(2%) lSI (95%) 8 (5%) 
... Uncertainty 64 (89%) 8 (11%) 82 (95%) 4(5%) 146 (92%) 12 (8%) 
... Disruptions/chaotic routine 64 (88%) 9 (12%) 74 (86%) 12 (14%):1: 138 (87%) 21 (13%)' 
tTop three most reponed barriers for refugees 
:j:Top three most reponed barriers for host community 
'Top three most reported barriers overall 
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Table vii: Proportions of clients reporting specific facilitators of adherence 
FadUtator Refugee Host Total 
NeverlRarely Sometimes! NeverlRarely Sometimes! NeverlRarely Sometimes! 
Often Often Often 
... Mcds lake priorily over 14 (19%) 59 (81%) 8 (9%) 78 (91%) 22(14%) J37 (86%) 
subslance or alcohol abuse 
.. .1 have accepled my HIV 
slalUs and learned 10 manage 1(1%) 71 (99%) 1(1%) 85 (99%) 2 (1%) 156 (99%) 
il 
... My HAART gives me good 3 (4%) 69 (96%) 3 (4%) 83 (96%) 6(4%) 152 (96%) 
resulls 
.. .1 undersland why I musl 1(1%) 71 (99%) 3(4%) 83 (96%) 4 (3%) 155 (97%) 
adhere 10 HAART 
.. .1 believe Ihal HAART 3(4%) 70(96%) 6(7%) 80 (93%) 9(6%) 150 (94%) 
works 
... My HAART regimen is 7 (10%) 66(90%) 13 (15%) 73 (85%) 20 (13%) 139 (87%) 
simple 
... My rouline is fixed 20 (27%) 53 (73%) 12 (14%) 74(86%) 32 (20%) 127 (80%) 
.. .1 use reminders like my 47 (65%)t 25 (35%) 39 (45%)* 47 (55%) 86(54%)· 72 (46%) phone alann 
.. .1 live for someone (child. 22 (30%) 51 (70%) 15 (17%) 71 (83%) 37 (23%) 122 (77%) 
spouse. elc.) 
... 1 was pari of Ihe decision 10 12 (16%) 61 (84%) 8 (9%) 78(91%) 20(13%) 139 (87%) 
slart HAART 
... My family and/or friends 51 (70%)t 22 (30%) 38 (45%):1: 47 (55%) 89 (56%)* 69 (44%) 
remind me 10 lake HAART 
... My family and/or friends 41 (56%) 32 (44%) 36 (42%)* 50 (58%) 77 (49%) 82 (52%) 
support me emolionally 
... My family and/or friends 59 (81%)t 14 (19%) 44 (51%)* 42(49%) \03 (65%)* 56(35%) 
support me financially 
.. .1 respecl my doclor and 2(3%) 71 (97%) 0(0%) 86(100%) 2 (1%) 157 (99%) lislen 10 their advice 
... People know I am HIV+ so 27 (37%) 46 (63%) 29 (34%) 57 (66%) 56 (35%) \03 (65%) 
I have nOlhing 10 lose 
.. .Ilrusl in my abilily 10 lake 2 (3%) 70 (97%) 3(4%) 83 (96%) 5 (3%) 153 (97%) 
myHAART 
.. .1 have a brighl future ahead 5 (7%) 68 (93%) 12 (14%) 74(86%) 17 (11%) 142 (89%) 
tTop three leasl reported facilitalors for refugees 
nop three leasl reported facililalors for hosl community 
*Top Ihree leasl reported facililalors overall 
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ABSTRACT 
Refugees may face challenges maintaining adherence to highly active antiretroviral therapy 
(HAART). However, there is little research exploring how such challenges are navigated or how 
they may differ to local host communities or across refugee settings. We therefore sought to 
document refugee and host community accounts of threats, barriers and facilitators related to 
HAART adherence in urban and camp settings. We conducted semi-structured interviews in a 
purposive sample of refugees (n=14) and local host participants (n=ll) in a public, urban clinic 
in Kuala Lumpur, Malaysia (July-September 2010), and similar groups (n=12 and n=6, 
respectively) in a camp-based clinic in Northwestern Kenya (February-March 2011). We used 
framework methods, process-tracing, and between-case comparison to analyse and interpret the 
data, with a view to delineating social factors influencing adherence. Food insecurity, treatment 
delivery insecurity, stigma and discrimination, economic hardship, and lack of social support 
were typically reported barriers, accentuated in the Kenyan camp setting. The urban Malaysian 
accounts shared thematic similarities; however, the resulting treatment outcomes were 
considerably better in this group. We found evidence of resilience among refugees and host 
communities in the face of difficult conditions, and while refugees experienced some unique 
barriers in both settings such as crossing borders and integrating into treatment systems, these 
were seldom linked to treatment interruptions. We drew on levels of influence and the concept 
of "bounded agency" to argue that relative success of individual efforts to transcend social and 
environmental threats to adherence were important determinants of adherence behaviours and 
treatment success. Easing food insecurity, treatment delivery insecurity, and the threat of 
treatment discontinuity for refugees upon arrival in asylum - while bolstering treatment support 
for clients who experience intensive stigma and discrimination, should provide strong 
intervention opportunities. 
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INTRODUCTION 
There is now general agreement that, as a public health and humanitarian issue, forcibly-
displaced and conflict-affected persons who clinically require highly active antiretroviral 
therapy (HAART) for HIV, ought to receive it (The Sphere Project, 2011), although this had not 
always been the case (The Sphere Project, 2004). Assertions have been made about the potential 
consequences of displacement for adherence, often in the absence of empirical evidence 
(UNHCR & Southern African HIV Clinicians Society, 2007). Adherence to HAART is a 
modifiable determinant of HIV treatment outcomes but must be consistently excellent to prevent 
treatment failure and drug resistance (Lima et aI., 2008). Among the few studies of HAART 
adherence among forcibly-displaced populations, encouraging estimates of 87-99.5% were 
reported (Mendelsohn, Schilperoord, Spiegel, & Ross, Submitted). 
Many research models of adherence are premised on a highly "individuated" conception of 
health behaviour (Fisher, Fisher, Amico, & Harman, 2006; Weinstein, 1993). By contrast, 
alternative accounts seek to capture adherence as a product of social condition and action and 
often emphasise an interplay of factors exogenous to individuals that mediate individual-
environment interactions, thereby creating the specific contexts which constrain or enable 
individual decision-making and action (Ewart, 1991; Rhodes, 2002). Advocates of these social 
models of HIV prevention and treatment (Blankenship, Bray, & Merson, 2000; Gupta, 
Parkhurst, Ogden, Aggleton, & Mahal, 2008; Wolfe, Carrieri, & Shepard, 2010) have stressed 
an interplay of macro-level forces (legal, political, and economic), meso-level forces 
(institutional, system, network effects), and micro-level forces (interpersonal relationships and 
social interactions) (Rhodes, Singer, Bourgois, Friedman, & Strathdee, 2(05). Recent discussion 
has specifically called for more focus on social influences in studies of adherence to HAART 
(Castro, 2005; Krusi, Wood, Montaner, & Kerr, 2010; Wolfe et al., 2010). Qualitative research 
is well-positioned in this regard (Pope & Mays, 1995), however, a recent review found that few 
qualitative studies had critically examined the role of social and structural factors in shaping 
adherence (Vervoort, Borleffs, Hoepelman, & Grypdonck, 2007). Of the limited qualitative 
work among internally-displaced groups, social barriers to adherence included travel, insecurity 
in attending clinics, food insecurity, distance to health centres, and inadequate planning for the 
return phase of the displacement cycle (Garang, Odoi, & Kalyango, 2009; Olupot-Olupot et al., 
2008; Wilhelm-Solomon, 2009). 
Among forcibly-displaced groups, refugees are particular in that they have crossed an 
international border, are unable to return to their home country, and have be~n granted an 
internationally-recognised legal status that entitles them to public relief, including health care, 
on an equivalent basis to host nationals. Given this imperative to provide refugees with a 
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locally-acceptable standard of care, our investigation aimed to examine the opportunities and 
limitations afforded by the treatment "system" in which HAART was delivered and the 
comparative experiences of refugee and host community participants within these systems and 
between two different settings. Two recent surveys of refugees and local host communities by 
our research team found a marked difference in outcomes (measured as the proportion with viral 
suppression, defined as <1000 copieslmL) between a camp-based population in Kenya (11 % 
suppressed) and an urban population in Malaysia (91 % suppressed) (Mendelsohn, Schilperoord, 
Spiegel, Burton et aI., In Preparation; Mendelsohn, Spiegel et aI., In Preparation). Drawing on 
participant accounts from these two studies, we sought to consider how social and 
environmental factors may structure threats and barriers to adherence and treatment outcome. 
METHODS 
Research design and case selection 
We adopted a case study approach, selecting an urban public hospital in Kuala Lumpur, 
Malaysia and a refugee camp clinic in Kakuma, Kenya. These settings were different from each 
other in terms of their geography, remoteness, and attributes of the treatment facility (Table 1). 
We hypothesized that any differences in treatment outcomes, if observed, would be related to 
aspects of this contextual variation. 
["'''''''Table I, p.140, near here"'''''''] 
Participants and sampling 
Interview candidates were drawn from a sampling frame of refugee and host community clients 
who had recently participated in a structured survey interview focused on adherence to HAART 
(Mendelsohn, Schilperoord, Spiegel, Burton et aI., In Preparation; Mendelsohn, Spiegel et aI., In 
Preparation). Participants were purposively sampled with respect to sex, refugee status, and 
their self-reported HAART adherence over the past month. The target number of participants 
was 24 in Malaysia and 18 in Kenya. Refugees and sub-optimal adherers were intentionally 
over-sampled. "Refugees" were defined as individuals claiming a statutory designation as 
defined by the Refugee Convention and Protocol (UN General Assembly, 28 July 1951,31 
January 1967). Eligible clients were at least 18 years of age, had been on HAART for at least 30 
days, and were willing to give informed consent. 
Interviews were conducted with 26 refugees and 17 host community clients (N=43). This broke 
down into 12 refugee and 6 local host participants in Kenya, and 14 refugee and 11 local host 
participants in Malaysia (Table 2). The median age of the Kenyan sample was 33 years (IQR 30, 
41) and 61 % were women. In the Malaysian sample, the median age was 34 years (IQR 31,42) 
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and 44% were women. The median self-reported adherence score among the interview 
participants was 86% (IQR 76, 98) in Kenya and 94% (IQR 81. 100) in Malaysia. while the 
proportions who had achieved viral suppression (defined as <1000 copies/mL) were 17% in 
Kenya and 68% in Malaysia among the qualitative study participants. Tables 2 and 3 further 
summarise key characteristics of the participants. 
[***Table 2. p.140. and Table 3. p.141-142, near here***] 
Case study settings 
At the start of the study (April 2010). over 91,985 individuals were registered by UNHCR as 
refugees and asylum seekers in Malaysia. Most had fled the protracted internecine conflict in 
Burma. The Malaysian government has not signed the Refugee Convention; however, the 
Ministry of Health issued a circular in 2006 that permitted refugees to access public health 
services, including HAART. The study recruited both refugee and host study participants 
receiving HAART from Sungai Buloh Hospital. the national reference hospital for HIV located 
on the outskirts of Kuala Lumpur (Malaysia). At the start of the study. there were 315 HIV-
positive refugees registered with UNHCR, 171 of whom were listed as on HAART (98% 
Burmese). The Malaysian host community is composed primarily of Malays, Chinese, and 
Tamils. For host nationals, the national treatment program fully subsidised first-line treatment 
and virological monitoring; second-line treatment was partially subsidised. For refugees, the 
national program fully subsidised first-line fixed-dose treatments but more expensive first and 
second-line drugs (e.g. efavirenz; lopinavir/ritonavir) and virological monitoring are supported 
by UNHCR. Expensive first and second-line drugs were collected form an alternative private 
pharmacy. Financial assistance was provided by UNHCR for travel to the clinic and pharmacy 
to refugees on a case-by-case basis (similar support is not provided to host nationals) . 
. In Kenya, the study recruited refugee and host community clients accessing services at the 
"Comprehensive Care Clinic", Kakuma (CCCK), a clinic managed by a non-governmental 
organisation in Kakuma refugee camp, located in a remote, arid part of Northwestern Kenya. 
When the study started in February 2011, 446,946 refugees were registered by UNHCR in 
Kenya as a whole, and the population of Kakuma refugee camp was 82,409. The Kenyan 
government has signed the Refugee Convention and Protocol and access to first- and second-
line HAART is provided by the national program to all clients who meet national clinical 
eligibility criteria. The local host community is primarily Turkana, a nomadic-pastoralist ethnic 
group. CD4 counts, nutritional support, and counselling services were routinely provided, but 
virological monitoring was not available to either group. Prior to the study period, 389 clients 
had been enrolled since the start of the HAART program in 2004. 
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Interviews 
Data were collected from semi-structured interviews administered by trained interviewers, and 
facilitated by a topic guide translated into local languages, back-translated into English, and 
reconciled with the original English versions by two independent translators. Interviewers were 
trained to probe in-depth when they felt this would yield detailed accounts. Interviews were 
audio-recorded, lasted between 30 and 120 minutes, and were usually conducted in a language 
shared by the interviewer and participant. Where this was not possible, a third-party interpreter 
was used. Interviews were conducted in Kuala Lumpur from July-September 2010 and in 
Kakuma from February-March 2011. 
Analyses 
All the interviews were transcribed verbatim, translated into English, and uploaded into NVivo 
9.2 for coding. The framework method, a systematic process of sorting and charting data 
according to key themes, was employed to analyse the data (Ritchie & Spencer, 1994). 
Between-case comparisons and within-case process-tracing methods that aim to identify causal 
mechanisms, were used to assist with interpretation (George & Bennett, 2005). Coding began 
with an initial scheme and novel themes were allowed to emerge from the data. Sub-themes 
were refined and aggregated into higher-order themes during analyses. In the initial coding 
scheme, we distinguished themes on the basis of social levels of influence in relation to 
adherence (macro, meso, micro) to explore links between environment and individual agency. 
When accounting, participants often evoked barriers to adherence without directly describing an 
actual adherence lapse or interruption. We therefore also attempted to distinguish between 
potential threats to adherence as "imagined future possibilities" (Evans, 2007), barriers that 
were directly linked to reported treatment interruptions, and facilitators of adherence. To this 
end, we sought to uncover the continuum of threats and barriers, and the countervailing 
techniques employed by participants. 
Ethical approval 
Ethical approvals were received from the London School of Hygiene and Tropical Medicine 
(Approval 5547); the Kenya Medical Research Institute (Approval 1884); and the Malaysian 
Medical Research and Ethics Committee and Clinical Research Centre (Approval 3275). All 
participants consented to their anonymous participation, to the audio-recording of their 
interviews, and to the use of their anonymous quotations in reports. Participants' reported names 
are pseUdonyms. Participants were offered refreshments during the interview and a small cash 
incentive was provided to offset travel costs and the approximate cost of one meal. Counselling 
referrals were facilitated upon request. 
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RESULTS 
Analyses of refugee and host community interview accounts (N=43) yielded multiple 
interacting factors risking or precipitating adherence interruptions, clustering thematically as 
follows: crossing borders, integration upon arrival, food insecurity, treatment delivery 
insecurity, stigma and discrimination, economic hardship, social support and resilience. 
Crossing borders 
Adherence threats were reported in some refugees' experiences of crossing borders. For 
example, Keren, a Chin refugee who was originally diagnosed with HIV and treated in Burma, 
eventually sought treatment across the border in India and reported a close call when returning 
home, before she opted to flee Burma for good. 
"My CD4 was about 200 at that time .. .! was questioned by the soldiers at the 
border on my way back home ... Since I was carrying a lot of medicines, I told them 
that I was hospitalized at Lamka [capital of Churachandpur district in Manipur 
state, India] ... When I was asked what sickness I had, I just showed my book 
because there were many others with me being questioned and I do not want those. 
people to know about me ... They asked me how much money I had with me ... their 
senior said there was not enough money and it would not be possible to give [my 
medications] back. I begged them to give me back the medicines telling them that 
the medicines might not be that useful for them while if I did not take the 
medicines I would not be able to live ... They .. .let me go with my medicines bag. 
They also swore to me that...1 would have much more trouble if I went there 
again." (Keren, refugee, Malaysia, 25) 
Similarly, Jeffrey told of a treatment interruption resulting from the crossing of borders in 
search of asylum. 
"I did not come with medication because I fled, but I tried to run away with an 
empty bottle of medication that I used before. I did not even manage to come with 
my treatment record. I think that I stopped for at least one month ... when I went to 
Ethiopia ... they allowed me to pick-up my medication from their clinic ... " (Jeffrey, 
refugee, Kenya, 36) 
Integration upon arrival 
In Malaysia, worry was a pervasive theme in refugee accounts of their early experiences in 
asylum. especially among refugees who had started HAART prior to their arrival. Integration 
into the health system occasionally resulted in "close calls" in relation to treatment continuity, 
but also did not result in any actual reported interruptions. 
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"They [UNHCR] asked me to go to the hospital and collect my HAART 
medication, but the hospital had not received any instructions ... I had to go to 
hospital every day, morning and evening and had to argue ... " (Khun, refugee. 
Malaysia, 31) 
By contrast, Aye described how, on account of perceived bureaucratic obstacles, she delayed re-
engagement with treatment that she had started before displacement. 
" ... they told me that I had to go to Hospital. To go to Hospital was difficult as I did 
not have a [UNHCR] identity card then, so I just prolonged the time due to my 
difficulty and did not go to Hospital. When September/October came I could not 
take it anymore. I was ill and feeling very, very weak." (Aye, refugee, Malaysia, 
33) 
Understanding their new treatment "infrastructure" was problematic and caused some refugees 
to temporarily interrupt their treatment. For example, many participants accessed a portion of 
their HAART regimen from an alternative pharmacy. For some. this led to confusion and 
resulted in treatment interruptions. 
"One kind of tablet was given to me for two weeks only while the other two were 
given for one month ... when the medicine I was given for two weeks was 
finished .. .! did not take it for two [more] weeks." (Maung, refugee, Malaysia, 32) 
Food Insecurity and hunger 
Food insecurity and hunger were identified by many participants as common difficulties often 
underlying other threats and barriers, and echoed by host nationals most intensively in Kenya. 
The feeling that HAART required sustenance in order to tolerate the medication, or that it 
caused an increase in appetite. was typical but most commonly reported among the camp-based 
participants in Kenya . 
..... this medicine is bringing appetite ... so I can eat a lot and sometimes if there is no 
food what are you going to do? If the ration we receive is finished I cannot get 
power or energy." (Sarah, refugee, Kenya, 31) 
For some, food security conCerns were not merely threats to adherence but had resulted in 
a treatment interruption. For example, Leila identified hunger as the main reason why she 
missed her medications for three days, while hunger galvanised Samson to migrate to 
Nairobi in search of employment, which eventually led to a depletion in his personal 
medication stock and a long-term treatment interruption. 
" ... if your stomach is empty the drug will make you dizzy but if you take the drug 
with food it is OK. I did not have food." (Leila, refugee, Kenya, 21) 
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"After I started [HAART] I felt better and I went to Nairobi...when I got ajob I did 
not have anyone here to send me [medications] and I quit for one year. We did not 
have enough food here and we cannot get money." (Samson, refugee, Kenya, 33) 
Concerns relating to food insecurity were also typical among host community participants in the 
Kenyan setting. During the interview of a participant who had been lost to follow-up, he 
initially indicated that he failed to return to the clinic on account of having lost his clinic card. 
Later in the interview, however, his account suggested that hunger had informed his decision to 
halt treatment. 
"It is hunger, hunger [is the reason]. When you take this drug you cannot even go 
to work ... because I feel like falling s~metimes. When I have eaten nothing ... you 
stop [HAART] only to stop for a long period." (Peter, host, Kenya, 30) 
Treatment delivery insecurity 
Refugees in both settings experienced a number of health system threats to adherence linked to 
disrupted provider networks and pharmacy stock-outs. For example, while living in "protection" 
(refugee housing with augmented security), one participant became dependent on a provider 
who subsequently left. This abrupt change in provider arrangements was the source of a threat 
to adherence. 
"When Sid [pseudonym for doctor who no longer works at clinic] was at the clinic, 
I was told to stay there [in protection] ... they will go and pick me up, take blood and 
take me back, but when Sid left all things became problems." (Christine, refugee, 
Kenya, 35) 
Similarly, the interaction of a physical disability with the departure of a treatment supporter 
created a barrier to treatment reported by a refugee participant in Kakuma. 
"There is no medicine that time because the person who used to collect for 
me ... went to Nairobi." (John, physically-disabled refugee, Kenya, 47) 
Meanwhile, limited availability of medication stocks at the pharmacy forced some clients to 
disrupt their refill schedule. For some, this led to treatment interruptions. 
" ... sometimes the HAART I am taking will not be available or maybe the types of 
medicines will be changed .. .! will be given for a week or three days, and I will be 
told to come back after three days to confirm if [my] HAART is available ... [or 
sometimes] they will give me another type in order to wait [for] those which were 
finished ... " (Sarah, refugee, Kenya, 31) 
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Though not commonly reported, we also found evidence of treatment interruptions brought 
about by tensions between traditional and biomedical approaches to treatment. For example, one 
refugee described how he ceased HAART on the advice of a group that claimed to possess a 
cure for HIV. 
"People came with other drugs and said that those drugs can heal 
HIV/AIDS ... when I heard that people are being healed I stopped the treatment 
which I took from the clinic ... they told us to stop the treatment that we have 
received from CCCK [clinic] ... " (Jeffrey, refugee, Kenya, 36) 
StJgmaand discrimination 
Refugees in both settings faced stigma and discrimination of different kinds. In Malaysia, 
refugees described an interplay of threats and barriers to adherence that were linked to arrest or 
fear of arrest on their journeys between their home and the clinic or in search of employment to 
help offset treatment-related costs. 
"Even with the [refugee] card, I was arrested on my way back from Hospital .. .! 
showed them [police] my card but to no avail. They took 30 Ringgit...There is no 
guarantee in our life, anything can happen. [He continues] If I go to the hospital for 
a check up, I have to pay administrative costs every time. I will have to earn the 
costs first. Work is available but I have to be careful where I am going." (Saw, 
refugee, Malaysia, 44) 
In Kenya, stigma and discrimination typically originated from within participants' own families 
and ethnic communities constituting threats for some, but insurmountable obstacles for others, 
especially in the camp setting . 
..... when my family found out that I am HIV-positive, they chased me [out] and I 
was not able to take my drugs .. .I faced problems with my family, that is the reason 
I stopped taking medication, because of stress." (Leila, refugee, Kenya, 21) 
..... if [you] go to fetch water maybe you will quarrel with somebody ... I am getting 
a lot of abusive words in the community, so with all of that you forget to take your 
medicine." (Sarah, refugee, Kenya, 31) 
Stigma and discrimination was often reported in the context of an interplay of systemic factors 
that also included food insecurity, especially in the camp setting. For example, Imara described 
an array of challenges but it was ultimately an armed raid on her home that forced her to 
abandon her medication supply. 
"The biggest challenge that I am going through is the distance from my home to 
where I am supposed to take my HAART ... footing up to that place, sleeping two 
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days on the way, and lack of food at home, insecurity from my place of 
stay ... sometimes raids occur where you have to run away from home and the drugs 
remain back [at home] ..... (Imara, host, Kenya, 18) 
Economic hardship 
Both refugees and host community participants reported economic hardships. Efforts at finding 
employment were often derailed due to a prevailing fear of arrest in Malaysia, while others 
lamented their inability to afford basics like a watch to act as an adherence reminder. 
"We receive financial aid [from the UNHCR] ... We have to struggle to survive. 
When my son arrived, he worked with friends, but as there were many arrests, he 
stopped working." (Shwin, refugee, Malaysia, 39) 
.... .It would be a bit easier [to remember dosing time] if I had an alarm. Now that I 
do not have a small watch and do not know how to buy one, it becomes difficult." 
(Hajima, refugee, Malaysia, 31) 
Social support 
Participants often linked improved adherence and better relations with friends and family to the 
visible benefits of HAART. Perseverance was often linked to the presence of children in the 
family . 
..... my kids are young and if I died, what would the kids do? If the mother has it 
[HIV] and not the father, it wouldn't be so bad, but when both parents have it then 
if they pass away, who will look after the kids?" (Hajima, refugee, Malaysia, 31) 
Moreover, some participants who had disclosed their HIV status to their partners or their 
community reported benefits in the form of moral or financial support and feelings of self-
empowerment. 
"When others know your status you can make consequential decisions as to the 
kind of life you would like to lead." (Samson, refugee, Kenya, 33) 
In turn, improvement in health resulting from good adherence acted as a prominent facilitator of 
continued treatment engagement across all groups. 
"Just imagine when my CD4 went down from 500 to II. I was really very sad 
about this ... At least due to my medication my health has improved. I made a 
determined effort to take my medication regularly." (Shwin, refugee, Malaysia, 39) 
Personal resilience 
Personal resilience and problem-solving skills were commonly mentioned in both settings and 
consisted of a range of "self-help" techniques including "strong will", contingency planning, 
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and the use of medication reminders. Reminders varied widely and consisted of techniques 
rooted in individual and social experience such as phone alarms. linking treatment to regular 
religious activities. and the use of treatment supporters. 
"He Ldoctor] asked me to take Combivir with another medicine which caused my 
body to break out in a rash and get itchy and swollen .. .! was feeling dizzy and was 
burning inside ... but I decided that I would take the medication whether I lived or 
died ... " (Mya Mya. refugee. Malaysia. 29) 
"I never missed or defaulted ... When my medication was half way (15 days) I used 
to start sourcing for medicines ... (Khun. refugee. Malaysia. 31) 
..... what reminds me of my medication time is the morning prayer just before day 
break. I wake up. pray. and then take my medicine ... (Aziza. refugee. Kenya. 46) 
Individuals' resilience was also demonstrated through strategies of coping to navigate perceived 
systemic and social threats to adherence. For instance. in navigating perceived social stigma 
some participants strategically concealed their HIV status while other participants reported 
drawing on their community networks for support. These support networks helped participants 
obviate threats and barriers. 
"Always in the morning they come they gave me tea and mandazi [donuts] ... they 
tell me to take this medicine always ... And one day another mother came to tell me 
we are here [in the refugee camp] 20 years. why are you giving up?" (Samson. 
refugee. Kenya. 33) 
"There was a neighbour who had been in Malaysia about 3 to 4 years. We got a lot 
of help from them since we arrived. They looked for ajob for us and took us to the 
work place ...... Then three of us went to the hospital." (Keren. refugee. Malaysia. 
25) 
DISCUSSION 
Recent estimates indicated that at the end of 2010.6.6 million people or 47% of those eligible. 
were receiving HAART in low- and middle income-countries (UNAIDS, 2011). These numbers 
on HAART are encouraging in a context of global efforts to maximise "universal access" but 
run the risk of obscuring the diversity of treatment experiences in different social settings. 
Noting the deartb of qualitative research describing such experiences especially among refugees 
in asylum settings, we sought to describe the social and environmental factors linked to 
treatment adherence in refugee and host community interviews. We focused specifically on 
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adherence threats and barriers and the limits they placed on agency. as well as on factors 
identified by participants as enabling adherence in spite of constraints. 
Initially. we set out to explore how differences in adherence outcome might be attributable to 
variation in the two settings in relation to national context. remoteness. or treatment delivery 
systems. We envisaged that camp-based refugees would be easier to follow-up within the 
confines of the camp environment. and might therefore have better treatment outcomes. 
However. the camp-based population in Kenya did considerably worse than their urban 
counterparts in Malaysia in quantitative assessments. Following Evans (2007). highly structured 
environments can be associated with reduced capacity for individual agency. wherein 
individuals' "bounded agency" describes situations where experience is influenced but not 
entirely determined by social environments. Our findings supported this framing by uncovering 
extensive accounts of social and environmental threats and barriers. while revealing how 
participants used countervailing strategies towards facilitating their treatment in spite of these 
challenges. Resilience occurs when adverse outcomes are mitigated by effective personal coping 
(Bonanno & Mancini. 2(08). In Kenya. however. it appeared that social and environmental 
factors such as food insecurity. treatment delivery insecurity. stigma and discrimination 
hindered the maintenance of adherence over time. revealing how an interplay among various 
systemic and social factors can lead to adherence lapses or interruptions. 
Refugee status. and linked processes such as border crossings and integration to the treatment 
system upon arrival in asylum were factors of concern in both settings. These incidents. 
however. were experienced as threats more often than as barriers to treatment continuity. 
Although not emerging directly from participant accounts. differences between the Kenyan and 
Malaysian national contexts were important insofar as they helped to condition the systemic 
factors experienced by participants and their ability to overcome them. Moreover. many threats 
and barriers experienced by refugees in either setting were also shared by host communities. 
highlighting the importance of local context for adherence. 
Importantly. camp-based participants in Kenya reported intensive food insecurity. In previous 
studies. food insecurity had adverse effects on adherence (Franke et aI .• 2011). morbidity. 
patterns of healthcare utilisation (Weiser et al .• 2012). and virological outcomes. lowering them 
by as much as 77% (Weiser et al., 2009). Previous studies have identified a number of 
mechanisms linking food insecurity to non-adherence or treatment interruptions (Weiser et al.. 
2010). The links between hunger. food insecurity. and adherence suggested that this challenge 
has the potential to contribute to frequent and/or longer duration treatment interruptions over 
time. 
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The disruptions in provider support networks reported in the camp clinic in Kenya echoed 
findings from South Africa (Nachega et al .• 2006) and conflict-affected Uganda (Wilhelm-
Solomon. 2009). In the present study. reported disruptions of support networks were usually 
related to HIV -related stigma and discrimination or the departure of treatment supporters. as 
opposed to disruptions in personal support networks resulting from original episodes of forced 
displacement (UNHCR & Southern African HIV Clinicians Society. 2(07). Refugees in both 
settings elaborated how their social support networks were important for assisting them with 
medication collection and daily adherence. but were sometimes contingent on the visible and 
public success of treatment. However. consistent with the deep cultural embeddedness of HIV-
related stigma in sub-Saharan Africa (Mbonu. van den Borne. & De Vries. 2009) and Kenya in 
particular (lzugbara & Wekesa. 2011). the stigma and abuse experienced by many participants 
in the camp setting was intensive. often overwhelming positive support networks and individual 
resi lience. 
Refugees reported "close calls" in relation to their adherence during and immediately after 
cross-border displacement. However. there were few reports linking these experiences to actual 
treatment interruptions. suggesting that many participants remained resilient during these 
periods of disruption. In Malaysia. refugees faced the threat of confrontation with law 
enforcement. especially during their lengthy transit times to the clinic. Discrimination was 
therefore situated within these overlapping landscapes of health care and law enforcement, and 
conditioned on the contested role of immigration in society. Given the harmful consequences of 
intentional treatment holidays or unstructured interruptions (Li et al.. 2005; Oyugi et aI .• 2007; 
Parienti et al .• 2004). awareness of the dynamics of cross-border displacement. integration into 
treatment systems and local travel away from treatment centres. are critical for managing 
treatment for newly arrived refugees. or for assisting refugee and host community clients with 
contingency arrangements. 
Validity, relevance, and future research 
One limitation of this study was the need for translation of the interviews. To minimize this. 
experienced translators were used and regularly debriefings were conducted with interviewers in 
order to gain their interpretations of participant accounts independent from translations. 
Furthennore. we experienced challenges in fully interviewing until saturation given the high 
levels of ethnic diversity in the refugee and local populations. Nonetheless. purposive sampling 
attempted to represent as many members of each community as possible. 
The relevance of this work was enhanced by producing new knowledge through an approach 
that leveraged within and between-case analyses of two distinct groups (refugees and host 
communities). in two common refugee environments (urban and camp). and in two different 
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geographical locations (East Africa and Southeast Asia). Given the dearth of qualitative 
research focusing on how refugee ell.periences shape treatment adherence. further study is 
needed to delineate the relationships between the processes of refugee experience and systems 
of HIV treatment delivery. 
CONCLUSION 
Prior to this work. no previous qualitative data of refugee experiences on HAART were 
available. Rather than envisaging adherence as primarily a product of individual decision-
making. we considered it in relation to a "bounded agency" where individual behaviours are 
influenced but not entirely determined by social context. We found that. while both refugee and 
host community participants faced systemic threats to adherence. most were able to navigate 
these obstacles through resilient coping strategies. We also outlined the constraining effects of 
settings upon agency. which helped to explain variation in treatment outcome. We therefore 
argue that relative differences in the success of individual efforts to transcend social and 
environmental threats and barriers to adherence were important determinants of adherence and 
treatment success in the study settings. These factors in the Kenyan refugee camp setting proved 
to be more extensive and difficult to overcome and ought to be urgently addressed to ensure that 
the clinical and public health benefits of HAART are realised. Overall, interventions are needed 
that will reduce systemic barriers linked to food insecurity. treatment delivery insecurity. stigma 
and discrimination. treatment discontinuity for refugees upon their arrival in asylum. and to 
bolster personal resilience through treatment support for high risk individuals, such as those 
experiencing intensive stigma and discrimination. In scaling-up HAART or transitioning to a 
treatment-as-prevention strategy in challenging settings. social and environmental threats and 
barriers should be critically assessed in all programmatic stages including planning. initiation. 
and maintenance. 
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SUPPLEMEiARY MATERIAL 
igur i and Tabl j highlight th range of thematic overlap among refugee and host 
communil partl Ipant and between participants in the different field settings based on initial 
oding. 
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congruency between clients groups and settings (Legend for Figure 2) 
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Box: SUMMARY POINTS 
.Refuaea and host ~munilies achieve 5imilar oulcomes where services arc equitable 
• Acceptable 0Ul~ arc IIChievable in a ranle of Rllinls Rrvinl refulces and local hosl communities 
-Trianaulatina muhiplc indlcalon for routine adherence monitorinl will help improve monitoring and treatment outcomes in these 
POUJII 
-Future wort amon, refllaea and local host communillcs should focus on strengthening adherence monitoring and implementing 
Iow-c:ost. evidencc-bued IUpport interventions 
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BACKGROUND 
Desperate to secure antiretroviral therapy (ART) that she could not access in her native Chin 
State. Burma. Ning (alias) and her husband crossed the border to Manipur State. India. and 
travelled onwards in search of medicine. After finding a clinic willing to provide her with 
treatment and seeing her husband detained by police, she set off for home only to have her 
ARTs confiscated by officials at the India-Burma border. After borrowing bribe money from a 
local merchant. Ning successfully pleaded with the officials to return her medication, but was 
warned never to return. Unable to afford ARTs in Burma, she later became one of 10.6 million 
global refugees who reside in asylum countries [I]. ARTs can achieve HIV viral suppression 
provided optimal levels of adherence (~95% of doses taken on time) can be sustained long-term 
(2). Globally. less than two-thirds of ART clients report ~90% adherence [3]. Refugees share 
adherence barriers in common with other groups, while facing the threat of additional barriers 
unique to their social and environmental contexts [4,5,6]. This policy forum describes recent 
issues in relation to HIV treatment and care for refugees and makes recommendations for 
ensuring that refugees and their host community counterparts initiate treatment in a timely way 
and sustain optimal adherence and treatment outcomes. 
Refu,ee5. health care, and the policy environment 
The humanitarian and public health communities have debated the merits of ART provision 
among conflict-affected populations, echoing earlier discussions on the wisdom of rapid scale-
up in resource-limited settings [7,8]. Four key arguments may be advanced in favour of 
providing refugees with access to ARTs. First, principles of fairness ought to govern decisions 
when faced with scarcity [9,10]. Second, from a public health perspective, the evidence of 
clinical benefit. reduced transmission. and cost-effectiveness argue for expanding access to 
ARTs for all individuals in need. regardless of their nationality [11.12,13]. Third, the right to 
health including access to essential medicines is codified in international human rights law and 
supports provision of ARTs as a life-saving, non-optional intervention for HIV -positive persons, 
including refugees [14,15.16]. Finally, international humanitarian law includes the requirement 
for host countries to provide refugees with a standard of medical care equivalent to that 
routinely available to host nationals [17]. 
However, countries do not uniformly provide access to ART for refugees [18], and where ART 
is provided, there may be financial obstacles to providing the monitoring and support that is 
necessary for optimising treatment outcomes. This deficit often originates at the level of the 
National Strategic Plan (NSP) and is reflected in proposals to the Global Fund. In 33 African 
countries with ~ I 0,000 refugees, 48% of NSPs failed to mention refugees, while only 21 % 
referenced refugees in conjunction with explicit activities. Similarly, in 30 African Global Fund 
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proposals from rounds 1-8, 47% failed to mention refugees at all, while only II % referenced 
specific activities for refugees [19). In Asian countries, 45% of NSPs explicitly mentioned 
refugees, while only 18% spelled out specific activities for them. Positive developments in Asia 
have included improvement in access to key HIV services and equitable ART program coverage 
for refugees in all countries hosting ~ I 0,000 that routinely offer treatment to host communities 
[20]. The low proportion of NSPs that include specific activities for refugees may place them 
lower on the agenda when it comes to drafting Global Fund proposals. 
Evidence on adherence and treatment outcomes 
Refugees are found in specific refugee camps, or are dispersed in rural or urban settings, with 
trends towards more urbanisation, increased life expectancies, and increased prevalence of 
chronic non-communicable conditions [6). A recent systematic review revealed a scarcity of 
data on adherence to ART and treatment outcomes comparing refugees and their host 
communities in different settings [21). Acceptable outcomes were reported among refugees in 
high-income countries, but delayed treatment initiation occurred [22,23,24,25). High levels of 
adherence, good survival probabilities, and the expected associations between poor adherence 
and mortality were found among lOPs [26,27]. Studies among mixed lOP/refugee and other 
conflict-affected groups also reported acceptable levels of adherence, positive CD4 gains, and 
good survival probabilities [28,29,30,31,32]. No differences between groups were found in 
comparisons between refugees or other conflict-affected groups and local communities 
[22,25,26). Less encouraging findings came from western Kenya, where 16% of clients reported 
a treatment interruption during the period of post-election violence (PEY) in 2008, compared 
with 10% in the comparison period [33] and increased mortality in HIV-positive lOPs when 
compared with mortality prior to PEY in the same catchment area [34]. Overall, no studies were 
found that compared refugees and host communities on adherence indicators and treatment 
outcomes in asylum settings. 
In response, we conducted cross-sectional studies in urban and camp-based settings where HIV-
positive refugees and host population were accessing HIV services from shared clinics. In an 
urban setting (Kuala Lumpur, Malaysia), similar proportions of refugee and host community 
groups on treatment for~25 weeks had achieved viral suppression (81% v. 84%,p=O.54) while 
proportions optimally adhering to treatment were also similar according to the pharmacy's refill 
records (74% v. 66%,p=O.15) and self-reported one-month recall (72% v. 70%,p=O.79) [35]. 
By contrast, in a camp-based setting (Kakuma, Kenya) we found that very few refugee or host 
clients who had been on treatment for ~25 weeks had a suppressed viral load (12% v. 11 %, 
p=O.89) despite acceptable pharmacy-based adherence estimates (85% v. 74%, p=O.09) and in 
the presence of low levels of self-reported optimal adherence (62% v. 28%, p=O.OO2) [36]. At 
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first glance. this discrepancy was counterintuitive but not unique [37.38] and interpretable in the 
context of treatment outcomes that are sensitive to long-term adherence dynamics that are 
difficult to capture in cross-sectional studies [39]. Refugee status itself was not independently 
associated with virological outcomes in either setting. In the urban setting. men and clients who 
had suboptimal adherence to pharmacy refills, clients who had temporarily migrated for ~ 1 
month in the past year. had shorter times between diagnosis and treatment initiation and those 
experiencing longer transit times to clinic were less likely to have a suppressed viral load. In the 
camp setting, there was weak evidence for a harmful effect of suboptimal dosing (measured by 
comparing self-reported dosing with recommended guidelines) and good evidence for a 
protective effect of larger household sizes. Parallel qualitative interviews with clients drew 
attention to the impacts on adherence of crossing borders, integration into the treatment system 
upon arrival in asylum. food insecurity and hunger. treatment delivery insecurity, economic 
hardship. stigma and discrimination, social support and the notion that personal resilience may 
be overwhelmed by extensive social and environmental barriers present in local contexts. 
Imponantly. many studies among forcibly displaced populations on ARTs have been conducted 
among relatively stable refugee groups attending HIV clinics after periods of acute instability 
and displacement. Very few (if any) studies have examined the barriers to adherence 
experienced during displacement. when treatment has already been initiated. If sufficient 
medication supplies are obtained prior to transit. the period of displacement is short, and ARTs 
are made available quickly in asylum. then the threat of treatment interruptions resulting from 
personal stock-outs will be reduced and the greatest threat to adherence will be retaining 
sufficient supplies of medication and sustaining daily adherence. Yet. when one or more of 
these three conditions do not occur. there may be a greater risk of poor treatment outcomes, as 
was found in the studies of PEV in Kenya where displaced people on treatment appeared to 
have significant problems during the actual period of instability. Responding rapidly to 
treatment interruptions is critical as longer interruptions and lower "coverage times" (proportion 
of time with sufficient drug concentrations) have been associated with increased odds of having 
a detectable viral load [40]. 
These results suggest that refugees can achieve excellent outcomes if they are provided with 
consistent access to ARTs and effective support. In some settings. both refugees and host 
communities may experience the same barriers that may result in inferior outcomes. However. 
when in stable settings. refugees do as well (or as badly) as host communities. These findings 
echo previous work that reponed successful treatment outcomes among the very poor in settings 
where structural barriers were properly addressed and minimised [41]. Policy for forcibly 
displaced and conflict-affected people is now catching up. A recent update to the Sphere 
Handbook, the most widely accepted guidelines for humanitarian assistance. recommended 
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provision of ART to these groups. in a change from the previous view that ART was not 
feasible in such settings [42,43.44]. The public health benefits of ART provision cannot be 
realised without sustained access. monitoring. and support. To this end. the challenge for 
donors. implementers and host countries is how to simultaneously increase access and effective 
support. In short. how can we secure the best possible outcomes? 
RECOMMENDATIONS 
For the clinical and public health benefits of HAART to be realised. it is essential to expand 
access to ARTs for all clients meeting national guidelines for when to start treatment. Host 
countries should include refugees in their NSPs and Global Fund proposals and detail specific 
results-oriented activities with them. By engaging in partnerships with humanitarian 
organisations through commitments to expand access to ARTs. forward looking host countries 
will be in a position to leverage funding for the benefit of refugees and host nationals. 
particularly in rural and underserviced areas. Expanding access requires continued scale-up of 
HIV testing and counselling (HTC) among refugees so that those who are unaware of their 
status are given a chance to initiate ART at the optimal time [45]. This will save lives and costs 
through better survival outcomes and reduced transmission [11,46,47]. Some countries are 
reluctant to provide HAART to illegal migrants. economic migrants and even asylum seekers. 
fearing additional costs or that starting them on HAART will make it difficult to expel them. 
However. international humanitarian law clearly entitles refugees to the routine standard of 
medical care available to the host population in the asylum country. The global population of 
14.7 million IDPs [I] share similar entitlements to protection and standards of care as refugees. 
It is therefore important that NSPs and Global Fund proposals are explicit in which types of 
migrant are or are not entitled to HAART and which agencies will be responsible [48,49]. 
Refugees have been forcibly displaced and may travel again for purposes of repatriation. 
resettlement. or family reunion. Similarly. host community members are mobile when seeking 
employment. visiting family. or when living a traditional nomadic lifestyle. Both groups may 
experience unstructured treatment interruptions that have been sho~n to increase the risk of 
death. opponunistic infections virological failure. development of drug resistance. while 
slowing immunological recovery [50]. Therefore. preparing for onwards movement and 
implementing best practices for managing continuation or re-initiation of treatment for new 
arrivals in a program is essential to the continuity and sustainability of ART in any group [51]. 
For refugees. this will require active responses in all phases of the displacement cycle where 
ART is accessed [52.53]. Distance to clinic and associated transportation costs are also crucial 
as longer travel times or higher costs may increase the chance of treatment interruptions 
[33.54.55.56]. In response. efforts to minimise costs and bridge distances have been helpful 
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[27.57]. and provide valuable lessons for refugee settings. Refugees in urban settings also 
require freedom of movement without fear of arrest or detention when travelling for routine 
appointments or medication refills. To this end. awareness interventions within the police and 
other law enforcement institutions of the rights accorded to refugees. IDPs and asylum-seekers 
is an urgent step for host countries to undertake [58]. 
As our recent findings from Kenya demonstrated and others have pointed out [59]. there are 
dangers in providing ART in under-resourced settings. yet few would argue that this is a reason 
to limit access. Inferior outcomes should serve as a call to fix programs that are not achieving 
acceptable results. At the implementation level. adherence monitoring and support are crucial 
for achieving optimal. consistent treatment outcomes. The feasibility of delivering ART in 
unstable settings has been demonstrated in relatively well-resourced programs. In the absence of 
expensive laboratory support and motorcycle-equipped treatment monitors. a basic package of 
support and monitoring can be effective [60]. To this end. thorough adherence monitoring 
should be implemented in all refugee settings as a minimum indicator [27,61] including 
pharmacy-based adherence measures and client self-reports as has been recommended for low-
income settings [62). Self-reported measures are feasible, have been significantly associated 
with virological outcomes in most studies [63], and encourage client self-assessment while 
usefully revealing adherence patterns. Pharmacy-based measures are objective, have been 
strongly associated with virological outcomes in most studies [64], and are better than CD4 
changes at predicting virological outcomes in the first 12 months of treatment [65]. 
Triangulating multiple indicators for routine adherence monitoring will help to promote valid 
monitoring by overcoming the limitations of any single measure. Supporting routine adherence 
monitoring with integrated electronic medical and pharmacy records, where feasible, will be an 
important tool for optimising treatment outcomes. Although adherence intervention trials have 
typically shown small and transitory effects [66], proven support interventions such as mobile 
phone text messaging [67]. enhanced counselling [68] and peer-support [69] ought to be 
implemented and evaluated at the clinic level. Operational research among refugees and host 
communities should aim to assess the acceptability and effectiveness of low-cost adherence 
support interventions. With a few exceptions [70,71]. most research on adherence and treatment 
outcomes in conflict-affecte~ populations has focused on adults. highlighting a need for studies 
focused on young people. Further recommendations may be found in Table 1-3. 
[*** Table 1. p.154-1 55. Table 2. p.156, near here ***] 
In summary. equitable and acceptable HIV treatment outcomes have been shown to be 
achievable in a range of challenging settings serving forcibly displaced clients including . 
refugees. Refugees have a right to equal access to HIV treatment based on principles of fairness 
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and human rights. in addition to the individual and population-based public health benefits. 
Since HlV-positive individuals on HAART with good adherence will rarely transmit HIV to 
their sexual partners [11 J. it is also in the enlightened self-interest of host country governments 
to support HIV programs that serve HIV -positive refugees and host clients equally and to a high 
standard. Since an average refugee spends 17 years in asylum [52], there is an obvious public 
health and humanitarian interest in guaranteeing access to ART and promoting optimal 
adherence among this group. 
Table 1: Key recommendations for providers and Implementers 
Theme Recommendation 
Access 
Adherence 
Pharmacy 
Provide treatment on an equitable basis to refugees and local host 
communities, leveraging national and international resources to achieve 
good treatment outcomes and reduced transmission of HIV. 
Upgrade community health and counselling teams to ensure uninterrupted 
personal HAART supply, rigorous progress monitoring, and optimal 
adherence. 
Consider providing small personal grants to subsidise transport and meals 
for a monthly clinic trip for medication pick-up or doctor's appointment. 
Given that refugee counsellors are often refugees themselves. each 
counsellor should partner with a back-up counsellor such that if the 
primary counsellor goes on leave or is resettled their duties to specific 
clients are effectively handed over. 
Where appropriate. counsellors should deliver medication directly to 
clients who are disabled. or who do not regularly attend the clinic due to 
stigma, prohibitive costs, or other reasons. 
Consider pilot-testing a mobile phone SMS intervention to facilitate daily 
adherence reminders and monthly medication refill reminders. especially 
for clients at higher risk of erratic adherence. 
Monitor gender and other sub-group differences in adherence and 
treatment outcomes. to ensure services are distributed consistently and 
equitably. 
Where feasible. encourage clients to join support groups, so they may 
benefit from support in rel,ation to ensuring consistent pharmacy claims 
and mitigating local adherence challenges as they arise. 
Consider using small personal grants to subsidise transport and meals for a 
mOnthly or bi-monthly clinic trip for medication pick-up or doctor 
appointment. 
Assess future travel plans at regular nursing or refill appointments and 
conduct risk assessments for clients who travel for any reason. Provide 
contingency plans and emergency hotlines. Partnerships among 
pharmacies in major centres might facilitate access in the event that an 
emergency prescription refill is required. 
Install or upgrade the electronic medical record (EMR) such that 
pharmacy records are linked to the main medical record and adherence 
data may be easily extracted so that clients who begin to default from 
clinic appointments or pharmacy refills are identified and traced by home-
based care workers. Remove any existing barriers between medical and 
pharmacy records. 
Manage changes in treatment guidelines such that a transitional overlap is 
allowed between the discontinuation of old regimens and the 
implementation of new ones. In this period. consider purchasing both 
regimens to avoid situations where stock-outs or the threat of stock-outs 
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Table 1: Key recommendations for providers and implementers 
Theme 
Training and turnover 
Food security 
Operational research 
Recommendation 
leads to forced alteration of client pick-up schedules and treatment 
interruptions. 
Implement routine adherence monitoring using a combination of a 
counsellor-administered or self-administered self-report using a visual 
analogue instrument. pharmacy refill measures (where feasible), and 
feedback results to providers and clients. The system should be rights-
based (voluntary consent required for participation). 
Consider issuing extended supplies of HAART for those who live far from 
the hospital, have difficulty attending, and are otherwise in good health. 
Distribute HAART through partnerships with a single provider where 
possible. 
Ensure that medications are disbursed with clear prescription guidelines 
that may be understood across multiple languages and cross-culturally. 
Ideally this should be provided in writing as well as verbally. Pictorial 
instructions illustrating dose times and tablet numbers may be helpful. 
Consider formal training of designated nursing and/or home-based care 
staff in adherence counselling. 
Implement appropriate plans to manage staff turnover, which occurs often 
in humanitarian and fragile settings. 
Evaluate food security. Where supplementary rations are provided. 
consider adjusting them based on the total number of household members 
(clients who live in group settings may be expected to share their 
supplementary rations across the household leading to shortages and food 
insecurity). 
Support operational research assessing adherence and treatment outcomes 
over time. 
Pilot-test interventions such as enhanced face-to-face counselling and 
mobile-phone based communications that support adherence and solicit 
feedback from clients. 
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Table Z: Key recommendations for host country Ministries of Health and donors 
Theme 
Access 
National Strategic Plans 
(NSPs) and Global Fund 
Funding 
Recommendation 
Expand HIV treatment and scale-up treatment support on an equitable 
basis to refugees and local host communities. 
Provide awareness to the police and other law enforcement institutions of 
the rights accorded to refugees and other displaced persons to ensure that 
access to medical care is not interrupted. 
Include refugees in national strategic plans and Global Fund proposals 
with specific activities noted for them. 
Distinguish between different types of displaced groups in NSPs and 
Global Fund proposals. 
Formalize responsibilities for refugees in NSPs, identifying all 
stakeholders with national governments and Ministries of Health, and non-
governmental actors including UNHCR and implementing partner non-
governmental organisations. 
Leverage national and international resources to achieve good treatment 
outcomes and reduced transmission of HIV among both refugee and host 
community groups. 
Fund enhanced community health and counselling teams and adherence 
interventions to ensure uninterrupted personal HAART supply, rigorous 
progress monitoring and optimal adherence. 
Fund and support the development and implementation of routine 
adherence monitoring systems. 
Fund an intensive package of adherence interventions for groups at high 
risk of sub-optimaJ adherence and/or loss to follow-up. 
Manage changes in treatment guidelines such that transitions do not lead 
to stock-outs or the threat of stock-outs. 
Consider augmented training for designated nursing and home-based care 
staff in adherence counselling. 
Support operational research assessing adherence and treatment outcomes 
over time, acceptability and effectiveness of low-cost adherence support. 
such as mobile-phone based interventions. 
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LU IONS 
Prior I thl work, v ry fe\! ' ludie had b en conducted among conflict-affected and forcibly 
di pIa ed gr up . Thoe thai had been done uggested that consistent adherence to HAART and 
a ept:lble treatm nt ut ome ' were po ible. All tudies of internally-displaced persons (IDPs) 
,er e ndu ted 10 r ouree-limited ettings. However, most studies of refugees were conducted 
am ng tho claiming a ylum or re ettled to high-income countries. Only one study compared 
ul me am ng r fug e in a ylum and local host communities but this study limited its 
companon to elf-rep rt d adherence [1]. Therefore, the primary aim of this thesis was to 
a and e mpare 11 RT adherence and treatment outcomes among refugees and host 
c mmuOlU' attending the am HIV treatment clinic in one urban setting in Southeast Asia 
(Kuala Lumpur, ala ia, Paper Two) and one camp setting in rural East Africa (Kakuma, 
K n a, Paper Tlrrt!e). c ndaryobjective ought to explore factors associated with viral 
~upprl! i n in 3ch tudy elling, to under land client perspectives on sustaining adherence over 
lim. nnd on Ih ba 'i of lh 'e finding, to make recommendations for policy. From these aims, 
f ur re · arch que lion .. er propo ed. Table I links the research questions to the sub-study, 
the i · paper. and meth d ' employed. 
Thesis paper(s) Method(s) 
Paper Two (Malaysia) Structured questionnaire on adherence 
Paper Three (Kenya) Phannacy refill adherence 
Viral load 
2 Paper Two (Malaysia) Structured questionnaire on adherence 
Paper Three (Kenya) Phannacy refill adherence 
Viral load 
3 Paper Four (Kenya and Malaysia) Semi-structured mterviews 
4 Paper Five (Kenyu and Malay.ia) All data collected 
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SUMMARY OF FINDINGS 
Do refulees adhere to treatment and achieve viral suppression while In asylum at levels that 
are comparable to local host communities? 
The initial hypothesis was that refugees would adhere to prescribed regimens and achieve viral 
suppression. but at lower levels than the local host community. In both study settings, there 
were no differences between groups in the proportions virologically suppressed and very few 
differences between the groups in levels of adherence to HAART. In the urban, Southeast Asian 
setting (Kuala Lumpur, Malaysia, Paper Two), similar proportions of refugee and host 
community groups on treatment for~25 weeks achieved viral suppression (81% v. 84%, 
p=O.54) while proportions optimally adhering to treatment were also not statistically 
significantly different according to pharmacy refill records (74% vs. 66%, p=O.15) and self-
reponed one-month recall (72% v. 70%, p=O.79). By contrast, in the camp-based setting in East 
Africa (Kakuma, Kenya, Paptr Three) we found that very few refugee or host clients who had 
been on treatment for ~25 weeks had a suppressed viral load (12% v. 11 %, p=O.89). This was 
despite acceptable pharmacy-based adherence estimates (85% v. 74%, p=O.09) and in the 
presence of low levels of self-reponed optimal adherence, which were poor in both groups but 
significantly worse in hosts (62% v. 28%, p=O.OO2). In multi variable analyses, refugee status 
itself was not independently associated with virological outcomes in either setting. In contrast to 
the Malaysian setting, the very poor Kenyan outcomes' were stark and surprising in light of the 
presumption that, since refugees in camp settings may be viewed as ,icaptive audiences", 
management of their treatment ought to have been easier relative to those living in urban areas. 
Proportions optimally adhering to pharmacy refill were not ideal in this setting, however self-
reponed one-month recall findings were clearly low, especially so among the host community. 
When taken together with the moderate proponions of clients who were collecting their 
prescriptions refills in an optimal manner, these findings were indicative of routine adherence 
difficulties. However. each measure alone was not independently associated with lack of viral 
suppression. The proponions of unsuppressed virological outcomes that were not explained by 
sub-optimal adherence echoed previous studies [2,31, and may be interpretable in the context of 
long-term adherence dynamics that are difficult to capture in cross-sectional studies using proxy 
adherence measures [4J. 
If dllferences In treatment outcomes between refulees and local host communities exist, 
why do the outcomes vary? What are lbe risk factors for lack of ~ral suppression In lbe 
study settlnp? 
Consistent with the plethora of previous studies on the effect of adherence on virological 
outcomes. the expectation was that sub-optimal adherence would be a strong independent risk 
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factor for poor virological outcomes in this study. Initially, we thought that other important risk 
factors might include serostatus disclosure and recent travel. 
The findings showed that, in the urban Southeast Asian setting (Paper Two), women, and clients 
with longer times between diagnosis and treatment initiation were less likely to have an 
unsuppressed viral load, while suboptimal pharmacy refill records, temporary migration for one 
month or more in the past year and longer transit times to clinic were associated with lack of 
viral suppression. In the East African camp setting (Paper Three), there was only one 
statistically significant association with failure to suppress the viral load. There was strong 
evidence for an association between smaller household sizes and lack of viral suppression and 
weak evidence (p::()'()9) for an association between underdosing (measured by comparing self-
reported dosing with routine guidelines) and the outcome. In contrast to the Malaysian study, in 
the camp-based East African setting neither sub-optimal adherence measured by pharmacy 
refills and self-reports, nor reported serostatus disclosure, recent travel or temporary migration 
were independently associated with this key outcome. The main covariate of interest, refugee 
status, was not independently associated with virological outcomes in either setting. In 
Malaysia, adherence to pharmacy refill schedule was better than the self-reported measures of 
adherence at predicting inadequate suppression (Paper Three). In Kenya, none of the adherence 
measures were associated with the virological outcomes; however the weak evidence for the 
association with client underdosing in relation to routine prescriptions suggested that clients 
were often nOl having sufficient coverage time by HAART. Possible explanations include 
simple misunderstandings of required dosing abetted oy changes from once-daily to twice-daily 
nevi rapine on the basis of initial assessments of tolerability andlor refill prescriptions being 
given to the patients without clear dosing instructions. Moreover, at the time of the study, many 
home-based care workers had been laid off and there was dissatisfaction among the remaining 
team suggesting that active follow-up and engagement may have been lacking for many of the 
patients. There was no direct evidence to support or refute these assertions. The finding that the 
phannacy refill measure of adherence was not significantly linked to the virological outcome 
suggested that in spite of the fact that the majority of clients were collecting their HAART 
prescriptions at optimal levels, either their comprehension of the recommended dosing schedule 
or daily adherence had indeed been problematic. However, self-reported proxy measures of 
adherence were not able to capture this dynamic. Clients may also have developed drug 
resistance or medication potency may have been adversely affected by storage conditions or less 
likely but still possible, by drug counterfeiting. Again, there was no direct evidence to verify or 
refute these possibilities. 
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How do refupes and host nationals experience their treabnent and what do they perceive to 
be the major threats, barriers, and facilitators of adherence? 
In advance of qualitative interviews. we hypothesised that semi-structured interviews with 
clients would show that a key adherence challenges in both settings would include stigma and 
discrimination. The qualitative interviews suggested that. for refugees. crossing borders and 
integration upon arrival (in asylum) were important threats. while food insecurity, treatment 
delivery insecurity. stigma and discrimination, and economic hardship were experienced in both 
settings and by both groups. Social support and personal resilience were important facilitators of 
adherence for participants across the settings. Stigma and discrimination seemed less intensive 
(but was still present) among the Kenyan host community. Clients in both settings reported 
using a variety of adherence support strategies and demonstrated resilience and personal agency 
in response to challenges; however. when compared to the urban Malaysian group, treatment 
agency in the Kenyan camp-based group appeared to be "bounded" (ie. constrained) by the 
extent of the systemic challenges they faced. This was perhaps also worsened for refugees by an 
underlying lack of hope as resettlement to a high-income country is uncommon in Kenya, and 
more common in the Malaysian setting. 
What polldes can Improve adherence to HAART In clinics shared by refugee and host client 
lfOups? 
The initial working hypotheses were that earlier initiation of therapy, better adherence 
monitoring programs and access to appropriate counselling services would help to optimise 
future treatment outcomes. There was no evidence from this study to support an effect of earlier 
initiation of therapy on virological outcomes despite observational findings that earlier 
treatment start increases life expectancy [5.6]. The effect of earlier initiation of therapy on 
virological outcomes. mediated by adherence. could work in both directions. Earlier therapy 
may lead to treatment fatigue that compromises adherence and outcomes or earlier initiation 
could lead to tighter linkages with care that would positively impact adherence and outcomes. 
The START study will be the first randomised controlled trial to examine the optimal time to 
start antiretroviral therapy [7]. Other trials such as HPTN052 and TEMPRANO are also 
addressing the issue. The findings from the present study supported our more modest initial 
hypothesis that better adherence monitoring and counselling services might help to mitigate 
adherence barriers. improving adherence and treatment outcomes. The findings were elaborated 
into the following recommendations. addressed to different levels of the treatment system. 
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For UNHCR and ImpiementllllJ partners: 
In Kakum8, Kenya: 
I) Urgently investigate the reasons for the high proportion of clients lacking viral suppression 
including the clinic and pharmacy systems. storage of medications. effectiveness of 
community-based health workers. whether clients are drug selling or sharing. 
• Once the investigation is complete and remedial measures have been implemented. 
collect a second viral load sample to confirm treatment failures and perform drug 
resistance testing to identify the proportion of treatment failures that are due to 
resistance. Adjust treatment and care accordingly. 
In general: 
2) Access to HAART 
• Continue to provide treatment on an equitable basis to refugees and local host 
communities. leveraging national and international resources to achieve good treatment 
outcomes and reduced transmission of HIV among both groups. 
3) Direct adherence support 
• Where possible. introduce and provide adequate support to community-based health 
workers to ensure uninterrupted personal HAART supply. rigorous progress monitoring 
and optimal adherence. 
• Each community health worker or counsellor should be responsible for tracking 
medication collections and adherence for a defined list of clients. Each counsellor 
should panner with a back-up counsellor so that. if the primary person goes on leave. 
their duties to specific clients are covered effectively. 
• Counsellors should deliver medication directly to clients who are disabled. who do not 
regularly attend the clinic due to stigma. prohibitive costs or for other reasons. 
• Pilot-test adherence support interventions. such as mobile phone SMS intervention. to 
facilitate daily adherence reminders and monthly medication refill reminders especially 
for clients at higher risk of inconsistent adherence. 
4) Pharmacy support 
• Install or upgrade the electronic medical record (EMR) such that pharmacy records are 
linked to the main medical record and adherence data may be easily extracted so that 
clients who begin to default from clinic appointments or pharmacy refills may be 
quickly identified and traced by home-based care workers. Remove any existing 
disconnections between medical and pharmacy records. If records remain paper-based. 
devise a system that routinely assesses pharmacy records while identifying and 
following-up clients who have failed to collect their prescriptions. 
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• Manage the ordering of drug supplies when treatment guidelines are changed such that 
an appropriate transitional overlap is allowed between the discontinuation of the supply 
of the old regimen and the start of the supply of the new regimen. In this period, both 
regimens should be ordered to avoid situations where stock-outs or the threat of stock-
outs leads to forced alteration of client drug collection schedules and increased risk of 
treatment interruptions. 
• Implement a routine adherence monitoring using a combination of self-reports 
measured using visual analogue instruments and pharmacy refill measures, where 
feasible. The monitoring system should be used to give regular feedback to providers 
and clients. To protect human rights, voluntary consent from the clients should be 
required for participation through an opt-out approach. 
• Consider issuing extended supplies of HAART for those who live far from the hospital 
and have difficulty attending. Distribute routine HAART through partnerships with a 
single provider where possible. Promote linkages among a network of regional 
pharmacies to facilitate contingency access in the event that an emergency prescription 
refill is required. 
• Ensure that medications are disbursed with clear prescription guidelines that may be 
understood across multiple languages and cross-culturally. Ideally these should be 
provided in writing as well as verbally. Pictorial instructions illustrating dose times and 
tablet numbers may be helpful. 
5) Peer support 
• Encourage clients to join active support groups, so they may benefit from support in 
relation to ensuring consistent pharmacy claims and mitigating adherence challenges as 
they arise. 
6) Food support 
• Evaluate food security. Where supplementary rations are provided, consider adjusting 
them based on the total number of household members (clients who live in group 
settings are likely to share their supplementary rations across the household leading to 
shortages and food insecurity). 
7) Travel support 
• Consider providing small personal grants to subsidise transport and meals for monthly 
medication refills or doctor's appointment. 
• Assess travel plans at regular doctor appointments and conduct risk assessments for 
those clients who might travel for any reason. Develop contingency plans in partnership 
with clients. This could include emergency hotlines. 
8) Health care providers 
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• Consider advanced fonnal training of designated nursing andlor home-based care staff 
in adherence counselling. 
• Implement appropriate plans to manage staff turnover especially in camp settings. 
Enhance the role of the home-based care system to provide continuity when staff 
members depart. 
For Ministries 0/ Hnlth lind Donors: 
I) Access to HAART 
• Expand HIV treatment and scale-up treatment support on an equitable basis to refugees 
and local host communities. 
• Provide awareness interventions within the police and other law enforcement 
institutions of the rights accorded to refugees. IDPs and asylum-seekers. 
2) National Strategic Plans and Global Fund 
• Include refugees in national strategic plans (NSPs) and Global Fund proposals with 
specific activities related to their treatment and care described and budgeted. 
• Distinguish between different types of displaced groups in NSPs and Global Fund 
proposals. 
• Formalize responsibilities for refugees in NSPs. identifying all stakeholders within 
national governments and Ministries of Health. and non-governmental actors including 
UNHCR and implementing partner Noos. 
• Leverage national and international resources to achieve good treatment outcomes and 
reduced transmission of HIV among and between refugees and host communities. 
3) General support to the treatment system 
• Support enhancement of home-based care and adherence interventions to ensure 
uninterrupted personal HAART supply. rigorous progress monitoring and optimal 
adherence. 
• Support the development and implementation of routine adherence monitoring systems. 
• Support a basic package of adherence interventions. and a more intensive package for 
groups at high risk of adherence lapses and loss to follow-up. 
• Manage changes in treatment guidelines such that transitions do not lead to stock-outs 
or the threat of stock-outs. 
• Fund additional training for nurses and home-based care staff in adherence counselling. 
• Support operational research for assessing adherence and treatment outcomes over time. 
acceptability and effectiveness of low-cost adherence support interventions. 
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ETHICS AND UNDUE INDUCEMENT 
This research was conducted with highly vulnerable clients. An incentive was offered in 
exchange for participation. which amounted to a stipend to offset transport costs and the value 
of approximately one meal. Clients with greater transport needs were offered additional money 
to offset their costs. Although acceptable to all Ethics Committees with jurisdiction over the 
project. these ethical issues are nonetheless important to re-examine in detail. Among ethical 
violations. Emanuel and colleagues (2005) distinguish three which are most relevant here: 
undue inducement. coercion. and unfortunate circumstances. In general, inducement itself is an 
acceptable means to affect a personal judgment with respect to study participation. provided 
clients are fairly able to make effective judgments. If no sort of inducement were ethical, no 
incentive would be appropriate in research, thus compromising the ability to affect 
improvements in health on the basis of evidence. Undue inducement refers to situations that 
meet all of the following criteria: an individual is offered a valuable good to incentivise an 
action; the offer is so excessive as to be irresistible in the context; the offer leads to poor 
judgment in an important decision; the poor judgment leads to a high risk of serious harm 
against their interests [8]. Coercion refers to the threat of an outcome that is worse than the 
status quo. if a choice is made by a participant not to engage in the incentivised action (e.g. your 
money or your life). Unfortunate circumstances denote an ethical situation where a combination 
of vulnerable circumstances and tempting offers compromise autonomy. Therefore. the first 
question that ought to be asked is: does the incentive structure actually give participants no 
choice at all; in other words. are participants effectively being coerced? Second. is the incentive 
large enough so as to encourage reasonable people to accept excessive risks that far outweigh 
the benefits of participation? Third. are circumstances sufficiently abject as to render almost any 
incentive unethical? The distinction is also reflected in proposed remedies. For coercion. the 
remedy is to remove the threat; for undue inducement the solution is to reduce the incentive [8]; 
while for unfortunate circumstances. the answer is presumably not to undertake the research or. 
more controversially. not to give any incentive. In the present study. a sceptic would be hard-
pressed to argue that participants were subject to undue inducement. Complete information is 
necessary. but not sufficient. to avoid undue inducement. In the consent procedure. detailed 
information on potential risks and benefits was offered at the outset. The variation in the 
languages spoken among clients created a risk that some participants would not fully understand 
the information. To control this. the protocol directed enumerators to read the information sheet 
and the consent form aloud at each interview. in order to ensure that illiteracy did not preclude 
participants from having complete information. Clients were then asked questions to ensure they 
understood the content. If. in the judgment of the interviewer. a client was not sufficiently fluent 
in the language. the interview was rescheduled with an interpreter. The potential harms in 
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participation were largely related to discomfort in giving a blood sample, and the possibility of 
anxiety or emotional discomfort while providing responses relating to illness and treatment. 
These risks were not considered substantial, nor were the potential hanns considered extremely 
serious (9). All appropriate precautions were taken to minimise discomfort and medical risk in 
blood sampling. Efforts included the use of professional phlebotomists in Malaysia and close 
training and supervision of research assistants who took the dried-blood spot samples in Kenya. 
In the event that a participant became emotionally distressed, our protocol instructed 
enumerators to discontinue the interview. In the event of such incidents or upon request, follow-
up counselling was made available. 
In relation to coercion, a choice to abstain from participation in the study would not have 
created an unfair choice, as there was no threat to the routine standard of care. In essence, 
abstention from the study did not affect a participant's status quo. In the event that participants 
were invited. arrived, but later deemed ineligible for the study. they were still provided with the 
incentive. A sceptic might press the argument that such research is structurally unethical, to the 
extent that participant's abject circumstances result in the impossibility that any participation 
choice could be construed as fair. To press this argument is to advance a view that research 
among vulnerable individuals who live amidst the deepest structural violence is either an ethical 
impossibility or ethical only under the most restrictive conditions [8]. However, there are 
objective and subjective <as participants perceive them) benefits to research that are contingent 
neither on the presence of incentivised participation, nor on the full realisation of benefits by 
participants alone. Ideally, the benefits of research accrue to participants by improving their 
outcomes; however, participants may also see value in research that may not benefit them 
directly but will help people who may eventually suffer from their condition. The reasonable 
view is that ethical decisions must balance these legitimate concerns in an effort to avoid undue 
inducement, such that incentives do not interact with unfortunate circumstances and 
compromised judgment to create a "a seriously unfavourable risk-benefit ratio that threatens 
fundamental interests" of the participant [9,10]. Among refugees, HIV -positive individuals, and 
other vulnerable groups such as conflict-affected and forcibly displaced perSons, this balanced 
view is most appropriate given the value and benefit of research. For forcibly-displaced and 
conflict-affected groups, a proposed ethical framework has set key benchmarks for ensuring that 
research is conducted to the highest possible ethical standard [11]. 
ONGOING WORK AND NEXT STEPS 
After the very worrying findings in Kakuma. UNHCR responded by initiating remedial efforts 
to improve staffing levels, adherence counselling and support, and client follow-up in advance 
of potential regimen switches. Decisions to switch regimens will be based on algorithms 
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provided in the K~nya Nalional Clinical Manual for ART Providers that use viral load and serial 
CD4 measurements to govern switching decisions. According to this algorithm, clients with a 
viral load ~ I 0.000 copieS/mL will have their adherence reviewed and changed to second line 
treatment. After implementing remedial measures in the program including enhancement of 
adherence support and client follow-up, UNHCR has agreed to confirm treatment failures with a 
second viral load and to fund drug resistance tests among these clients. Led by the HIV 
Laboratory at the KEMRI (Kisumu), this additional work will elucidate which resistance 
mutations. if any. are causing the widespread treatment failure and will assist with the choice of 
second line regimens. Phylogenetic work will also be undertaken in order to shed light on the 
relatedness of circulating viral sub-types and to check the possibility that resistance was 
disproportionately transmitted, rather than acquired. 
The candidate also conducted in-depth interviews with providers that have not been analysed or 
presented for the thesis. They will be analysed as soon as possible, with the aim of examining 
provider perspectives on the challenges faced by the study groups in relation to adherence. 
In addition to this ongoing work, I recommend that interventions to improve the proportion 
successfully achieving viral suppression in Kakuma are documented and evaluated in detail 
within a before-after study that also assesses adherence. This would involve administering a 
new questionnaire to assess self-reported adherence, risk {actors and taking a further set of viral 
load samples to confirm treatment failures. 
FINAL THOUGHTS 
This was a complex project in logistical terms and four of these complications deserve to be 
outlined for future researchers who may pursue related questions. First, UNHCR's logistical and 
financial support for this project was essential. However, there were trade-offs in collaboration, 
and these were made more acute given the nature and objectives of the PhD when contrasted 
with professional assessments or evaluations. UNHCR's programme evaluations are usually 
short-term and aim for sufficiency. On the other hand, a PhD requires a depth study that consists 
of components of an evaluation, but much more detail and depth than a typical programmatic 
evaluation would include. All stakeholders were very keen that the work should include studies 
in more than one setting, and were concerned about the time commitments involved. In 
retrospect. preparation time, ethics procedures. research clearances. ethics approvals and 
preparatory work in two settings using a mixed methods approach. was excessively time 
consuming; however. little could be done to rectify this situation without taking undue risks in 
relation to the rigour and thoroughness of the work. 
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As much as the study methods were reasonably straight forward. the politics and logistics were 
not. From the PhD perspective. the post-election environment in Kenya. instability in Sudan. 
and their potential effects on Kakuma. amounted to a threat that the field period would coincide 
with a political development that could severely delay or render the work altogether unfeasible. 
This risk put additional pressure on fulfilling a rigorous. defensible study in Malaysia as the 
thesis centrepiece and more time was taken in Malaysia in response to this risk. After Malaysia. 
an effort was made to delay the Kenya sub-study until doctoral requirements were fulfilled; 
however. this was nOl acceptable due to the consultancy agreement that had previously been 
negotiated. UNHCR can use a "nil consultancy agreement" with a PhD student in which the 
consultant (PhD student) receives expenses but no fee. but these are not allowed by UNHCR 
rules with non-students. This agreement was initially negotiated over six months through a 
Memorandum of Understanding (a copy may be found in Registry or upon request from the 
candidate). With the nil-consultancy. the contract would have required an open bidding process 
which would have added cost and amounted to a substantial change to the structure of the 
project. Fortunately. in the end. all were very satisfied with the project outputs. 
Second. there were considerable delays in receiving all the approvals needed for the research; 
approximately four months in Kenya. and in excess of 8 months in Malaysia. The difference in 
clearance times between the two countries was large due to refugee politics. The ethics 
clearance in Malaysia was delayed as a result of concerns linked to uncertain and contested 
domestic refugee policy. Malaysia has not signed the Refugee Convention. yet the Government 
actively cooperates with UNHCR to manage refugee issues. Moreover. governmental Ministries 
and Units including the Ministry of Health and branches of law enforcement. defer to Home 
Ministry authority on issues of immigration or refugee policy. This dynamic engenders some 
bureaucratic gray areas where jurisdictions overlap. An ambiguous ethical approval was issued 
by the national Ethics Committee. which stated "From the ethical aspects of the study design. 
the MREC [National Ethics Committee] has no objection to the conduct of the study. However 
there are sensitive issues pertaining to this study in relation to refugees status and its association 
with national security issues; the concern on the interpretation of the study and its findings 
especially future presentation. utilization, and dissemination of the findings." After months of 
delay. an agreement was reached to sanction a final, unambiguous ethical clearance. where an 
official in the Ministry of Health agreed to act as the liaison between the Home Ministry. the 
Ministry of Health, UNHCR, and the Study. 
Third. there were distinct challenges pertaining to study implementation in each field setting. In 
Malaysia. it was decided to recruit refugees on the day of their normal clinic appointments 
which occurred only once per week. and. similarly. to restrict host community recruitment to a 
second day per week (nationals have three days per week available for appointments). This 
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decision was taken with consideration for the wide variety of languages spoken, the costs of 
assembling a full team to cover a range of languages each day with the possibility of low 
turnout by a single language group on any particular day, and the desire to balance the time to 
full recruitment between groups. In hindsight, the work could have been accelerated by actively 
recruiting refugees and interviewing them on multiple days per week (and doing the same for 
the host community). However. slowing down the work in the early stages allowed us to debrief 
as a team thoroughly at the end of each interview day and to make appropriate adjustments to 
any aspects of the protocol that were not functioning efficiently. Later in the study. we adopted 
an active recruitment protocol to accelerate the work in the face of pressing deadlines. In doing 
so. it became clear that using the normal clinic appointments was in fact the safest way to 
approach refugees and to ensure they were eligible. Inviting ineligible refugees on days where 
they did not have a scheduled appointment was asking them to sacrifice potential wages and 
placed them at increased risk of arrest while in transit to the clinic. In Kenya, the challenges 
were of a different sort. and largely more physical in nature. The environment is harsh in 
Kakuma. and research interviews took place in UNHCR-issued tents equipped with chairs and 
fans. Temperatures in the tents were typically very high and when the winds picked up the tents 
were coated inside and out with grit. Refreshments were provided to participants during 
interviews but the conditions in relation to heat and comfort were not ideal. Incentivising home-
based care workers allowed us to effectively track and recruit both refugees and the host 
community. who sometimes lived as far away as Lodwar (40 kIns from Kakuma). It is typical 
for the Turkana to walk great distances. and our Turkana home-based care colleagues would 
often walk ("foot" in their terms) considerable distances in an evening after a regular day of 
work in order to contact prospectively study-eligible clients or to discreetly enquire about their 
whereabouts. 
Lastly. the thesis took a mixed methods approach. which brought accompanying challenges. 
Mixed methods are rewarding hut complicated to undertake with a large research team in 
relatively short periods of time. In this particular study. I do not think the mixed methods 
approach compromised depth of either method as significant time was spent collecting and 
analysing both the quantitative and qualitative components; however. this approach added time 
to the study overall. It seemed that one method would have been limiting. On the one hand. a 
survey-only study would have precluded more intimate contacts with clients who were able to 
provide important insights into the barriers and facilitators of adherence that they faced. An 
exclusively qualitative study would have made it impossible to measure treatment outcomes. a 
key objective of the study. The learning curve for each method. both for the candidate and for 
the local staff. however. did cost additional time in preparation and training both before and 
during fieldwork due to inexperience methods and a decision taken to conduct qualitative 
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interviews outside of the clinic in Malaysia in order to create a more casual interview 
environment (this option was not practical in Kenya). 
CONCLUSION 
Refugees have a right to equal access to HIV treatment based on the principles of fairness and 
human rights. and this access will help confer both individual and population-based public 
health benefit. Given limited resources for expanding treatment, questions have been raised as 
to whether this group would achieve sufficient levels of adherence and viral suppression to 
justify sustaining and expanding their access. Equitable and acceptable treatment outcomes had 
previously been found in a range of settings serving forcibly displaced clients. However, most 
of the studies that had been performed were among populations who were conflict-affected, 
internally-displaced, or among refugees based in high income countries. The present study 
added to the evidence by showing that refugees residing in asylum were capable of treatment 
success, and when problems achieving and sustaining viral suppression occurred, they were not 
due to previous forced displacement or to refugee status itself. To remedy or prevent 
occurrences of virological failure where refugees access treatment, interventions ought to be 
implemented for both refugee and host communities wherever necessary. Evidence from 
Malaysia suggested that men, clients with documented sub-optimal adherence to pharmacy 
prescription refills. shoner time from diagnOSis to HAART start. clients who had temporarily 
migrated for ~ I consecutive month in the past year. and those who spend ~'1 hour in transit to 
the clinic had increased odds of having an unsuppressed viral load and should be targeted for 
intervention. Meanwhile. in Kakuma. smaller household sizes were associated with lack of 
virological suppression. The weak evidence for an association of this outcome with self-
reponed underdosing by clients was also suggestive of intervention opportunities. Since HIV-
positive individuals on HAART with good adherence will rarely transmit HIV to their sexual 
partners [ 121. it is in the enlightened self-interest of host country governments to suppon HIV 
programs that serve HIV -positive refugees and host clients equally. There is a clear public 
health and humanitarian interest in guaranteeing access to ART. promoting optimal adherence 
and sustaining viral suppression in these vulnerable groups. 
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ApPENDIX A 
MALA YSIA OAT A COLLECTION FORMS AND TOPIC GUIDES 
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FORH 1 
Eligibility and Registration Form: Adherence to 
HAART in Refugee and Host Communities 
(Sections 1-6) 
INSTRUCTIONS: 
mJy WIth the dlGn\ln front of you 
2 IOOS they are 'Millen on the page. 'Be sure to read all the additional prOOlptS in quotation marks.' 
3 bold IIlstruchons 10 square brackets Do not read them out loud.) 
4 IT IS ~Ifled, remember to specify. 
5 a ng a question, be sure to prompt -Mth response options unless it is indicated [do not prompt). ercie 
ny rQSpOnse gIVen unless It IS Indicated [circle only one). 
6 Wflere IC bltl. erde or 'MIte In boxes, or 'Mrte In the right-hand margin. 77=Not a~licable , 88=Declined to 
8 ,99 Do not know Never prompt WIth these options. 
01 00 1M'll n "ration only! Client Code: 1 B-YYYY = 1 DOD 
Ro~oo B=1 Participant =000-499 
Host B-2 Nof}-partlClpanl =5OQ..999 
SECTION 1: Identification 
0101 Interv (Ent.r your retearcher code) DO 
0102 T y's date ( ddlmmlyyyy) DO 0020 DO 
0103 
0104 
o 05 
0106 
(Sldp 10 Q 02.01) 
Data entry 1 [Enter your r, .. archer code) DO 
Date of data entry 1 (ddlmmlyyyy) DOD 
o ta entry 2 [Enttryour r ... archercodeJ DO 
Date of data entry 2 (ddlmm/yyyy) 0 0 
(n-Nol i1PpHcable; ea-Decllned 10 answer; ai-Co not know) 
EI Ibillty and Registration Form (MALAYSIA): Adherence 10 HAART In Refugee iIIld Host Communites 
1 
20 00 
20 00 
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fORM 1 
SECTlON 2: Language 
English 01 Shan 11 
Bahasa Malaysia 02 Burmese 12 
Tamil 03 HakkaJlai 13 
'f04I mothor tongue? 
Mandann 04 Cantonese 14 
Kachln 05 Tedm 15 020t Ielrd. 0Il1y 011. Ind do not Karenni 06 Mlzo 16 prompt) 
Poe Karen 07 Falam 17 
SagawKaren 08 Hokkien 18 
Mon 09 Other (Specify ) 50 
Arakan 10 
he you ClbIe to understand and to express yourself in one of Bahasa Malaysia, No 0 02C2 TlWTlit, nd3r1ll, Burmese, or EngtlSh? Yes 1 
IR.tttIrthtl only) Wdl an Interpreter be required? No 0 
0203 II YES, I k ~ttent to wlltlnd 1M Coordnator - tntervlaw will be rescheduledl Yes 1 
English 01 Shan 11 
Bahasa MalaYSia 02 Burmese 12 
Tamit 03 Hakkallai 13 
IR.tttIrch.r OIlly] InlervlOw 10 Mandarin 04 Cantonese 14 
be conduded 10 Kachin 05 Tadim 15 
0204 Karenni 06 Mlzo 16 Iclrdl only on. Ind do not 
promptl Poe Karen 07 Falam 17 
SagawKaren 08 Hokkien 18 
Mon 09 OIher (Specify ) 50 
Arakan 10 
SECTlON 3: Information Sheet 
IGI ... \he ~h"'tl copy of Ihllnformltlon form. Read thtlnformatlon form 01111000. Offer the client a drink., 'Do you have any 
~ions?' 
0301 IRet .. rch.r only) Has the chent read/heard the Information sheet? No Yes 
he you 'M1I1Ilg to partiCipate? No (Sldp to Q 06.01) 0302 Yes Ilf YES, go to StctlOll Q 04.01 . II NO, end) 'Thank-you: 
-
SECTlON 4: Eligibility 
0401 
Male 
IR .... rth.r only) ndor Female 
Transgenderltransexual 
[77-Not appHcable; aa-Decllned 10 answer; "-Do not know] 
Ellglblllly Ind RtglSlr1tlon Form (MALAYSIA): Adherence to HAARTIn Refugee and Host Communltes 
2 
0 
1 
0 
1 
1 
2 
3 
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FORM 1 
0. 0' of blr1h (dd/mmtyyyy) 0 000000 
0.03 ~ (CaiCUlIIt from Q 04 02.nd wrlfywlth client IC or UNHCR DO yell's Clrd) 
0. 
IRtMlrchtr only) Respondent >=18 years of age? No [End) 0 
(If NO •• JCpIlin why they etnnot t>. Included In Ih.lludy end end thtlnlervlew) 'Thank-you.' Yes 1 
~ Wha1 day month and year ad you start on HAART? (dd/mmlyyyy) DO DO DODD 
06 
IRnllrch.r only) Was HAART Inlliated >=30 days before today? No [End) 
(If NO, tJCpIlln why Ihey etnnOI be Included In thl. study and end thelnlervlew) 'Thank-you' Yes 
Do you norm Ily pICk-up your HAART from this clinIC and/or the Standard Phamnacy In Kuala No 07 L put? Yes 
No [Sldp to Q 04.09) 
0.088 HaI/8 you elier picked up your HAART from someplace else? 
Yes 
0.0It> Speedy s1 te of pick-Up from other phamnacy (ddlmmtyyyy) DO DO DODD 
Spee'y pharmacy/clinic Specify c~y : 
MalaYSian 
Burmese 
0400 What 's yOUI' current natlonatrty/oountry of CItizenship? If IndoneSian you NlI/8 ther please list your country of origin. 
No crtizenshlp 
Other (Specify: ) 
Does the chent have MalaYSian citIZenship? [Check with Identify Card) No 0.10 Yes [Skip 10 Q 05.01) 
Do you currontly have refugee status in MalaYSia? [Check with UNHCR Card) No 0411 Yes 
Ilf YES 1211tn.r Q 04.10 or Q 04.11. candidate I, eligible to partlclpat •. Go to next lectlon. Q 05.01. If NO t2 both gyeetjon •• 
tJCpI_n why Ihey etnnol be Included in the study and end the Interview.) 'Thank-you' 
l17aNOI applcable; sa-Declined 10 answer; "-00 not know) 
Ellglblllly Ind Rtgl.trallon Fonn (MALAYSIA): Adherence to HAART In Refugee and Host Communlt" 
3 
0 
1 
0 
1 
0 
1 
01 
02 
03 
15 
16 
0 
1 
0 
1 
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FORM 1 
SECTION 5 Informed Consent 
(GI ... It!. d..,tl copy of the eon..,t fonn. Rtld Ihe con.tnt form out loud.) "Do you have any questions?" 
0501 (RHllrchtr only) Has client heard'read the consent form? No Yes 
rchtr only) Old the chent agree to participate by signing the consent form? No 0502 ( Yes 
(nES 10 Q 05 92. go 10 MAIN Qulliionn.r., Q 07.01)·Thank-you Let's start the main questionnaire: 
I_ !Q 12 g 2~ O~ go to Q 06 .01) "Before you go, may I ask you just a few quick questions?' 
--
SECTION 6' Renons for Non-Participation 
Not interested in the study 
(If NO 10 Q 06 02) Why did you decide not to Did not have tine 
~te? This IS Important for us to know so Did not understand information about the study 
0601 can inprove future studies Not comfortable, but do not know why 
(00 not prompllnd clrcl •• 11 that apply) Other (SpecKy: ) 
Declined to ans.wer 
Disabil~y (RHtIrthlr only) If the citent was unable or Language dKficuHies ~02 IJ1C8 Ie 01 glVl/lg Informed consent or 
8 ng the questionnaire, why? Other (Specify: ) 
Do not know 
END. 
[l7aNot appUcable; as-Declined to answer, ""Do not know) 
EllgtbUIIy.nd Reglslratlon Fonn (MALAYSIA): Adherence to HAART In Refugee and Host Communites 
4 
0 
1 
0 
1 
1 
2 
3 
4 
5 
88 
1 
2 
3 
99 
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FoUow-up Form: Adherence to HAART in 
Refugee and Host Communities 
FORM 2 
Contact detail 
00 
000 
0002 
0003 
00 
0005 
0006 
000 
0006 
0009 
00 10 
I coda (Tr."cl1bt from Form 1]: 10 -000 
ICftJNHCR No DDDDDDDDDDDD 
Sungal Buloh No DDDDDDDD 
Telephone No (Home)' 
Telephone No (Mobile). 
Email 
Street number: 
Street name: 
Flat or partment nurrbllf 
City: 
Post code: 
• k lure to list 2 contact telephone numbers (e.g. mobile + friend's mobile or mobile + home 
etc.) 
Folow-yp Form (MALAYSIA): Adherence to HAART In Refugee and Host Communles 
1 
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E'ORM 3 
ain Form: Adherence to HAART in Refugee and 
Host Communities (Sections 7-12) 
SECTION 7: Identification 
07 
0701 
0702 
003 
070 
0705 
0706 
t code [Trtn.crlbe from Form 1) 10 -000 
Inl lEntil your r .... rch.r cod,) DO 
0 0If) I (dcVmm/YYYY) 0 0 2000 
IS ptoQ0801) 
o t en I IEnter your r .... rcher code) DO 
0 01 entry 1 ( dc)'mm/yyyy) 00002000 
o lunlfy 2 IEnt.r your r .... rcher code) DO 
o t of t entry2 (dc)'mm/yyyy) DO 0020 DO 
C77oNot applicable; aa'Declined to answer; "sDo nol know) 
M~n Fonn (MAlAYSIA): Adherence to HMRT In Refugee and Host Communities 
1 
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fORM 3 
SEcnON 8: Socio-Oemographic and Background Information 
~O 
0802 
Burma 
In COIJntry e you born? Malaysia 
Icmt. only on.) 
I 'f04S religIOn? 
tarde only on'l 
(eltd' only on.) 
Indonesia 
Other (Specify' ) 
CatholIC 
Other Chris1ian 
Muslin 
Hindu 
Buddhist 
Other (Specify' ) 
Currently married or hVlng as married, 1 spouse 
Cl6rently married or lIVing as marned, > 1 spouse 
Not married, currently in a relationship with 1 person 
Current Iy married, hVlng as married, and/or In a relatIOnship With >1 person 
DlVcrcediseparated from marriage and currently single 
Widowed and currently Single 
01 
02 
03 
15 
01 
02 
03 
04 
05 
11 
01 
02 
03 
04 
05 
06 
Single 07 
of accommod tIon do 
08 04 011 t\.fferily live Ill? 
[Qrde only onel 
Private house or apartment 
Dormitory 
Tent 
Gues1 house/hotel 
None 
Other (Specify: 
~ 05 many people .ve With you In your current household? By household, I mean one 
person cr a group of po'sons who usually live and eat together. 000 
01 
02 
03 
04 
05 
06 
0806 MalaYSian Rlnggrts. 0000. 00 
0807 00 you currently work for pay outSide or IOSlde the home? (circle only one) No 0 
Yes 
0808 00 you CUrT oily have chllcien? (circle only one( No [Skip to Q 08.10) 0 Yes 
08f:S f 011 ha~e chllcien, how many currently lIVe with you In the s!ITle household? Reccrd number 00 
[77ttNoI applicable; n ' Oeclined to answer, " =00 not know! 
MIIn Fonn (MALAYSIA): Adhennce to HAART In Refugee and Host Communities 
2 
185 
FORM 3 
Very poor 
Poor 
00 0 Id you rate your current standard of liVIng? [circle only one) AVErage 
Good 
Very good 
.I! ell",ll. HOT cumnlya r"us .. · r."rto Q04.11· SKIP to Q 08.14) 
~ 
~12 
0813 
~14 
085 
0816 
081 7 
08 18 
monthtt dd you enter thts country? (mmJyyyy) 0 DODD 
w mont eet did you galO refugee status? (mrrJyyyy) DO' DODD 
Yfrypoor 
Id you rate your standard of liVing poor to leaving your home country? Poor Average (circle onlY ont' Good 
Very good 
In I mt 12 months have you beon away from the city No [Skip to Q 08.16) 
v.'hI!re you currently live for OnG con\lnuous month or more? [circle only one) Yes 
I es. t slhemlln Employment 01 P1'Ison or detenllon In country 
rGa$'Ol'l ~y you e way Trade 02 Heanh-felated 
trom Ih OCy for one month FamllY-felated 03 Rehglon-felated 
or more? 
100 not prompt and clrcl. Political reasons 04 Holiday 
only on., Confhct-fslaled 05 Deportation 
Educatlon-felaled 00 Other (Spoofy-
Have never attended school 
Did not complete prlma-y educahon 
• \he hlghe$1level of educa\lon you Completed p'mary 
hi". cctnp Q(f1 [clrclt only ont) Some secondary but did nd complete ij 
Completed secondary 
Some college or UOlVersijy but did not complete tl 
Completed college or univers~y 
10 times or more 
7-9 times 
olten haw you VISited thiS clinIC (Sungai Buloh Hospital) for 4-6 times 
nyl son 'Mthln the past 3 months? [elrelt only ontJ 1-3tmes 
Never 
Amays 
01 n do you collect yo\!' HAART medication from thIS cliniC (Sungai Most ci the time 
Suloh Hosp4al)7 (clrclt only OI1e) Some of the lime 
(77 ... 01 applicable; ... Ottllned to answer; "-Do not know) 
M»n Form (MALAYSIA): Adhtnnce to HAART In Refugee and Host Communities 
3 
Never 
) 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
0 
1 
07 
08 
09 
10 
11 
12 
01 
02 
03 
04 
05 
06 
07 
1 
2 
3 
4 
5 
1 
2 
3 
4 
186 
06 goosed 8S haVIng HIV? 
e you diagnosed 9S having HIV? 
E'ORM 3 
(mmlyyyy) DO DODD 
Your heme country 
This host country 
O1her (Specify: ) 
1 
2 
3 
06 71 Is HIV. rus that k 1t'l$lde your body? (clrcll only on I) 
No 
Yes 
Do not know 
o 
1 
99 
0622 
0623 
e HIV vrllS cause AIDS? [elrele only one) 
No 
Yes 
Do nol knCIN 
you cnglll811y k an HIV 
100 nol PIOl1lPIJ 
Voluntary test as genEral precaution 
Voluntary test recommended by a heaHh clI"e provider 
Mandatory test 
Fear of exposure to HIV 
SyfTllloms such as fatigue weight loss, etc. 
Other (Spec~y ) 
o 
1 
99 
01 
02 
03 
04 
05 
06 
REFERENCE FOR RESEARCHER ONLY: STANDARD HAART PRESCRIBED 
• 
Tllelt 
name 
01 
02 S 30 
03 , NG\'pIII 
Ot SlOaln 
00 en II 
07 11< ..... 
OS I VICIP EC 250mQ 
IS I V\deX EC 4OO1!'g 
10 RtroW 
11 YIlO5I8Y 
11 3TC 
13 del Tetlel Mde(\ 
Gtn,r1cn..", Typlcal regimen 
I I11vucinMldoYudne One talle! (150 mg lamivudine .. 300 mg zidovudne) twice a day May be be taken with or Without food 
slavuane.18rr1vucinei One tellet (30 mg stavudne .. 150 mg lamivudne" 200 mg ne'lirapine) twice a day. May 
nl'JllIPlnl be taken with or wilhoul food. 
nl'JllIp ne One 200 mg tatlet daily for the first 14 days, followed by one 200 mg tallet twice a day May be taken WIth or Wllhout food. 
ellllllren2 One 6OO_mg tatletonce a day before bedtime May be taken v.ith or without food 
Indlnaw Two 400 mg capsules, three times a day. Taken 1 hour before or 2 hours after meal (At I east 2 liters of IIg\Ild should be consumed 11Jf!J'j 24 hOlrS 1 
nton VII If laken In cornblnabon With Groovan· CnxMan two 400 mg capsules twice a day and Norvlr 1 capsLle twice a da1 M~ be taken v.ith or v.ithout food 
IClPfnawfnlonaVlf Threej133.3jl'lgIOj:inavir .. 33.3 mg ritonavir) c~Lles twice a day. Take with lood. 
cldallOSln8 (entenc- One 250 mg capsule, once a day for patients <=60kg To be taken on empty stomach 
coetad) 
: cldilllOSlnt (entenc- One 250 mg capsule, once a day lor patients >=6Okg To be taken on empty stomach 
COOled) 
zldoYUdne (AlT) Three 100 mg cBpsues twice a dily. May be taken v.ith C1 without food. 
Stavudne (<:14 T) One 30rngcapslJe lwice a day. May be taken with or v.ithout lood 
LlInwucine {3TC) One 150 mQ t~et twice a day. May be taken with or v.ithout food. 
OSIn. (eId) Three 100 mg tstAets, once a day for patients <=6Okg. Four 100 mg t~ets once a day for patients >=60kQ.Of two 100 mg tallets twice a day. To be taken on ~stomach. 
[77oNot appllcabte; aa-Dtcllned to iIIlswer, ... 00 not know) 
t.u!I\Form (MALAYSIA): AdhtrellCe to HAART In Refugee and Host Communities 
4 
187 
FORM 3 
SEcnON 9: HAART Medications, Adherence, and Side-Effects 
I =~: · onalheet with 111, dltnt. 1f po_bit, Id,ntity regimen In advlnce. OthelWi .. , compare with record IUdl u medical 
,mteketlCWI Qrd. or phytlcal mtdlcltlon. Reconcile any <iff,rencH with the dlent.) 
1030 
~ 10 identify the HAART medlCslions you are currently taking, doses, pills per dose, and doses per day 
fAIIlVWrt on. rtl.tlng to mtdlcllion .rtln relation to THESE medications. Complete steps 1·5 below for .. ch 
HMRT mtdcallon curr.,tlv uMd by th, cll.,t.1 
St,p 1 Step 2 Step 3 Step 4 Step 5 
HAAR traoe name Dosa(mg) No. times per day Confirmed with No pills each tine records? (O=No. (elide . btr only and." thlt Ipply) (p9" tablet) (doses per day) I=YesJ 
Combivir 01 UOO 0 0 0 
SLN 30 02 000 0 0 0 
Nevipan 03 000 0 0 0 
Stocrin 04 000 0 0 0 
Crixivan 05 000 0 0 0 
Norvir 06 DOD 0 0 0 
Kaletra 07 000 0 0 0 
Videx EC(250mg) 08 000 0 0 0 
Videx EC(4OOmg) 09 000 0 0 0 
Retrovir 10 000 0 0 0 
Virostav 11 000 0 0 0 
3TC 12 000 0 0 0 
Ddl Tablet 13 000 0 0 0 
Other1 14 000 0 0 0 
Other2 15 ODD 0 0 0 
0ttI.r1 (SpKlty) : 
r2ISpedty), 
No 0 
0002 I~rchtr only) Was the chent able to list ALL of ther Yes 1 HMRT mOOic hons without assistance? 
Not applicable (records unavailable) n 
[HaNOI applicable, II-Declined 10 answer; H=Oo nol know) 
~n Form (MALAYSIA): Adherence to HAART In Refugee and Host Communities 
5 
188 
FORM 3 
H!V 11a~8 many p~1s to take at dlH9fent times dUring the day. Many people find ~ hard to always rememba' 
J*PIe g bIIsy and forg t 10 carry Ihe~ pills with them, some people find d hard to take lhelr pills accordng to 
s 'with me Is' or 'on an empty stomach', 'every B hours', 'with plenty ~ fluids', some people decide to 
ts a lor other reasons We need to understand how people with HIV are really doing with taking their 
us....n t you Ire actually domg Do not worry about telling us Ihat you do not take YOIr pills We need to 
mg not what you think we 'want 10 hear' This infomnatlon will not be repor1ed to anyone and is 
stiI::C")' 'coofdcn!i31 Th 100 oIlha questlOnnare asks about the medications that you may have mISSed taking over last four 
y If you 100 only a por1lOn of a dose (fCl' example, you missed taking one pIli in the morning) please report 
(ComP'" til. 11\)1. btlow wfth the ellent, u.lng Ont lin. for .ch HAART medication the client I. euppoted to bt 
/IG. nd ualng Ill. n,mlslead. from Q 09.01 . W cll.nt did not mi., any dotH, wri te a zero (0). Note that the table 
• ebout DOSES. NOT PILLS. K client reapondll that they took only a portion of a dose on one or more of the .. daY'. 
report Ill. doee{.) • being ml •• d. Prompt In rlverse time order.) 
Step 2 Step 3 Step 1 
fUll tltdl nlml Ind numlric codt 'rom 
Doses missed Doses missed 
yesterday (1 the day befCl'e Q 08 01) 'r e HV.RT me<ianec you lake day ago) yesterday (2 
.e ' days ago)' 
step.. Step 5 
Doses missed 3 Doses missed 4 
days ago. days ago: 
DO o doses Ddoses DdoseS Ddoses 
II DO o doses Ddoses DdoseS Ddoses 
DO Ddoses Ddoses Ddoses Ddoses 
DD Ddoses Ddoses Ddoses Ddoses 
None 1 
09 04 Chrllg ttl past 4 days. on how many days have you missed taking all your One day 2 
0900 
? Two days 
(circle only ont) Three days 
Four days 
Never 
Some a the time HAART medica lions need 10 be taken on a schedule, such as '2 
lmel. day' or '3 limes a day' or 'every 8 hours' HCM/ closely did you 
lolb.,., 'fOIl ~dlc schedule r1J9f the last four days? About half of the time 
(aldt only one) 
00 ny 01 your tudy medICations have special instructIOns, 
as't e WIth food' a 'on an emply s1omach' or 'wrth 
plonly oIlkJtds'? 
(drd' only ont) 
(77"'01 applicable; 88-Decllned to answer; " -Do not know] 
Most cA the lime 
All cA the time 
No (Skip to Q 09 .~) 
Yes 
Do not knCM/ 
~n Form (MALAYSIAI: Adhtrence to HAART In Refugee and Hosl Communities 
6 
3 
4 
5 
2 
3 
4 
5 
0 
1 
99 
189 
0907 
0908 
0909 
0 
, 
0911 
09.12 
0913 
09'14 
0915 
09.16 
0917 
0918 
0919 
0920 
0921 
0971 
0923 
0924 
0925 
0926 
09'll 
0928 
FORM 3 
Never 1 
II n <id you follow 1hose speclallnstrucbons over Some of the time 2 
\0" ys? About half of the time 3 
Ic:irdt only ant) Most eX the time 4 
All dthe time 5 
On 'dlys v.tIen poople do not work. such as days off 
~or end cilys some people find that they forget to No 0 
Ih Pli Did you mISS any of your HAART pills during Yes 1 
yoII b$I lMIIekendiday off? [elrelt only onel 
Within the past \Wek 01 
1 - less than 2 \Weks ago 02 
n the Ia tme you missed any of your medications? 2 - less than 4 \Weks ago 03 
Ielrde only on.) 1 -less than 3 months ago 04 
3 months or more ago 05 
Never slop medICations 06 
Ha\ .. you experl8nced ny ~I heanh since starting HAART? No [Skip to Q 09.33) 0 
lcird. only on.) Yes 1 
I hav81lQ! had this I have had this 
s';l'l1lloms have you e p9'tenced In the last 4 weeks?' Iymptom during the put symptom during the 
4 weeks 
F.~ue or losS 01 en .. gy? 0 
Fevers, chdlS or sweats? 0 
Feeling 01:Iy or hghtheaded? 0 
Poin. n(J'li)ness or tingling In the hands or feet? 0 
Trouble remerrbenng thtngs? 0 
NlIUM or Yanltlng? 0 
Fell sed dooM'i. or depressed? 0 
Fea n .. vous or anxious? 0 
DI!lCUlty falhng or staYing asleep? 0 
Skill ~obIems. such as rash. dryness or rtching? 0 
Cough or rouble breathing? 0 
che? 0 
l06S 01 appehte or a change In the taste of food? 0 
BIootng. pail'l or gas in your abdomen? 0 
Muscle ach8$ or 100nt pain? 0 
Ptoblems .,."Ih haVIng sex, such as loss of Interest or lack of 0 
satisfactIOn? 
Chang 11'1 the way your body looks, such as fat deposits or 0 ~hlg3\n? 
Ptobloms .,."Ih WOlght loss or wasting? 0 
[77-Nol appllcablt, " -Declined to answer, " -Do not know) 
~n Form (MALAYSIA): Adherence to HAART In Rtfugee and Host Communities 
7 
past 4 weeks 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
190 
FORM 3 
0929 HIli loll or changes II1lha way your hair looks7 0 1 
(9)) Mouth ulcers or dlHlCuly swallowing? 0 1 
093 ~ 0 1 
0932 Speedy her 
0933 (R efl.nl th.,lhelnlolTlllllon Ihey provide will not be reported to anyone. Remind client of the 
IMCIc;I onllhey IIlttd In Q 09.01 Tum the page around 10 lace the client.1 
'Put trQiS (X) on the hna below at Iha point showing your best guess about how much HAART 
1I0Il you h va laken In the last month, egO'll. means you have taken no medication, 50% means 
you • I en 1\8 YW medlCalion, 100% means you have taken every single dose of medlCalion We 
lei be SIIPfised ,f lhls was 100% for most people' 
j I I 
0% 50% 100% 
SECTION 10; Reasons and Barriers 
. 
00 
10a2 
003 
0().4 
1005 
you l s con\lnu9 How much do you beheve thai [circle only onel 
Notatall A little bit Very 
Voo .e lIbIe 10 lake all or mosl 01 your medica lion as 1 2 3 diredod? 
The medcahon WlQ have a poSilive effect on your hea~h? 1 2 3 
\I )W do noIlake your moolcatlon exactly as instructed, the 
IiIV VfUS In your body WIll become resistant to HIV 1 2 3 
medlcaltons? 
Extremely satisfied 
In g«Mlf t how sabsflOd ara you wrth the support you get from your friends Satisfied 
od dymem s7 Dissati&fied 
(elld. onlV on.) Very dissati&fied 
Not at all 
To t anI do your fnends and/or family members help you remember to Alrttle 
ta your medtcatlon? Somewhat 
,(lId. only on'l A lot 
[HaNOI applicable; ~·Pecllned to answer; .... 00 not know] 
~n Fonn (MALAYSIA): Adherence to HAART In Retugee and Host Communities 
8 
Extremely 
4 
4 
4 
1 
2 
3 
4 
1 
2 
3 
4 
191 
1028 
029 
la ng lhell' modlCSlions for various reasons, [circle only one1 
y you e~er mISS taking your Never Rarely 
2 
(89 at home or at ~) 2 
2 
2 
2 
2 
2 
to~lCIharmrul 2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
Detenbon or proon WIthout my HAMT 2 
Olher 'Can you think of any other reasons that were 
noI menhoned?' 
2 
• 2 
2 
(77-NOI appllcabl.; aa-Declined to answer; .. -00 not know) 
/AlII Form (MALAYSIA): Adhtlloce to HAART In Refugee and Host Communlltts 
9 
Sometimes 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
FORM 3 
Often 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
192 
103 
o 
033 
FORM 3 
aboul yOIl alcohol and aug use Please be honest In YOll answers. We will nol report whal you 
you had a alnk conlalOing alcohol (e g 
• lIQUOr samsu I pal) 10 the last 30 days? 
Imp/I' of loeeI drink. Ind circle only oneJ 
30 "f-i. how oRen have you had 5 eX' 
01 tohd in a row. that IS, WIthin a few 
2-4 hours)? 
IdteilonlyontJ 
Dally 
5 eX' 6 tmes per waek 
3 eX' 4 tmes per waek 
1 eX' 2 tmes per waek 
2 ()( 3 times in the pasl month 
Once in the past month 
Never [Sldp to Q 10.32) 
Daily 
5 ex- 6 times per waek 
3 eX' 4 tllTles per waek 
1 eX' 2 tllTles per waek 
2 ()( 3 limes In the pasl month 
01 
02 
03 
04 
05 
06 
07 
01 
02 
03 
04 
05 
Once in the past month 06 
Never 07 
No [Sldp to Q 10.34J 
Yes 
o 
Rarely 
«=1Iweek) 
Often 
(>=2!week) 
Drug 1 ______ _ 
Drug Ii _____ _ 
Drug 111 _____ _ 
I nonl, 111"1 bli nk] 
00 a 8~ernatlvet\radhonaVherbal mediCIne 
IC In the past 6 months? 
Idrdl onty onlJ 
1/11 ou aHa natlVailradrtlonaVherbal traatments ()( 
(h bs, I . Pills, eUs etc) WIthin Ihe past 6 monlhs? 
(drd. any onel 
you 1181' u ad a ernahveltracillonaVherbal treatments 
of HMRT 10 tl t your HIV Infecllon? 
lordl only III mOIl rlCtlll onlJ 
o 
o 
o 
No 
Yes 
No [Sldp to Q 10.37J 
Yes 
Never 
Yes, In the past 4 days 
Yes. In lhe pasl waek 
Yes. In the past 4 waeks 
Yes, In the past 6 months 
(HeNOI appllclble; as-Declined to answer; "",,0 not know) 
M.lin Form (MALAYSIA): Adhmnceto HAART In Refugee and Host Communilles 
10 
o 
o 
1 
2 
3 
4 
5 
193 
fO RM 3 
[circle only one] 
Not true Sometimes Often true true 
'To 
2 3 
2 3 
I should because I don't have enough money for 2 3 
2 3 
SECTlON 11: Patient-Provider Relationship, Clinic, and Social Trust 
[circle only one] 
Neither 
Strong Disagree disagree 
agree 
nor 
Agree Strongly 
agree 
Ith cae proViders 
often? 
disagree 
2 3 4 
2 3 4 
HMRT doctor [Sldp to a 11.06] 
NLfse 
HIV or HMRT counsellor 
Outreach home-based care 
5 
5 
01 
02 
03 
04 
Shetter home-based care 05 
Health coordinator or worker from your commumty 06 
Other cbctor 07 
Other (Specify: ) 08 
Do not know 99 
[circle only one] 
Neither 
ng abOut th person. hON much do you trust that ,, ' Strong 
disagree Disagree 
agree 
nor 
disagree 
Agree Strongly 
agree 
era the best medICal care they can provide? 2 3 4 
n $ to give you the best care possble? 2 3 4 
about YOLf expenence With this cliniC in the last month." 
Less than 30 minutes 
30 minutes - less than 1 hour 2 
1 hour - less than 1 5 hours 3 
1.5 hours -less than 2 hours 4 
2 hours or more 5 
No [Skip to a 11.09] 0 
I'n-Nol IjIpllclblt; sa-Declined to answer; .... 00 not know) 
M.lIn FOI1Il\MALAYSIA): Adhel'tnce to HAART In Refugee and Host Communities 
11 
Yes 
5 
5 
194 
FORM 3 
Malaysian Ringgits 000.00 
you ever unable to refill YOll HAART 
t the pharmacy even ~ you wanted lo? 
No 0 
Yes 
No [Skip to Q 11.12) 
Yes 
o 
It costs too much to go to pharmacy 01 
I cannol leave my chil<ten alone 02 
I cannol miss work or I will be fired 03 
I am nol motivated 04 
I I I warted 100 long at the pharmacy 05 
The stall al the pharmacy did not understand me 00 
The s1all at the pharmacy tllned me away 07 
Fear of being slopped by police if I travel ~ 
Other (Specify ) 00 
you about lhe people eround you 
00 iOU In t I most people would try to take advantage of you 
go! I challQl, or would Ihey try to be fair? 
Take advantage of you 
Try to be fair 2 Iclrd. only on.) 
• king would you say thai most people can be Most people can be trusted 
11 I ~. or I I you can't be 100 careful In dealing wrth people? 
(dldt onty one) 
Can't be too careful in dealing 
with people 
2 
11 t. 
11 6 
No 
Yes 
Not applicable 
He you dlscloaed your HIV status 10 others In your community? 
larde only on,) 
[7711ff0lIjlpllclblt; "-Declined to answ.r, .. sOo not know] 
~n Fonn lMALAYSIA): Adherenc. to HAART In Refuge. and Hosl Communities 
12 
No 
Yes 
No 
Yes 
0 
1 
T1 
0 
0 
195 
20 
2.02 
FORM 3 
you some final qucshons about your HAART medication The medications you said that you take 
d ent of mtck. on.lhty Ii.ttd In Q 09.01 and to think libout do.ta •. g. 1111 pills tlken at one tim • . Remind them 
II ttlty p/l)~cIt will bt compiltely confidential] 
o en did you take your HAART 
you ability to t ke all yoor medICatIOns as preserVed over the 
upl9d your HAART In the past month for any reason. for 
None ci the time 01 
A little of the lime 02 
Some ci the time 03 
A good bit or the lime 04 
Most or the hme 05 
All or the time 06 
Very poor 01 
Poor 
Fair 
Good 
02 
03 
04 
Very good 05 
Excellent 06 
203 Y consecutive days did the longest mtocruptlon last? 
1 day 
2 days 
3 days 
4 days 
01 
02 
03 
04 
05 
lartle onlyonl] 
>4 days 
Never Interrupted 06 
• you pr VIOU Iy takmg a different HAART regimen than the one you are 
curren' mg (it'lcluang In another place such as another cfty. province. or 
oountry 'o'Alore yoo lived 111 the past)? 
idtelt only one] 
205 1 YES to 12 03. can you Specify 
fi>tf'lMI/lAI the oanes 01 those 
'!OIlS thet you took 
y? 
(prompt client to rtmtmbtr tach 
pqv10Ut HMRT reglmtn. Uti ont 
ttQI en on mn lint (tach pill by 
trlde n.mt or detcrlbt pili by "'apl 
IIId colour I g Comblvfr/Stocrln or 
bill ,reula" .tlrtlng from thl moll 
rteent r men prior to currlnt 
men and going blckwardt In m., 
III 
iv 
No [End] 
Yes 
Do not know 
IOn Now we WlIlIlO to the place 'o'Alere you normally give a blood sample • 
(71 ... 01 appllclblt; UwOecllned 10 answer; "aDo not know) 
~n Form IMALAYSIA): Adhtrtnu to HAART In Refu",. and Host Communities 
13 
o 
99 
196 
CORM 3 
T NTEfMEWINSTRUCT10MS 
doUbI&-dlecked ther HAART medications with their medication card or medtcal record. 
CI I FolloW-up FOI1ll (FOI1ll 2) IS completed. 
In documanl9l1velope and make sure the Chent Code is Vofllten on the front cover 
[77.,.01 IIlpUclblt; '''Decllned to answer; ... 00 not know] 
M.JIn FOfIII lMALA YSIA): Adhertll(l to HAART In Refugee and Host Communilles 
14 
197 
Fot \I \tIQ 10.08 - 10.29 
NEVER RARELY I SOMETIMES I 
(77"'01 appllcabl.; aa-Decllned \0 answer; 99=00 not know] 
n 1'0l1Il (MALAYSIA): Adhtnnc.lo HMRT In R.lugee and Host CommuniUes 
15 
FORM 3 
OFTEN 
198 
zoo, 8 
10 
11 
12 
13 
,811 '" 
'i92 til 
,", 19 
1890 70 
1987 23 
1985 25 
'982 28 
'~1 21l 
INO 30 
--;eY8 31 
~. 32 
,971 33 
'- '87" a8 
~, 39 
1870 "0 
lM9 ", 
111 • 42 
1 7 "3 
1 5 "5 
1 ~ 40 
1 '6l "7 
Year AGE 
1954 56 
1953 57 
1952 58 
1951 59 
1950 60 
1949 61 
1948 62 
~47 63 
1946 54 
~4S 65 
194" 66 
1943 67 
1942 S8 
11141 69 
~ 70 11139 71 
11138 72 
1937 73 
1936 74 
1935 75 
1934 76 
1933 77 
'1932 78 
19~1 79 
1930 80 
1929 81 
1928 82 
1927 83 
1926 84 
1925 85 
1924 86 
1923 87 
1922 88 
11121 89 
1920 90 
1919 91 
1918 92 
1917 93 
1916 94 
1915 95 
1914 96 
1913 97 
1912 98 
1911 99 
1910 100 
1909 101 
1909 102 
1907 103 
1906 104 
1905 105 
1904 106 
1903 107 
1902 108 
1901 109 
1900 110 
(77""01 applicable: "-Declined to answer, "-Do not know) 
M.1In Fonn (MALA YSlA): Adhtnnce to HAART In R.fugee and Host Communities 
16 
FORM 3 
199 
FORM 4 
I W Form: Adherence to HAART in Refugee and Host Communities 
• art or wde 77 =Not applicable 
SECTION 13: tMdlcai record, 
13 
13 
10 -000 Sungal Buloh No. DDDDDDDD 
y 1 
T a 2 
Ch 3 
0000 1301b Age. DD 
Burmese 4 
Other 5 
Spoofy. 
Married 1 Divoroed 3 
Marnal 
13 02b status Single 2 other 4 
Specify 
d HAART I om records (d available) (ddlmmlyyyy) DODD DDDD 
PR ·HMRTIA) HAART START (8) 6 MO. FROM MOST MOST RECENT (0) RECENT (C) 
000 DOD DOD 
IXJIrnmJr;Yf ddlmml/yyy: ddlrnmJr;yy: 
OUOO DODD DODD 
lXJIrnmJr;yy: ddlmml/yyy . lXJIrnmJr;yy: 
,-,,-,,-,00[1 nOnODDD 0000000 0000000 
lXJIrnmJr;yy ddlmml/yyy 
Date (ddlmmtyyyy) DO DO DODD 
Dale (ddlmmtyyyy) 0000 DODD 
Dale' (ddlmmtyyyy) 0000 DODD 
Date DOD (ddlmmlyyyy) DDDD 
Dale 0 (ddlmmlyyyy) OOODDD 
Po Hnttf'Vllw Form (MALAYSIA): Adht",ncl 10 HAART In Refugee and Hosl Communities 
1 
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., 
1318 
1319 
1320 
FORM 4 
IloIOsmce most recent· 
Date (ddlmmfyyyy) DO DO DODD 
most recent' 
Date (ddlmmlyyyy) DODD DODD 
[clrcte only on.] No 
Yes 
o 
No 0 
Yes 
No 0 
Yes 
Rt'Ornen Defau~ Lost to 
~atus follow up I ndicahons for 
Drug 
(>%) mo. (> .. mo. change. rt any 
Ragmen start tOllsetutive ConstcUllve 01 V'nlioad rllCl 
lUst ptilsl and finish missed Rx) mined Rx flilurl) 
each from date of from d., of 02C[)I mgJP.1 PIUs/day lime (ddlmm/yyyy) interview or Interview or 
03 T oIerobityi 
tnt last oide-dodJ (dose) stheduled stheduled 04Achr ..... 
clinlt visit visit 
OS I'M) otag. 
00 Other 
NaO; Y-1j N=O; Y-1j 
Start 0 0 NA 
Finish 
Start 0 0 DO 
FInish' Other: 
Start 0 0 DD 
FInish Other' 
Start· 0 0 DD 
Finish: 1 Other: 
Start 0 0 DD 
FInish. Other 
Start 0 0 DD 
FInish Other 
,. Hnlervi,w Form (MALAYSIA!: Aclhtnnceto HAART In R'!ugH and Host Communities 
2 
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Background FORM 4 
nt (VI wForm: Adherence to HAART in Refugee and Host Communities 
SECTK)N 13" Medical record, 
13 yy Hospdal No 00000000 
DO 
00 
o Yoooo 
Malo 1 
Ftm"t 
0theI (t G trlntoendof) 
BuITnOIO 
othor 
Spotlfy 
MART START (8) 
OrJll 
[Jnoo 
ddJrnmJyyyy. 
1311 Researcher Code [EriCf researcher code) 00 
[Use lust recent of: study end (2t10Ul010) OR death) 
13 iv Date of Data Eolly 1 
13 vi Dale of Data Eolly 2 
1301b Ago 00 
1302b Marital 61atus 
Married 
Smgle 
Divorced 
Other 
0D'0D'2010 
o 0 2010 
Speclfy __ _ 
[ d<VInmlyyyy) 00'00'0000 
6 MO. FROM MOST 
RECENT (C) 
000 
ddlmrntyyyy: 
0000 
ddlmrntyyyy 
MOST RECENT (0) 
000 
ddimm/yyyy: 
DODD 
ddlmmJyyyy: 
......... ~J'-'D[l [J[ ][lnOOD ClDDDDDD ODDDDDO 
d<VInrntyyyy ddlmmJyyyy . 
"'t~.rvi .. lhc_Oround Fonn (MAlAYSIA): Adherence to HAART In RelUgee and Host Communities 
1 
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Background fORM 4 
Viral Load Hi to()' IP'tvIou, 24 month, from plt""t In reWrM chronological order] 
Date 
Data 
Date 
Data. 
Onto: 
Onto. 
Date: 
(tlltll only onll 
Idrtll only one) 
- en 0"1, .~o;onj.,g to reeo<dI h .. ~~ont OlIO< pick up 
olIIDt thin Sungal Blioh Hospital Pharmacy? 
Al Pharmacy1 
At Phermacy2. 
AI Pharmacy3: 
(ddmlml)'yyy 00 00 0000 
(ddmlml)'yyy) 0 00' 0000 
(ddhnml)'yyy) 0 0 0000 
(ddhnmlyyyy) DO 0 DODO 
(ddhnmlyyyy) 00' DO' 0000 
(ddhnmlyyyy) 0 0 0000 
(ddhnmlym) DODO' 0000 
No . 0 
Yes 
No 
Yes 
No 0 
Yes 
No 
Yes 
Data slarted 00 00' 0000 ( cWmmlyyyy) 
Date ended 00 00' 0000 (ddlmmlyyyy). 
Date started 00 00' 0000 ( cWmmlyyyy) 
Date ended 00 00 0000 (cWmmlyyyy ) 
Dale&larted 00'00' 0000 (cWmmlyyyy) 
Dale ended 00'00 0000 (cWmmlyyyy) 
I ""trvlew Blckground Fomt (MALAYSIA): Adherence to HAART In Refugee and Host CommunlllH 
2 
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Regmenstart 
pills! 
each and finish (rY;JJmmlyyyy ) 
Ime 
(dose) 
Stilt. 
Funh 
Start 
FIIllsh 
Start 
Funh 
Start , 
Start 
FInish 
Start 
FInish 
.. a , . .. ~ ... , .... '. 0' .... a10111>lIIIllddlmmlyyyyl 
11M . t dOCtor "0lIl>l1li0 (an:1e II that IPPIy) 
Bac kground FORM 4 
Default Lost to Indications for 
status follow up change, if any 
(>a3 mOo [>almo. Ot Vinolload fond 
consecutive Consecutive foIV.) 
missed Rx) missed Rx 02C04 
from from OlToltnobiltyf 
interview interview 1Id .. .wo<l. 
~'e dat, 04AIfI_ 05~Ostogo 
NaO; yatl NaG; ya11 !Ie ot.. 
NA 
DD 
Other 
0 DD 
Oth« 
DD 
Oth« 
DD 
Other. 
DD 
Other. 
No 
Yes 
No 
Yes 
'D DC1 DDDD 
Viral load ~ncl fakne) 01 
CD4 02 
Toierabjlty/sidc-elfects 03 
A<flerence 04 
WHOstage 05 
other (Specify, ___ -----J 06 
...... !VI .. Back9l'Ound Form (MALAYSIA): Adherenc.lo HAART in Refug .. and Host Communities 
3 
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, 
• 
Background FORM 4 
ilWd8I • . 
Routne 10 doctor blow-up 
RoLtne 10 blood 
Colll$elng 
[. J I...;]OO 132411 Emergency 10 np3liert admlSSlOIl 
Step down (PKKN) Vlsil 
lklsd1edJled 
OIIlor (Specify. 
RoLtlle ID doctor Iolow-up 
Routno 10 blood 
Counselng 
0 DOlJO 1325b Emorgoncy 10 npatienl edmiss.OIl 
Step down (PKKN) visil 
lklschedJled 
OIIler (SpeCify 
Routne 10 doctor 101~ 
Routine 10 blood 
Couo5e1ng 
[ I J[ Yl JDDO 1326b Emergency 10 npatlent admiss.on 
Step down (PKKN)vis.1 
lkoschedJled 
OIIlor(SpeClfy . ___ --l 
Routine 10 doclorlol~ 
Routlno 10 blood 
Couneelng 
[ [lDOO 1327b Emergency 10 inpatient admisSion 
Step down (PKKN) VIs.1 
lkoschedulod 
OIIler (Specif)' . 
Routn. 10 doclor bl~ 
Routne ID blood 
ColMlSelng 
[1 tl I YOIJ[][l 1328b EmellIency 10 Inpallenl admission 
Slep down (PKKN) visil 
Unscheduled 
OIIler(Specif1: ____ ) 
Routino 10 doclor blow-up 
Roulne 10 blood 
ColMlS.ling 
0 []I i LJODO 1329b Emergency 10 N1pa\1onl admisSion 
Slep down (PKKN) VlSlI 
lkoscheduled 
OIIlor (Specif1 : 
,..,·lrUMtw IIc_ground FOI'1II (MALAYSIA): Adhtrtnce 10 HAART In Re1ugee and Host Communlllts 
4 
01 
02 
03 
04 
05 
06 
07 
08 
01 
02 
03 
04 
05 
06 
07 
08 
01 
02 
03 
04 
05 
06 
07 
08 
01 
02 
03 
04 
05 
06 
07 
08 
01 
02 
03 
04 
05 
06 
07 
08 
01 
02 
03 
04 
05 
06 
07 
08 
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Background FORM 4 
Routine 10 doctor folow-up 
ROWle 10 blood 
Counselng 
l YOC}OOOO 1330b Emergency 10 npooent admioSioo 
Step down (PKKN) visit 
Ulscheduled 
Other (Specift --------J 
RoWri8 10 doctor folow-up 
RoWle 10 blood 
CoLmelng 
0 YO YO[[]O 13 J1b Emergency 10 npatlont admiosloo 
Step down (PKKN) visl! 
Ulscheduled 
Other (SpeCltt: 
Routn8 10 doctor folow-up 
RouI.IlelO blood 
Counseln9 
Ye i t JOO 1332b Emergency 10 npailont admISSIon 
Step down (PKKN) VISIt 
Ullcheduled 
Other (SpeClf1 . ______ J 
Routine 10 doctor folow-up 
Routine 10 blood 
Cocmelng 
e I 'r / l 1000 1333b Emergency 10 II1pabont admISSion 
Step down (PKKN) YISIt 
Ulscheduled 
Other (Speatt . ___ -----J 
Ro~e 10 doctor folow-up 
Routne 10 blood 
Col.llieing 
0 10 0000 1334b Emergency 10 npatlcnt admisSIon 
Step down (PKKN) visit 
UlSl:heduled 
Othor (SpeCIfy ,_ 
----) 
Roubne 10 doctor folow-up 
Routillo 10 blood 
Col.llsolng 
0 0 ;]000 1335b Emergency 10 inpatient admisSion 
Step down (PKKN)VI$d 
Ulscheduled 
Other {Specift, 
I~ Mtw s.c_,.ound Form (MAlAYSIA): Adhtrence to HAART in Refugee and Hosl Communities 
5 
01 
02 
03 
04 
OS 
06 
07 
08 
01 
02 
03 
04 
05 
06 
07 
08 
01 
02 
03 
04 
05 
06 
07 
08 
01 
02 
03 
04 
05 
06 
07 
08 
01 
02 
03 
04 
OS 
06 
07 
08 
01 
02 
03 
04 
05 
06 
07 
08 
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Background FORM 4 
Rottlne 10 doctor foI~ 
Roubno 10 blood 
Cooosell'lQ 
1OCJOmD 1336b Emergency 10 I'lpatJent admitSloo 
Slep down (PKKN) viSlt 
U,schecluled 
OIhor(Spectfy - __ --J 
RoulJ'le 10 doctor bl~ 
Roulr1. ID blood 
Co\l'lsell'lQ 
0 1000C 1337b Emergency 10 IIlpatlent admISSIon 
Slep down (PKKN) viSIt 
U,scheduled 
OIhor (SpeClf/ : ______ ) 
Rottl'le 10 doctor blow~ 
ROttl'll 10 blood 
Co\l'lSell'lg 
0 [ OJlJO 1338b Emergency 10 npabon! admISSIon 
Slep down (PKKN) VISIt 
U,sclleduled 
OIhor (SpeClf/ 
- ) 
ROubne 10 doctor bl~ 
Routine ID blood 
CoUO$elng 
ioe/ OOOO 1339b Emorgency 10 npabent admISSIon 
Slop down (PKKN) VISIt 
U,schoduled 
OIhor (SpeClf/ ' __ 
- ) 
Rottl'le 10 doctor blow~ 
Rout.,e 10 blood 
CounseinO 
10 0000 1340b Emergency 10 np3t1ent admitS!on 
Step down (PKKN) visit 
Unscheduled 
OIhor (Specif/: ______ l 
Roullne 10 doclor bl~ 
Rottine 10 blood 
Co\l'l$olno 
YO 1 []ODO 1341b Emergency 10 inpatient admISSIon 
Step down (PKKN) VISIt 
Unscheduled 
OIher (Specify: 
1-1"1 rrl... (~ground FOI1II (MALAYSIA): Adherence 10 HAART In Refugee and Host Communities 
6 
01 
02 
03 
04 
05 
06 
07 
08 
01 
02 
03 
04 
05 
06 
07 
08 
01 
02 
03 
04 
05 
06 
07 
08 
01 
02 
03 
04 
05 
06 
07 
08 
01 
02 
03 
04 
05 
06 
07 
08 
01 
02 
03 
04 
05 
06 
07 
08 
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FORM 5 
Ph rm 'I CI 1m F rm: A h r nee to HAART In Refugee and Host Communities 
fnd fHtI. F« h clarn. '" reverse chronological order. indicate the next Dispense Dale. 
PmJocn'bI~por Dey. calculate the To/al Expected Claim (TEC) Enter all tablets collected on 
m I TAC) (Note Claim Accvracy and Clarm status WlU be evaluated by the Study). 
tnlormaflOlllS provdad by the STUDY 
TEe. clfde 1 (Yes) If 3 < CA <·3 of TEe. circle 0 (No) 
~ claims. divided by total clams over the total clam period xl00. 
Hosphl No.: 0000000000 
/2010 ,. ii Researther Code {Erter mearcher code) DO 
UD 14 1\/ Oat. ot ~II Enlry 1 00'2010 
00 14111 ~t. ot ~tl Entry 2 0 0 0 0 2010 
o 00 2000 
o 00 2000 
DIY' Total 
Bttw .. n Expected Total Claim Claim 
DI pen .. Totll Claim Actual Accuracy statUI 
oat" Table .. (TEC) Claim (CA) (Circle. 
(Renge day Prttcribtd (Total tob/ets (TAC) (TEC- TACI O='N; 
.tor prevIOUS per DIy reqLJnld (Tolal tablcfs nO] 1=YJ 
tillmunti (tiD) Since coUected on ADMIN ADMIN 
day otnext p!ellIOUS DO) ONLY ONLY 
cllm] clllm] 
ODD 00 DOD DOD DOD 0 
DO DOD DOD DOD o 1 
DO ODD ODD DOD o 1 
DO DOD ODD DOD 0 
LJU UOU UUU DUD 0 
00 DOD ODD DOD o 1 
/lt11ll - Fo"" , (MALAYSIA), Adherent. 10 HMRT In RtlJgM and Hos! Communfties 
1 
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FORM 5 
DIY' Totel 
a.tw"" ExplCttd Total Claim Claim 
- - t.~ 01 pen .. Total Claim Actual Accuracy statUI 
• OlIn Tablet. (TEC) Claim (CA) (er-cte • 
. ... (lb. day Prtteribtd [T olall3blols (TAC) [TEC- TAC I O=N; t it • 
-nl . t prevlOUi per DIy leqIJred [Total lablets no) 1=Y) 
ctamurd (lTD! Slnee colocted on AOIoIN ADtofN 
dlY of",-' prevIOUS DO) ONLY ONLY 
'lallll) clam] 
lIYcr¥20 ] DOD DO DOD ODD ODD a 1 
[1 'Yfr ~20 nn ncn :JD DDCl ODD ODD a 1 
[11( lC/20 00 ODU .JD DOD 000 000 a 1 
[] Y[T.Y20 [10 O!JI] D[J DOD ODD ODD a 1 
[DO 120nJ ODD 00 ODD ODD 000 a 1 
[00[/20 ] DOn DO DOD DOD ODD 0 1 
[1f(OCf20 l ] OOU [J[] DOD DOD ODD 0 1 
rncr::V20 ] ODD DO DOD ODD ODD 0 1 
Dr{CI /20 10 Don DO DOD DOD ODD 0 1 
DOJITY20 tJO ODU DO DOD ODD ODD 0 1 
I C.I:YOC 20 no Don DU DOD DOD ODD 0 1 
cr/O[Y2~J O[JD DO DOD DOD DOD 0 1 
I [(;/0[/20 ] Don 00 000 ODD ODD a 1 
CDOCf20 J OOL] L.JO DOD DOD 000 0 1 
[[VO[Y20 I: o[llJ [JO DOD 000 DOD 0 1 
12 LIJDCf20 ] DUO 00 DOD DOD 000 a 1 
[[YO[Y20 t ] [JD DO DOD DOD ODD a 1 
- Summary[ADMIN ONL Y1 
I·U. 14 25 1426 
Total ~Im. O~I d tom penod Total pharmacycllfm, Raw Idherence acor. 
od r1 Oatl - Claim 
aubmlttad (Column 14.24 + Column ~erlod End DI"I 14.25xl(0) 
DOD UUU 00.00 
y Q - Form 5 (MALAYSIA)' AdMAn" 10 HAART In RekigM and Host Communkles 
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FORM 6 
I Gu d for CII nt : Adherence to HAART in Refugee and Host 
lid meal (obtain signature) AssIs! cken! 10 finding their way out of 
, nrequfed 
0000000000 
R .. urthtr NllllelCode 
.--00 
InltNIlW End nme 00:00 am,tlm 
Cllenl Gendtr [circle) 1 Male 2 Female 3 OIher 
Folder. File ,. 
o 
o 
x 
~:~=~~::.~ ... TIl CALL SUPERVISOR 014 m 8117 (Josh) or 017 308 80lG (MaIIlbi). 
~ <:AU SUPERVISOR OH.,. 11IT (Josh) or on 308 to30 (Mal Mal~ II SupelVisor Is unlVlllabl., clll 
" I nlllrm,d 0111 .... ' e. 
~J~~~~~~~~~ A dtnlff lIley .Ish 10 ",ctln counselling. If lhey tonstn~ CAll SUPERVISOR 014 na 8m 
III No III1d Cllenl COnlla TeL No. 
- Form I (MALAYSIA): Adherence 10 HAART In Refugee and Host COmmunities 
1 
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Notes [UM to .ni. with probingl 
(-15m!n] 
[-10 min) 
(-20 min) 
(-30 min) 
CONTINUE ON on NEXT PAGE 
.. Olen - FoI'II\ • (MALAYSIA): AdMrtnC. to HAAAT In R.~g.t and Host Communlles 
2 
FORM 6 
211 
[-16 min] 
QItf\ - Fo"" • (MALAYSIA); Adherence to HAART In R.lIg" and Host Communlles 
3 
FORM 6 
212 
FORM 6 
of III mlln polnltlhlllll1trged from th, inlerliew in relation 10 the r_rell 
....... "". "" .... ~ TIIjII IW ClMnIl • forni • (MALA YSlA); ""'-_ce to HAART In Rellvee and Host CommunliH 
~ 
213 
I c:._ ....... of .... _ . _ 'ft\'rlIt tlWlOtd eummtry 01 tI1, lnltMM using tI1, main topic." • guide) 
~ -1'01111 ' (MALAYSIA) : AdhtI'lllC8 10 HAMlin RefugH and Host Communities 
5 
FORM 6 
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FORM 6 
).nct WIlt. them hef • • U.1en to the recording. and write them both in the 
English 
0\Im ~""c:t Of th.lnttNfew and yoor thoughlt on this client and their derence to 
lid and eny obIItdt. they h.Yf ov.rcom.) 
Otrnb - 1m' (MALAYSIA). Adhtl'tncelo HAART 10 Refugee and Host Commun~lts 
6 
215 
FORM 6 
"'II wtIIl MIt IIbou1 thelnttMew Ind 3 thin!/, that you wilh 10 Improve about your 
- FoI'III • (MAlA YaAl' Adhtrenc. to HAART In Rttlg" Ind Host Communkies 
7 
216 
D TOPIC GUIDES 
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FORM 1 
Eligibility and Registration Form: Adherence to HAART in 
Refugee and Host Communities (Sections 1-6) 
I ItSTRUCTlONS , 
I E Iy Vwlth the ebenl 
2 
3 
4 
5 
6 
exactly as they are .",-rtten on the page Be sl.le to read all the adcitKlnal prompts In "QuolatJon 
bold tnstrucllOllS In square Inckets. but do NOT read them out loud J 
'Olher' remember to speofy 
ng a queshon be .u~ to prompt with r .. pon .. optiont unless rt IS indICated [do not prompt). 
ny OlV9n unless rt you are Instrucled (clrcll onlyonl) 
a, CIrcle a- .",-rte In boxes. or Wile in Ihe right-hand margin Senal7s (eg 7, 77. ro, etc);Nol 
• SeriaI8saOechned to 8nswer; Senal9s=Do not know Never prompt WIth Ihese optlOOS 
0100 jMnln only! Client Code: 20 -000 
SEcnON 1: Identification 
0101 ,. (Enter your ,. ... reher cOdl) 00 
010'2 T oday's date Iddlmmlyyyy) D 0 20 00 
l.,tlrvilWlI S p 10 Q 01.07) 
0103 De' entry I 00 0104 Dete of data entry 1 0 0 20 00 IEnter your ,.. .. IdI.r cod.) I ddlm mlyyyy) 
0eIa y2 []O Date of dala entry 2 ( ddlmmlyyyy) 0105 IEnter your r .... IdI.r cod.) 0106 I ddIm m/yyyy) 0 0 20 :]0 
rhll otnl til. f Ing) 
"Today 'flO people for e study about HIV treatment We 'M)uld like to assess Wlether or not you are ehgble 
"III can conmut ,thos 'NIl lake lUst a law second:; Afterwards you WIll be gIVen a choICe about your partlCpatlon' 
Routine doctor ~Intment 01 
Why 
Counseling awomtrnent 02 
va you corne Rouhne medication pick-up 03 olhednct 
-n 
0107 AccompanYing fnend, relative, or spouse 04 
Idldt only 0011 Contacted by sludy team and invded for scheduted IntervIeW 05 
Heard about study and hava come for InterVlswimore Information 06 
Oth. (Speedy ) 07 
(T7.Not ""pIt ble, 8"o.cllned 10 answ.r;It.Do not know) 
Eli ty Ind Rig! l'ltion FomI (t<E NYA): AdII."nu 10 HAART In "tug" and host communities 
1 
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FORM 1 
SECllON 2, Lenguage 
0201 
02 CD 
. , 
Id 
English 01 
KIswshlh 30 
Jube hablc 31 
Other (Specify 
, r;Ilef ontyl en IIlllllJ)reter be requlf'ed? 
02 03 ,_ YES, a'ICI ~c:II" 'en KI .. In Interpreter, continue. If not, ... th. Coordinator] 
I ' condUCIlid In 
02 If "'" pie III\gUIget lleed. 
clrcI • .,. pnmaty ngutge ueed] 
SECTION 3: Inf()I'fMtlon Sheet 
Enghsh 01 
KlswahJiI 30 
Jube hablc 31 
Other (Speclty 
.Amharic 
Somali 
Nga1urkana 
) 
No 
Yes 
No 
Yes 
.Amhanc 
Somah 
Nga1urkana 
) 
I Qt1f1'Iof 1M lnIonna'on 101m. ANd fl. Inform ilion th.,t out loud.) 'Vo you have any quesbons?' 
No 
Jdlt< only) lin 1M dJ8fl1 r d'h rd the IntormaiJon sheet? 030 Yes 
SEcnON 4: Screening 
0402 
a : aI bith - cient reported 
IdC'nvnI'mvI 
b oat aI bith -recorded 
on R Qlfd or bty 
card Icktmmlyffll 
0 0 
Dnn 
Male 
Female 
Other (8 9 transgenderntanssexual) 
onno 0403 
Age 
DODD (Cllcullte from Q04.021.) 
(R etfc:hw only) Respondent> 18 years of age? 
()404 (If NO, UP/1011 wily they cannol bt Included In Ihe study and end thelnlervlew] 'Thank·you • 
No [End] 
Yes 
04051 fa 01 HAART stJrt? [dd/lnmlyyyy) 040Sb 
Kenya 
Sudan 
0 [ IL YULJULJ Country at Somaha HMRT starl Ethl~la I"'''' llllIIre mm¥yyy I. compllll, Prompt DemocrallC Republic of Congo 
dlllt by. gil"." WII.' beginnIng of Rwanda 
r-r, mld·yell. or tnd ytlr) Other (Specdy ) 
/n-NOllPpaclbI., "-Declined 10 answer; ... 00 nol know) 
Ehll'D Ity Inc! Alglstmlon F""" (KENYA): Adh.ren .. 10 HAART In ",lug" and host communlles 
2 
32 
33 
34 
50 
0 
0 
32 
33 
34 
50 
o 
1 
2 
3 
Oel 
years 
o 
04 
05 
06 
07 
OS 
09 
15 
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FORM 1 
HMRT "ltl8ted >-30 days before loday? 
,"I " HMRl' at J1ed II'Id , .... for >1130 daY' before today. whatever their 
"'"' tIM," ""', "NO. 'lIPIlin why t!1,y CII'Inot be Included In thl. atucty and 
tnCI ) 'Tyou 
-Up ywt HAART from the ComprehensIVe Care Cllmc (CCC) In 
~, 
No [End] 
Yes 
No 
Yes 
up yOtS HMRT from someplace else? 
No (Sldp to Q 04.09) 
Yes 
yOII CllTIIlI na\lon8'tylcountry of 
cCIZens!:o? " you ha ne her pi ase tell me 
yof eng ... (tlrd. CIIly onl) 
().4 10 • yW NTenI Ius? 
lei"" only OM) 
[ddlmmlyyyyl 00'000000 
Kenyan 
Somali 
Sudanese 
EthloplSn 
Congolese 
Specify crty 
04 Rwandan 
05 BurundlSn 
06 Entrean 
07 Other 
08 (Specify ) 
Clllzen or Kenya 
Refugee 
Asylum seeker 
09 
10 
11 
16 
o 
o 
o 
01 
02 
03 
other migrant 04 
No (Sldp to Q 04.(3) 0 
Yes 1 04 I He you curen\ly p-egnanl? (clrcll only onl) 
No 0 
Yes 1 04 121 Nt you cur.nlly I 1119 HAART durinO your pregnancy? (clrcll only one) 
No 0 
Yes 1 HAART before your current pregnancy? [el rei. only one) 
No (Sldp to Q 05 011 0 
Yes 1 been pregnanr? (clrel. only on.) 
No 0 
Yes 
No 0 
Yes 
11"01 "'Wdng alflll'll prtgnll'lcy. lf .ny) Have you ever laken HAART 
01 8'1'( prevIOUS pregnancy? lei rei, only one) 04lo1t> 
(H-NOI IIlPlcilllI.; "-Declined to answer; "-00 not know) 
Ell Ity and AII;IlI'llUon Fonn (t<ENYA): Adh."nce to HAART In "full" and hosl communMlu 
3 
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FORM 1 
SECTION 5: Informed Con.ent 
r _I lonn Read thl conlMl'll fonn out loud.) ~Do )'Ou have any questions; 
No 0 
gree to partq>ate by SIQllIng the consent form? 
Yes 
No 
Yes 
• . J..Iio.OI.,I;ILlI.Xo1W~ go 10 F .you I wWd tY:1N like to start asking you the man study quesbons • 
VII 10 Q MOl) "llolor. you go, rrtIIf I you IU$t I lew qUick quasbon$7 
SECTlON 6: Re .. ont for Non-Pncipation 
01 
0602 
100 noc pfO!l'PC IIld CIrcle en lilt apply) 
Not Interested In the study 
Old not have time 
Old not understend informatIOn about the l.iudy 
Other (Speedy ) 
Other (Speedy 
Declined to answer 
Dlsabllrty 
Language ddflCUHI9S 
) 
l71oHollPpl"ble; ",o.ctlned to an,wer; ""00 nol know) 
Ell ~111Y Ind Ro;",,,, •• " FOIIII tIiENYAj: Adht",nctt. HAART In relugee and hosl communHles 
4 
o 
1 
2 
3 
4 
88 
2 
3 
22 1 
FoHow-upForm: Adherence to HAART in 
Refugee and Host Communities 
FORM 2 
Co l cl d tails 
00 
000 
OO~ 
0003 
0001 
0005 
0006 
00071 
OOO7b 
OS 
0009 
000 
code (Tl1necribt from f orm 11: 20 -00D 
ICAJNHCRNo 0000000000 
IIcIII\IC IdanhllCatlOn No DODD 
TeIep/lOI18 No (Home) 
T tItphOne No (Mobtle) 
email 
' name nOO1berN~1 ge n me' 
Zone number (In camp), 
Block number (In camp) 
Poslal number 
City ItaNn 
Post code 
'PI I It 2 contact telephone numbers (e.g. mobile + friend's mobile or mobile or home) 
FCIIlowUII ~onn II<ENYA) Adhertncelo HAART In Refuge. and Host Communllu 
1 
222 
Main Form: Adherence to HAART in Refugee and Host 
Communities (Sections 7-12) 
SECTION 7: Identification 
07 IT'" ~bt !tOrn Form I) 20 -000 
F'ORM 3 
DO 0702 Date of Int9rV1ew 0 0 2000 070 (ddimm/yyyy) 
0703 DO 0704 Date of data antry 1 0 20 00 )ddlmm/yyyy] 
0703 00 07.04 Date of data entry 1 0 20 00 (ddimm/yyyy) 
SE eTlaN 8 Soc o.Demographic and Background Information 
080 
0802 
0803 
Kenya 
Sudan 
In c:ounlry • you bcm? Somatla 
Ethlqlla 
IClrClI only ont) Democrahc Republic of lhe Congo (DRC) 
Rwanda 
Other (Specify' ) 
Chnslian • Catholic 
you r 19IOII? 
Chnstlan • Prolestanl (Specify: ) 
Muslm 
(dICIt ooly ant) 
IdlClt onty ont) 
No religIOn 
Tradrtlonahst 
Other (Specify 
Currenlly marrted or living as married. 1 spouse 
Currently marned Of liVing as married, > 1 spouse 
Not married, currently In a relationship WIth I person 
Current Iy married, liVing as married, and/or In a relationship Wllh >1 pen;on 
Dlvorcedlsepareled from marriage and currently single 
Widowed and currently Single 
(7)-NoIIPPMc ble; "-Declined 10 answer, .9·Do nol know) 
M.1n Fonn (KENYA)' Adhertnci to HAART In Retug •• iI/ld Host Communities 
1 
SlOgle 
04 
05 
06 
07 
08 
09 
15 
01 
02 
03 
06 
10 
11 
01 
02 
03 
04 
05 
06 
07 
223 
fORM 3 
Pnvate house or apartment 01 
Dormitory 02 
Temporary homeIT ent 03 
Gues1 houselhotet ().1 
None 05 
IypI 0/ lOCO 1IIIOOabon 
~ 04 do you currently Will? 
tdrdt 0tIIy-1 
Other (Spectfr ___ -I) 06 
DOD 
Kenyan Shillings DODO. 00 
Kenyan Shillings DODO. 00 
~07 Y \/Ok for pay outSIde or InSide the horne? [circle only onel 
~oe v chlkien? (elrdt onlyonel 
08.09 If you many cUlTenlly live wrth you In the same household? 
08 10 you Ii e your tvrent standard of bVlOg? [el rei, only onel 
I' eli.", II T CUI ... tly a rillugH or ttylum ... ker • SKIP '0 Q 08.141 
08 tt monthly_ did you enter this country? (mm/yyyy) 0 
0812 Mr' you regIStered wl1h UNHCR? (mrrJyyyy) 0 
'liQUid }'OIl rute your standard of hVlng prIOr to leaving your home 
08 13 c:ooo 
(circle ontyontJ 
In the list t2 montht havoyou been away from the communrty 
08148 you arrantly iva lor one continuous month or more? (circle only oneJ 
How many lmet have you been away from the community for one ~ 1 CO eontllUOUS month or more (10 the pesl12 months)? 
(77oNot ilPplcabl,; ".Decllned 10 IIlswer, .. ·00 nol know) 
No 
Yes 
No [Skip to Q 08.10J 
Yes 
Record number: 
Very poor 
Poor 
Average 
Good 
Very good 
DODO 
0000 
Very poor 
Poor 
Average 
Good 
Very good 
No [Skip to Q 08.161 
Yes 
DO 
~In Form (l(£NY Al Adhtrencllo HMRT In Re~~ee IIId Host Communities 
2 
0 
1 
0 
00 
1 
2 
3 
4 
5 
1 
2 
3 
4 
5 
0 
224 
~16 
~18 
f'ORM 3 
8nployment 01 PrIson or <iltenhon In country 07 
Trade 02 Healthofelated 08 
Famlly-related 03 RehglOnofelated 09 
PoirtlCal reasons 04 Holiday 10 
VIOlent conflict 05 Involuntary deportatIOn 11 
Educahonofelated 06 Other (Specify ) t 2 
rlO$Od 8S h8vlllg HIV? 
Started IlVlI1g here < 12 months ago 13 
Voluntary return to horne country 14 
Nomadx:lPastorahst 15 
Have never attended school 
Attended but did not complete prrnary educah(ln 
Completed primary but did not attend secondary 
Soma secondary but dd not complete ~ 
Completed socondary but did not go on to college/univerSIty 
Some college or unlVersrty but did not complete rt 
Completed college or UniverSIty 
01 
02 
03 
04 
05 
06 
07 
Language School only (Enter no of years completed _ 08 
DD 
f.Jways 
Most of the lime 
Some of the lime 
1 
2 
3 
Never 4 
(mmlyyyy) DO DDDD 
tn c:oun 8)OU diagnosed as haVIng HIV? ~ 20 (QrcM cnty OM! 
Your home country 
Kenya 
1 
2 
3 Other (Spady ) 
No 0 
~21 Is Va f mgda your body? Idrcl. only on.! Yes 
Do not know 
08 22 C#f\ HIV \"rU cause AIDS? Id rei. only on.) 
No 
Yes 
Do not know 
08 23 yad )OU orl\llll8l n HIV 
Voluntary test as general precaution 
Voluntary test recommended by a health care provider 
Mandatory test (e g In prison) 
Fear that t had been exposed to HIVand wanted to know 
for sura 
Had symptoms such es fahgue, v.elght loss, etc. 
Other (Specify ) 
t (11'1 fir )1 
(00"01 prompt elrd. only on.) 
171ofio1IPP.Clbft; "-Declined to answer, HoOo not know) 
IN" ""l1li (l(EHYAI: AdhtrenctlO HMRT In Rt"UH and Host Communltitl 
3 
1 
9 
o 
1 
9 
01 
02 
03 
04 
05 
06 
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F'ORM 3 
SECTION 9 HAART Medications, Adherence, and Side-Effects 
IComp'" W. ~ .. II lilt client IIId compere with rec:ordt. Rec:oncUe any dlfferenc. with the client.) 
PI.-~U$ to idantry the HMRT medlCSlions you are currently taking doses, pills per dose, and doses per day 
It e'e 1-5 below lor Mch HAART medication currently Ultd by the clllOl. Use POlt'f1IJl~or pill bookl to 
090 lfor S. -wlea on mUlt come Irom medical racord. Mark 0 II different; 111 um.; 911 not known. Wh.re the 
n. ,," tIIlt!han the on. prOvided. pl ... wrlt. thl brlnd nlmeln CAPITAL LmERS In th.l.ft~lnd margin . 
1 lilt d Int ~_ e mt<klIUon that I. not 1I,1td, pi .... write the brend n.meln "Other"l 
Slip 1 Sttp2 Step 3 Step 4 
T Dose (Iolal mg) No Imes per da Y No pills each 
IOrdtlllll"be' ~'Y nd I that IppIy) (pflr label) (doses per day) tme 
AZT+3TC 01 JOO [J 0 
3TC-+{j4T +NVP 02 DOD 0 0 
evirapine (~ 03 000 D 0 
Efcure (EFV) 04 000 0 0 
Aluvia (IF'V ) 07 000 0 0 
Zidovudine (AZT) 10 ODD 0 0 
Stavudine (<I4T) 11 OO[J 0 0 
t---
Lamivudine (3TC) 12 oO[J 0 0 
Abacavir (ABC) 16 000 0 0 
Viread (TOF) 17 ODD 0 0 
Viracept ( FV) 18 DOD 0 0 
-
AZT +3TC+NVP 19 000 0 0 
-
0902 
D4T+3TC 20 DOD 0 0 
Other 1 21 DOD 0 0 
Other 2 22 DOD 0 0 
--
I Rt ... rthet only) Was Ihe cilllnl able to IISI ALL a Ihelr HAART medica lions wrthout 
nee? IEnt.r -v,,'U client Cln name their medlcationl, or Identify them from I 
pot1tI, pili bOOlI. or tIIl/r own medlcldon bOllle) 
(77,,"01 IpplclbI.; "oDecllned to Inswar, •• 0Do not know] 
libln Form (l(ENYA) Adhtntnceto HMRT WI Re-'gee and Host Communities 
4 
Step 5 
Confrmed WlIh 
records 
U 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
No 0 
Yes 1 
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09 04 
0905 
09 06 
0907 
FORM 3 
1C«npIeIt!lle teb4. below wUh the cll.,t, uling on. lint for tlch HAART mtdiCition th. eli tnt It IUppo.ed to be 
II II>d v.n; fit .bbr .... atlon. from Q 09.01 . W client did not mill any do .... write. zero (0). W the cli.,t mined 
dOMt. wll" 1YI0 (2), II they ml"ed thr .. do ... (3) tte . Not. thlt Iha "bit .sklabout FUll DOSES MISSED, NOT 
Pl.I.S .!$SED 11 dltnl mpondt tIllllhty took onty a portion 01. do .. on one or mort 01 th ... deyw (e.g. 1 oul of 2 
pi .... ttport tht do .. (I) .. btlng ml.Md. lalt do ... do nol counl .. ml'18d.) 
fUll Irtdt nemt Ind numtric code !rorn 
QOIl 01 J"Tht HMRT meek.n,,"fO'J tQl(t 
ere ' 
00 
00 
• 00 
DO 
Doses mIssed 
ye::.1erday (I 
day ago) 
o doses 
[J doses 
o doses 
[l doses 
Doses mISSed 
the day before 
yesterday (2 
days ago)' 
o doses 
o doses 
o doses 
o doses 
Dlling IIIe ~ foUl d.Y' on how many days have you mISsed taking all 
Y\lII doses? 
~rdt 0t"Iy on., 
Mol;! HAART m«IIcahons neod to be taken on a schedule, such as '2 
tmes a day or '3 limes a day' or 'every 8 hours ' How closely did you 
'fO'S spec'lC schedule over the last four days? 
!dlde ody ont) 
Do any 01 your HAMT medlCalions have spectallnstruc1lons, such as 
'Ill e h fOO<f or 'on an empty stomach' or 'With plenty of fluids'? 
(elldt only ont) 
If • how often elld you follow those speciallnstruchons 
OVII Ihe ta· four dlyt? 
(elld. only on. J 
(11oNot applcable; "-Dectlned to answer; .. -eo not know} 
Doses mIssed 3 
days ago 
Doses mISsed 4 
days ago 
o doses o doses 
o doses o doses 
o doses o doses 
n doses o doses 
None 1 
One day 2 
T'M) days 3 
Three days 4 
Four days 5 
Never 1 
Some of the time 2 
About half of the time 3 
Most of the lime 4 
All of the lime 5 
No (Sldp 10 Q 09,08) 0 
Yes 1 
Do not know 9 
Never 1 
Some of the lime 2 
Abou1 half of the time 3 
Most of the lime 4 
All of the lime 5 
lOin Fonn (KENYA): Adht ... n •• lo HAART In Retugee and Host Communities 
5 
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0900 
0909 
09108 
09101> 
" 
0911 
0912 
0913 
091~ 
0915 
0916 
0917 
0918 
0919 
0920 
0921 
0922 
0923 
092. 
0925 
0926 
0927 
0928 
0929 
0930 
0931 
roRM 3 
On ~ ~ys people do not 'Mlrk, such as 'Ml9kend days, hotldays, or 
OIhet ~ they do not work, SOTle people find that Ihey forget to take their No 0 
Oid)OUm any of yout HAARTplUs during your lilt Illy off work, Yes 1 
_ktnd dly. Of hoIldlY? (drdt only ontl 
Wrthln the past 'Ml9k 01 
1 -less than 2 weeks ago 02 
Wllen tilt tme you missed any of your medICatIOns? 2 -less than 4 weeks ago 03 
(cirdeotlty_1 1 -less than 3 months ago 04 
3 months or more ago 05 
Never skip medICatIOns 06 
yOu ~ienced any .1 health SII1Ce starting HAART? No 0 
(elICIt only ontl Yes 1 
He yOu ~nced any dt health In the last 4 _ks? No (Skip to Q 09.33) 0 
(elfelt only _I Yes 1 
I HAVE NOT had this t HAVE had this 
CJTlS have you expenenced In the last .. week.?' SymptOfn during the 
past 4 weeks 
Fat'liUl or toss 01 energy? 0 
F4WIn. chats ()( S'Mlats? 0 
Fee/IIg emy ()( IIghlheaded? 0 
Pa n. nlJ1\blws$ ()( Inglll10 In the hands ()( feet? 0 
Trod:lle rem~lIlg thlllgs? 0 
NaUSl8lt ()( 1IOm(lng? 0 
Fell SlId ~. ()( depressed'? 0 
Fell net\'OU$ ()( arutlous? 0 
DilfiCUly fa1rl9 ()( slaYing asleep? 0 
SIOn problemS. such as rash, cryness or rtchlng? 0 
Cough ()( trouble breathing? 0 
Headadle? 0 
Loss 0( appeIl\e or a change III the taste of food? 0 
Bloating peln ()( 08S 10 your abdomen? 0 
Muse" aches or JOtIlI pain? 0 
Problems WIth havng sex, such as loss of Interest or lack 0 0( sabslacllOO? 
C .10100 Y your body lookS. such as fat deposrts 0 
or ~lQhl gSln? 
Prcblams WIth 'Mlight bss ()( wastlllg? 0 
Her toss or changes In the way your har looks? 0 
Mouth ulcers ()( dlfflcu"y swanOWlng? 0 
<Xher (Speedy ) 0 
(17·NolllppNcable; ".Decllned to answer, ".Do not know) 
Main Form (l<ENYA): Adherence to HAART In RekJge. and Has! Communities 
6 
SymptOfn during the 
past 4 weeks 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
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FORM 3 
0932 0,* (Specify ) 0 1 
0933 IRemlnd chtnlltllt tIlllnformltion they provldl will not be reported 10 Inyert • . Remind diem of the 
"Clben,they IIlttd In Q 09.01 Tum the plgl around to face the cll.nt, hand pen to client. Client must 
mw!IX Ihtm 11_) 
·Put • C10as (X) on the hne below at the POint shoWing your best guess about v.i1at proportion of your 
HAART medIC8!1on you have taken In the last month, e g, 0% means you have taken no medication, 50% 
1\$ you hav taken haK your medICatIOn, 100% means you have taken every single dose of 
tn8dIC&tlon We Id be surpflsed d thiS was 100% for most people' 
j i I 
'"' 
SO% 100% 
'Sc:rne P80IlIe w:lh HN •• also sked to take another aug catled cctrmoxazole (also called 'Septrin' or 'Bactrm') every day I Wlictt pr..... VlWlOUS IlfecOOns th t are more common In people With HIV, Here are some cotrinoxazole tablets' iShow tht 
eOlllmowoltllbltll Ihtt Irt most widely tvelltbltloeally) 
934 Since you a diagnosed WIth HIV, have you ever been prescribed cotrmoxazole No [Skip to Q 10.01) 0 10 .da (I 
935 . ha • you ever I en Ihe ootrmoxazole? 
938 lIIe you CI)'Ienlly on (be1l19 presCribed) ootrlmoxazole? 
937 DId you ta a n yesterday? 
-
SECnON 10 Reasons and BIITiers 
'Tha 
001 
1002 
1003 
1004 
(circle only one) 
Not A little bit Very you lei continue How confident are you thaI . ' confident 
atal! confident confident 
You In able to la e all or most of your medICa lion as 1 2 3 dncted? 
The medlcahon WIll have a posrtlve effect on your health? 1 2 3 
If you noIlaka YM medICatIOn exactly as ,"structed. 
lhe HIV vrus n your body Will become reSIStant to HIV 1 2 3 
tn8dIC&hons? 
Very dissatISfied 
In gelMtat how lisfiSd are you With the support you get from your fnends Dissatisfied 
ndfamiy~? Sansfled 
(drat only ontl Extremely sahsfied 
(U-NOI appNcabl.: "-Declined 10 answer, •• -00 nol know) 
M.Il Form (l(ENY A): Adht"n •• 10 HAART In Re1ug .. and Hos! Communities 
7 
Yes 1 
No 0 
Yes 1 
No 0 
Yes 1 
No 0 
Yes 1 
Exbemefy 
confident 
4 
4 
4 
1 
2 
3 
4 
229 
Not at all 
100S To I extlMll do ~ frI'iIlds and/or femlly members help you remember to A littie 
I )'W medICaI.on? Somewhat 
(circle «tty _I A lot 
"People 118 .~ISS "'big lhef medlQltlOns for vanous reasons [circle only one) 
I Wha' 811 lilt rstSOllS ~y you have ever missed laking 
yw HAAAT'r IPrompt to\' _chi Never Rarely 
1006 
1007 
10~ 
1OC» 
101O 
1011 
1012 
1013 
101. 
1015 
1016 
1011 
1018 
1019 
1020 
1021 
1071 
1023 
1024 
1025 
1026 
1027 
lOSUPa 
10SUPb 
10SUPt 
10SUf'Ij 
10SUPt 
10SUPI 
IOSUPg 
IOSUPh 
IOSUPI 
Away from heme 1 2 
~y w:h oIh. ''''ngs (e 9 at home or a' work) 1 2 
Sl'fll/yiorgol 1 2 
Have too many pillS to lake 1 2 
Wen! to el/Old side effects 1 2 
No! w.lnt oIhets to nolJce you taklng medICa lion 1 2 
Have. change III (1aI1y routll1e 1 2 
FtelIIk.lhII <tug 'Ir1IS 1000clhatmfui 1 2 
Fan asleep'sl~ Ityough dose lime 1 2 
FMlgckorii 1 2 
Feel dIIpr8SSedIoYe!emed 1 2 
Ha\ie problllm taking pits al specified limes 1 2 
Run oul 01 pills 1 2 
0e13111ed OIlflC3ICGrIIled by Ihe aulhOllll9s 1 2 
OIr.lCuly c:oncentraling 1 2 
Heling lIT_able 01 haVing oulbursls of anger 1 2 
l8S$IOIQrVI;I In dady aclivrtl9S 1 2 
Fee~ng lhal you have less skills than you had before 1 2 
Haomg dtfflCuly deakng with new Slluahons 1 2 
feebng unable 10 make daily plans 1 2 
Worrylng too much Iiloul things 1 2 
Feeling hopeless aboul lhe future 1 2 
Oelenhon 01 prison wllhout my HAART 1 2 
SusptCIOUS 01 treament 1 2 
Want to be free 01 mediCInes 1 2 
flO811Q81 constrants 1 2 
0Ih« ~Inossas 1 2 
Fe" fll'1e1heaHhy 1 2 
Oec:reased qualrty 01 Me 1 2 
~alnty 1 2 
O"I.phonslchaohc roullne 1 2 
[770Nol i1PpMcablt, ".Decllned 10 answer, ,.000 nol know] 
IiI.Jin Fonn (KENYA): Adherenc'to HAART in Rellgte IIId Host Communilles 
8 
Sometimes 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
f'ORM 3 
1 
2 
3 
4 
Often 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
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roAM 3 
(elrde only one] 
Never Rlrely Sometimes Often 
1029 Otnar 'can you Ihll'lk of any olher reasons Ihal were 
no! mtnIlOOIld?' 
l I 2 3 4 
• 1 2 3 4 
II 1 2 3 4 
'The ,questons lSkabout yox alcohol and drug use Please be hones! in your answers. We WIll nol report 'Mlat you 
cay 10 I/!yont' 
10lO 
1031 
t032 
1033 
10~ 
1035 
Daily 
5 or 6 tl11es per week 
ell hi". you had 8 amk conlalnlOg aloohol (e 9 3 or 4 trnes per week 
belir, cbanga. busaa ka da) In the last 30 days? 1 or 2 tmes per week 
(Prompt ,"til uampl .. of local d~n~ and elrelt only onll 2 or 3 times in the past month 
Once in the pas! month 
Never (SlOp to Q 10.32) 
Dally 
5 or 6 tmes per week 
INng \he pesl :xl days. how often have you had 5 or 3 or 4 tmes per week 
mot.1tl s of alCohOl., 8 row, that IS wrthln a few 1 or 2 tmes per week /lWS (eg 2-4 hOIJs)? 
(did' only on.) 2 or 3 tmes In the past month 
Once In the past month 
Never 
Ha, .. you ..... used In Inegal aug or not Illegal but potentially 
mlul (J unpresabed aug such as mrra, manJuana, valitrn, No (Skip to Q 10.34] 
/lOaCC;O k y8JI muganga. cocaine etc)? Yes 
(Prompt wllII.xampl" of commonly Ultd dlUga and drelt only one] 
Rarely 
«=ltweek) 
LISt I IIIf88 ~lIot augs you have used Drug I 0 
most 01180 WIthin the last 6 months, starting Drug II 0 
wlh llle one you have used most often Did 
you ute each rely (1 lime or less per Drug III . 0 ) or oflen (2 or more tmes per week) 
(I none. I .. ve blink) 
.• you VlSrted 8 aHOInatlVeMldltlOnaliherbal medICine No 
practoc;dl(Jl8t ., the pest 6 months? (elrel. only on.( Yes 
HaY8 you Imd afternahvellracillonaVherballrealments or No 
prlldOO8S (herbs. t s. pills, spells etc.) wrthin the past 6 Yes 
mooths? lelrclt only on_] 
(770 Not IIPpMcable; II-Declined 10 answer; "oDo not know) 
~In Form (KENYA): Adhtrenc,'o HAART In R111ugee and Host Communities 
9 
01 
02 
03 
04 
05 
06 
07 
01 
02 
03 
04 
05 
06 
07 
0 
1 
Often 
(>=2Iweek) 
I 
1 
1 
0 
1 
0 
1 
231 
Never 
~ 1\1. used elternatlVllllradltlOnallherbal treatments 
Yes, In the past 4 days 
1036 01 HAART to treat yotf HIV InlecllOn? Yes, in the past week 
lellde only onto mOlt recent) Yes, In the past 4 weeks 
Yes, In the past 6 months 
Yes, more than 6 months ago 
Icircle only on.) 
"To t aret I ng sl taments true?' Sometimes Not true true 
1037 I ca n' afkJd to eat p-operly, 1 2 
1038 l.n or.on hu~ blrt I don~ eat because I can~ afford enough food 1 2 
039 I t lea than I think I should because I don' have enough money for 1 2 food 
10.co IS p to Q 10 ~llf dllNlt hn no children I deptndlNlta) I cannot give my 1 2 c:h1~f9n) I dependents II balanced meal because I can'l affeld tha\. 
'P8gpIe fT8 be \,€RY CllOO t ta IIlQ the~ medlca\ions lor (elra, only one] 
VWIOUI What are the main reasons Ihat have halped Newr Rarely yr:N not 10 11118& laijng YfU HAART7 
10.1 
1042 
10.-3 
10 t4 
1045 
10~6 
10~7 
10~ 
1049 
1050 
10~1 
1052 
1053 
10!)'! 
10~ 
1056 
1057 
1058 
Md 13k. pna~y OWl' substance or alcohol abuse 1 2 
I ha .. ec:oepted my HIV status and learned 10 manage rt 1 2 
I;'f HAMT 9'* me good rasuls 1 2 
I ulldarstand ~y I must adhere to HAART 1 2 
I beMve that HMRT works 1 2 
My HAMT ragmen IS SImple 1 2 
My routlll8 15 fixed 1 2 
I \lit rlJlllnders ike my phone alarm 1 2 
I he lor someone (child spouse. etc) 1 2 
I vas f*1 01 the decisIOn to start HAART 1 2 
\loy lamlly an<b Ir.ends remlrc me to lake HMRT 1 2 
My family anQ'or mends support me emollonally 1 2 
My family anQlor fnends support me finanCIally 1 2 
I respect my doclor and hstan to their advlC8 1 2 
People knoW I em HIV.so I have nothlOg to lose 1 2 
11M! ... my aMly 10 lake my HAART 1 2 
I h .... brlghlluture ahead 1 2 
Other 'Can you think of any olher reasons thaI were not 
lione<f'r 
l 1 2 
• 1 2 
In-Not apple.blt, "-Declined 10 anlwer, II-Do not know] 
Main Form (KENYA): Adntrene. to HAART In ReNg" and Holl Communities 
10 
Sometimes 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
roAM 3 
01 
02 
03 
04 
05 
06 
Often true 
3 
3 
3 
3 
OftBn 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
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f'ORM 3 
SECTION 11: Patient-Provider Relationship, Clinic, and Social Trust 
. ng about IIle ooctor Ihat prescroes your HAART medICation, [cirde only ona) 
much <b you IruSllhal ' Not at all A little Quite a Extremely bit 
II 01 HeI$he 0(1., Ihe besl medeal care Ihey can prOVide? 1 2 3 4 
1102 He Ishe puts yoII' l\ealh above everything else? 1 2 3 4 
Doctor [Sldp to Q 11.06) 01 
Nurse 02 
1103 Of llle oIIowwlg heallh care providers HIV or HAART counsellor 03 
do you IItarlCl With most often? Outreach hane-based care 04 
[elide only one) Health coordinator or worker from your canmuntty 05 
Other (Specify' ) 06 
Do not know 99 
[elrde only one) 
"TIm ng about \his penon, tow much do you Irusl thai • Notatall A little Quite a bit Extremely 
1104 HaIshe 0/1., the bast meQcal care they can prOVide? 1 2 3 4 
\I~ He /she puiS yOU' heafth above everything else? 1 2 3 4 
'The IoIIcrwYIO QIlesbons asll aboul yOOf experience With thiS climc.' 
Less than 30 minutes 1 
How long on a'VO'ago. do you spend Ira veiling from 
30 minutes -less than 1 hour 2 
1106 1 hour -less than 1 5 hours 3 yOU' Ilane 10 thIS ClinIC? [eirde only one] 
t 5 hours -less than 2 holts 4 
2 hours or more 5 
1 07 00 you Incur c06ls related 10 laking HAART (e 9 tranSlJOfl to No [Skip to Q 11.09J 0 diloe, speaal dlel ele)? [elrd. only ont) Yes 1 
Thill tng about Ihe lasl v.9&k (Including today), how much 
Kenyan Shillings DODD. DO 11~ (1I1oce1 currency) did you spend on any HAART related-
1l~ 
11 to 
costs hke transport to c~nlC or phamnacy? 
tn the slIhree months have you left the clintc before a No 
sc edJled eppotntment due to Ihe waiting tme bemg too Yes 
long? Iclrcl. only ont ) Not Applicable (e g. I never attended) 
In the last Uree months, were you ever unable to refill No [Skip 10 Q I1.SUPaJ 
yctIJ HAART medoeatlOll prescr"tlon even If you wanled Yes 
lo? [elrda only ona) Not applicable (e.g. I never refitled) 
(77.Nol appNcable; " . Decllned to answer; , •• 00 nol know] 
M In Form (t(EHYA): Adheren ce to HAART In Refugee and Host Communities 
11 
0 
1 
7 
0 
1 
7 
233 
It costs too much to go to pharmacy 
t cannot teave my chltd-en alone 
y • }QU unable to I cannot miSS work or I will be fired 
rill ywHAART I am not motivated 
1111 III ()O? I waned too long at the pharmacy 
[Do 110( prompt.,d clrclt The staff at the pharmacy did not understand me 
tny lit! IpPI)1 The staff at the pharmacy turned me away 
Fear of being stopped by the police If I travel 
O1her (Specrty ) 
, IIQ!J \IS much }QU feel about the following Strongly Agree Uncertain DISagree 
slall!mor:l.· (cirdl only onel Agree 
11 SUFI t IITI keeled JUstly and 'MIh respect dunng my VISIts 1 2 3 4 10 the dIIlC 
I SU WIlen I go fot medlCSt care, they are careful to 1 2 3 4 CheCk ,v8l'flhlllg when treallng and examining me 
11 SUP\; Sanelrnes I v.onder If the prOVIder'S tests and 1 2 3 4 Iree~ts at, COllect 
11SUPO I grven 8 chOICe concerning the type of 1 2 3 4 treab'nenl that was preso-bed to me 
'The loIo\I.'ng qv8Sbons as!< you about the people around you 
11 12 
1113 
I 14 
1115 
1\16 
00 you 1 t t most p8q)le would try to take advantage of you ff Take advantage of you 
1/18y goIlhe chance, ot v.ould they try to be fair? (circle only one) Try to be fair 
Generally spealang, v.ould yoo say that most people can be Most people can be trusted 
1lusIed ot would you say that you must be very careful in Must be very canefulln dealing 
dealrlg v.lth people? (elrclt only onel 'Mth peopIa 
No 
Hav. you dISClosed your HIV status to your current spouse or sexual Yes partner? (circle only onel 
Not appticable 
Have you d<sclosed your HIV status to other members of your family No 
anO'or closest frlOnds? Iclrclt only onl) Yes 
Have you diSClosed your HIV status to others In your communijy? No 
lcildt only ontl Yes 
(HoNol applcable; "oDecllned 10 answer; "000 nol know) 
MlIIn Form tKENYA): Adhtrencelo HAART In Re~g .. and Host Communities 
12 
F'ORM 3 
01 
02 
03 
04 
05 
06 
07 
08 
09 
Strongly 
Disagree 
5 
5 
5 
5 
1 
2 
1 
2 
a 
1 
7 
a 
1 
a 
1 
234 
FORM 3 
SECTION 12: Supplementary Adherence Measures 
'To I" I v.ouId be to ask yoo some final ~esllOns aboul your HAART medicatIOn The medlcalions you said thai you lake 
ere 'IR.."ind eIl."t of medCllllon,lilltd In Q 09.01 and to think Ibout do .. , •. g. III pill' liken .t on. tim •. Remind them thlt III 
lilt inlom'llUon \hey provide 101111 be complMely conftdtntill .) 
1201 
202 
12031 
12 o:tl 
12 03c; 
1203d 
None of the lime 01 
A little of the lime 02 
In lilt I8SI month, IlO'N often dtd you take your HAART Some of the tme 03 
medlcahore? A good bit of the lime 04 
(dra, only on'J Most of the lime 05 
All of the lime 06 
VefYpoor 01 
rate yw ab~~y to take all your medlcallons as prescribed Poor 02 
cw«the tmonth Fair 03 
,dra. only on,) Good 04 
Very good 05 
Excellent 06 
1 day 01 
If yoo rNfII slopped taking your HAART In the past month f()( any 2 days 02 
reason. for IlO'N many conSI9CUtlve days did the longest 3 days 03 
mt8lT\4lltOn Ie ? 4 days 04 
(clrclt only ontl >4 days 05 
NevfII Interrupted 06 
I 1 month (from today)? No DO 
many HAART Interruptions of 2 days or m()(e while 
DO ta I1Q your HAART meacahon have you had In the last II 3 months (from today)? No (If nO Interruption, w~lt 00) 
III 6 months (from today)? No DO 
I 1 month (from today)? days DO 
What 1$ the k)ngest HAART interruption (in oonsecutlve 
days) that you have experlenoed in the last. ii 3 months (from loday)? days DO 
'_110 Interruption, wrttt 001 
iii 6 months (from today)? days 00 
The I3sIIm8 you 
Your own decISIOn (Skip to Q 12.03eJ 0 oppedt IIlg 
HAMT ,()( 2 days (rnmlyyyy) 0 LfJDD Your doct()( 'S decISIOn (Skip te Q 12.031] 
or tn()(e It , Not awhcable ISklp to Q 12.04J (clrclt Only ontJ 
InoNot IPpIClbl.; II-Declined to InSWlr; "000 not know, 
MoIl1 Fonn lKENY AI: Adhlrenct 10 HAART In Rllug •• and Hosl Communities 
13 
, 
7 
235 
FORM 3 
I fen well 01 
I was having SIde effects from medications 02 
, you opped YOlf HAART I was lravelling and could not refill medications 03 12 b1 'fOII$8If. srt 
use I tcok herbal medlCStlOns Instead of HAART 04 
I am afraid to be seen taking my medicatIOns 05 
other (Specify- ) 06 
1 YOlf I was laking HMRT from another clinIC and was not prescrbed HAART at thIS dinle 01 
HAMT S My doctor found nne uSing alcohol or ctugs 02 
12031 oppedby My doctor said I was healthy 03 IN doCtor, I was not taking my HMRT so my doctor stopped giving rt to me 04 
• My doCtor SWItched my medications and I warted to receive the new one 05 
other (Spec~y ) 06 
120A ere you previously taking 9 dlfferenl HAART reg men Ihan the one you are No [End) 0 
elll tly 18 IIlg (for example In another place such as anolher city, province, or Yes 1 
anotller country where you lived In the past)? ,clrcl. only on.) Do not know 9 
I YES to a 1204. cen you ra'Tlamber the names of those medications that you took prevIOusly. before the HAART 
1205 pitlou e presently taking? 
(Prompt client to ,.",.mb.r ttch prtviOUI HAART pili tlken. Ust .Ich according to Which pills wer. tlken together • 
• t on. 1m • • "PIrated by \ (.g Sell: ComblvirlEfcurt). Start from the current regimen. If dient Clnnot rtmembertfle 
n.m. 01 thtir pUll. .. k them to descrtbe Nch HMRT pUt they previously took by shipe Ind colour] 
Start 0 0000 Crty 
~en1 
FInish OD'OOOO CountrY' 
Start· 0 0000 Crty 
SEl2 
FInish OD' ODOO Country 
Start 0 0000 Crty 
SET 3 
Finish 00 0000 Couniry 
Start 0 0000 Crty. 
SEH 
FInish DO DODO Country 
·Tha~k·YOU for your partiCIpation We have now finIShed the main part of the questionnaire but I Will now take a blood sample' 
POST·INTEIMEW INSTRUCTIONS: 
1 
2 
3 
T e dJ8lltfor bklOd semple Ensure that eilidenblymg Information (Client to. CliniC #) are COITedly transferred to the 
S~ beI - the TechnICian Will fill out the information 
Donat v the chent until the sample has been taken 
Ranilld the clteot thai once the sample IS gIVen, the IOtervl8W IS ~eted 
(77-NolappNeable; ,,-o.cllned to answer; "-Do not know) 
M~1n Fonn (KENYA): Adhe"nce 10 HAART In Re~g" and Hos! Communities 
H 
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FORM 6 
'n-depth Intervlew Topic Guide for Clients: Adherence to HAART in Refugee and Host 
Communitl S 
'fOJ IIa\'e necMSaI)' materias (r8Clll'der, 2 pens, notebook, (jinks, topic guide, and dient reimtxnement 
Grell cIieI\t ,n tonI t1 prerMe6 and enSllr& InlefVlew space Is confidenbal 
RIad a &on SlII8I EnSlltl IllS understood and you have anslWrad dlent's questions. Sign consent fam 
4 RemarK eep quesbont ~n, do nalleld C/ien~ and use probing techllques. 
5 IfId CIIIOIIIMIw r.u11>1n8 dlent fa transport and meal (oblaln Slgnaflre) Assist cheot to fincing their way out of p-emiS18S and 
~ or puI:j~ IJ80$pCJ1, If raqured-
1. Background Information 
c. c.do t l - DDD Hospital No. 0000000000 
IRho.. OD'OD'2010 
It( SUII n a DOOD oml\lm 
u..guOOe(s) (UtI aI'anguoo" uted WI ord" of mos! use) 
/lull LKnon Record • • )S., batk of nlCOroOf) 
2, lnformation & Consent Form 
13. Interview 
14. Adh ... .,. teif<eport 
4. Reimburnment Signature 
caUl' RalllllNntMent SllIIIllure 
(2Ot t<[S) 
Referrals for counselling 
o 
Researcher NamelCode 
Interview End Time DO:OO'm\lm 
Client Gender Iclrcle) 1 Male 2 Female 
Foidor File It 
I Rtsea",her1ctlent sign consent fonn (c;heck box) 1 0 
x 
In Il1o a .. nt ola dJlI""td s!i.nl CAlL SUPERVISOR om ... , H7 (Josh) 
'n-daptll II'IImlew Topic Guld.lorClI.nts - Fonn • (KENYA): Adherence 10 HAART In Refugee and Host Communities 
1 
DO 
3 OIt1er 
237 
TopIc Guide for Clients 
InlroductlOn nd client history 
• current hVlng lIuallon, work, relationship 
IUlIU5 nd y-to-<llly hIe 
Ie g "Where do you lIVe In Kakuma ' ) 
• ldertl c:l1OOt II home country and region Ask client 
to dHcribe (brlerly) hlsiher migration sequence from 
hOme country to present country of asylum. 
• Whetel\Nhen wit HIV diagnosed? When was 
HAART 1111l! prescnbed and taken? 
Hlg"')' Actlve Antlretrovlrnl Tnernpy (HAART) 
• current HAART regimen and day-to-day life 
re hon to HAART 
(E 9 "Tell me about your HAART medication') 
[E 9 'How he your life changed ever since you 
taki! HMRT?") 
Ev ryday expariences with adhatlng to HAART 
• the client's undel1ltandlng of what 
adherence to HAART means to them? 
IE 9 "Whet does rt mean to you to 'adhere' to 
HAART"?) 
• u p!eS8nt strategle used to remember 
HAAAT 
IE 9 '1 am Intereated to know about the strategies 
you Ulie to remember your HAART 'J 
• ()acu present Challenges In relation to adhering to 
HAART 
IE 9 Can you tell me about anything that has 
prevented you from taking your HAART medication 
as prescrltled? 
Adh rance timet ln. 
• Develop a HAART adherence tlmellne With the 
ctoent 
IE 9 'You mentlOl1ed that you first started taking 
HAART on (date) In (country) I would like to Know 
more about your experiences With HAART over 
time TeU me about your first week of taking 
HAART 'J 
• AI you discus the tlmehne, ask about 
• MajOr 5UCCesseS and failures on HAART from 
'tart to present 
• Reg,m n Wltct1eS and reasons for switches. 
• CritICal moments when adherence was difficult, 
tMatenad or not Bchiev d and turning points 
when adherence challenges wers overcome 
• Memorabt rI1I sed doses andlor penod of time 
wt\en adherence to HAART WIIS challenged 
• If Idf\erence II excellent, ask Client to explain 
why Wh!lt helps make rt so? 
Notee [UII to 1I.t! with probing) 
[-15 min) 
[- 10 min) 
[-20 min) 
CONTINUE ON on NEXT PAGE 
In.dtplll II'II.IM .. Topic Guld, 10rell,nI. - Form. (KENYA): Adh,rence 10 HAART In Retuge. and Hosl COl:'lmunitles 
2 
F'ORM 6 
238 
~ 
Summary and lessons learned (-16 min] 
• 
. 
A Cloenllo summarise the most Important 
factors fect.ro their adherence (both helping and 
c/'Ia ro1ro Il'llllr Idherence) In the last 1 month, 6 
moo , and nee starting HAART 
(E g ' T me about Ihe mosllmportllnl fector(s) that 
hive effectt.>d yotJ adherence In the last month 
How.bout sinee atllrt lng HAART? rEg ' W het IS the 
I\'IQII lmport.nI lesson you have leamed ebout 
taktnQ HAART ellecttvely?"] 
0Itcuu the cltenl's future expectations of I~e with 
HAART 
IE g How do you plan the future and frt In HAART 
In 1M plan?' 
In-dtjlllllntlNftw TopiC G~d. for Cllenls - Form' (KENYA): Adhersnceto HAART In Rotuge. and Host Commlllities 
3 
F'ORM 6 
239 
FORM 6 
Post-Interview Not .. IAnICh page' If nee .... ryl 
MaIn Summary of interview (Mlk' I polnt form lilt of all meln points that emerged from the InteNtew In ralatlon to the research 
~-I 
IlI-\ltplll IT'll""" Topic Glide torCllenll- Fonn • (KENYA): Adherenc. to HAART in Refugee and Host Communities 
4 
240 
Extended Summlry of Interview (Write an extended lummary of the Interview using the main topics as a guide) 
I" depth tnttMew Topic Guide forentnll - Fonn I (KENYA): Adh .... nce 10 HAART in Refugee and Host CommLllities 
5 
FORM 6 
241 
FORM 6 
Selected quotations ($tied quotationa (2 or mort) and write them here. Ueten to the recording. and write them both In the 
\1191. of1l'ltlnl eMI'IIf. and In Engli,hl 
Languag of Interv1ew English 
Imervlower Renectlons (Wi'it.lbout your own experience 01 "'elnterAew and your thoughts on thl. client and their adherenca to 
HIINIT. tVtcu .. my challengea they hive Ilced and any obstacles they have overcome] 
Iflo4tplll Il'ottr;l .... TOJIle Guld. IorCII.nls - Form' (KENYA): Adhtnlnci to HAART In Refugee and Host Comml.Wllties 
6 
242 
F'ORM € 
ln1e~lewer Sef·Evaluatton (UII 311llngt that went well about the Interview and 3 things lIlat you with to ImproVIIlbout your 
own ttehn'qut for Ill. n.x1lnl.rvlew] 
l/l-d.pllllncfflftw TOille Guld. forClltnc. - FOm!' (KENYA): Adh'l'1Inc. 10 HAART in Reluget and Host Communitin 
7 
243 
R H CLEARANCES, ETHICAL CLEARANCES, 
I TIO HEETS, AND CONSENT FORMS 
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LONDON SCHOOL OF HYGIENE 
& TROPICAL MEDICINE 
ETHCS COMMITIEE 
APPROVAL FORM 
Application number: 5547 
N me 0 Pnnclpallnvestlgator Joshua Mendelsohn 
Department Epidemiology and Population Health 
Head of Dep rtmant Professor Laura Rodrigues 
TItle : Assessing adherence to Highly Active Antlretrovlral Therapy 
(HAARl) In Refugee and Host Populations 
ThiS apphcatlon IS approved by the Committee. 
Chair of the Ethics Committee 
( . c.'v f'\./ -<. . .;: 
Date .............. " ... ..... 29 July 2009 
Approval Is dep nd nt on local ethical approval having been received. 
Any subsequent changes to the application must be submitted to the Committee 
via an E2 amendment form. 
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C. 1 r I'I'IU 'Ct\ "I; l':kONO\ll 
ftolh Iml(' rta"um,r: l/nil 
J \11 \1 A " 1'1 JU>.<\ N -\ \\E'I11FRI 
r f ~ ' In \f( ~,L).'lklomC'nt 
III .0" 115 oS. B6 
I'l S '\T I'H '"I· ... UBTRAN KEIU .I ,V •. ,'rR!mKUTUAN 
r.~;;01~ l TR \J ,) \ 
EPU 
............. "' .... 
.. ~ .. " ,--,.' 
\1 \1.\\ '., 
Joshua Mendelsohn 
14 Warbonnet Dnve 
ep en 
0". Canad" 
R,' T, , 
lid 
R .... , .... 
O"r- I<,'J 
h,rd ..h 
I)',rr ' 
APPLICATION TO CONDUCT RESEARCH IN MALAYSIA 
.v:h rcference Iv your ap;)licat Oi' datee 10 August 2009. I am pleased to 1:1'o'm ),0.1 
thaI your appllcalion 10 conduct research III Malaysia has been approved by the 
Research Promotion and Co-Ordination Committee . Economic Planning Unit. 
Prime Minister's Depa rtme nt. The details of the approval are as follows 
Researcher s name 
Passport o. I C No 
allona'l ty 
Tllia 01 RC1S Rrch 
JOSHUA MENDELSOHN 
LJ577483 
CANADA 
"ASS ESSING ADHERENCE TO HIGHLY ACTIVE 
ANTIRETROVIRAL THERAPY (HAART) IN REFUGEE 
AND HOST POPULATIONS" 
Penod 01 ReSO:lrch Approved , SIX MONTHS 
Ilm of MalaYSian Counterpart : DR SUSHEELA BALASUNDARAM 
2 Pluaso col.ect your Research Pass In person from the Economic Planning Unit 
Prime Ministers Department Parcel B Level 1 Block B5. Federal Government 
Adll1 ln1Slra llv~ Centre. 62502 Putrajaya. MalaYSia and bllng along two (2) passport size 
photographs. a copy of your passport and payment of RM150 only All payments must 
he mMe In bank draft (from any MaluysicHl bank) or money order/postal order (from any 
MalaYSIan POSI olflce) In lavour of the Director General, EconomIc Planning Unit. 
Payment In cash or personal cheque Is not allowed. 
246 
3. Please ake nOle that the study should avoid sensitive Issues perlalnlng 10 local 
f8lu S 81ld norms as well as poillical elements while undertaking your research proJee: 
In Malays a. You have 10 adhere to the conditions slated by the code of conduct for 
for tg researchers You are also reqUIted to comply With Ihe rules and regulations 
stlpufated from time to lime by Ihe agencies With which you have dealings In the conduct 
of your r search 
.I You must always keep your local counterpart Inlormed of activities af'd 
In orm&lton or knowledge re:ated 10 the research work 
5 I woutd like to draw your atten!lon to the t..ndertaklng signed by you that yOl; WI I 
ubmlt wlthoul cost to Ihe EconomiC Planning Unl: the follOWing documents 
ct) /\ bllel summary 01 your research ftndlngs on completion of your research 
and before you leave MalaYSia. and 
0) Threo (3) COplClS of your final dissertation/publication. 
6 Lastly plea c submit a copy 01 your preliminary and hnal report directly to the 
S::\t Go~crnnlent where you carried out your research Thank you 
Yours Sincerely 
(MUNIAAH BT. ABO MAN AN) 
For Director General. 
Economic Plilnntng Unit 
E·mall ll1~e.lllijNym"'y 
Tel 88725281 188725272 
Fa 88883961 
ATTENTIO N 
ThiS 'ptler 'S only to Inform yOll Ihe statlls 01 your application and cannot be used as a 
researCh pass. 
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Cc 
Dr Sushee1a Balasundararn 
UNHCR Health Officer 
UNHCR Malaysia. 
'10570 Jalan Buk.t Pctallng. 
POBox 10185 
50706 Kuala Lumpur (Malaysian Counterpart) 
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JO$hUd Mende olln 
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t~· r 0'1. "",. Y J , • 
T uanlPu:ln. 
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Asses In9 Adheronce 10 Highly ActivlI Antlrctrovlral Therapy (Haart) In Refugee And Hosl 
Populations 
Oon I n honn"lllya perkara dl (l~Jr, ildal(1h dlrlJjuk 
2 8o;;I'llama deng(ln ruml 101 dll<lmplrI<.an sural keltJItJsBn s(llnllfik dan elika bagi pro)ek Inl 
3 Adal(l/t d.mnkltlrnknn bahuw(l Tlmn perlu mengclTlukakan laporan tahun[lll laporan lamal kajian 
dan juga lapelrsn rnongel1<l1 "All adversu ovont.~ bollr senous aod unexpected' kepada Jawatankuasa 
Ft I\)IlYf'idlkon P!!IlIbatan KKM 
18'1 'In1(l klsrh 
UNTUK NEGARA 
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Kem nl rian K rhOlan Maloysla 
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rr JABAT TIMBALAN I~ETUA PENGARAH KESIHATAN 
OrflCE OF TIfF Of::;PUI Y DIReCTOR-GENERAL or HEI\I TH 
tpENYFllOIKAN & SOI<ONGAN TEKNIKAL) 
(RESEARCH 8. TECHNICAL SUPPORT) 
KFMENl ERIAN KESIHATAN MALAYSIA 
MINISTRY OF HEAL TIl MI\LAYS/A 
AI a~ 12, fllok f:7 , Parsel E, Preslnt 1 
I ('vc'I '2, lJIock £7, P{lrc~1 F F'wcmCI 1 
Pus,,! P.,r.tiuJb,ran Keraisan Pcrr,ckliluan 
' ·v<Jf:r.JI OI)vOflimenf Adml1)lsll~'lvn CCltlrc 
Cl~!JO PUTRAJAYA 
1 el 03 686::25(3 
Faks 0368895184 
MEDICAL RESEARCH & ETHICS COMMITTEE 
MINISTRY or HEALTH MALAYSIA r 
-. 
RUJ Kami ' (6)dlm KKMlNIHSEC/08108041P09 285 
cJo Instilute for Hellith Management 1 arikh 21 December 2009 
Jalan Rumah Sakit, Bangsar 
59000 Kuala Lumpur 
I-'Ioloeol Title . 
As!>csslng Adherence to Highly Active Antiretroviral Therapy (Haartlln Rerugee And Host 
POPUl:ltionli 
PIII1Clpallnvcstl9ator 
L_. 
.JO~tlUi1 Mundelsohn 
London School of Hygiene and Troplcol MediCine 
Dr Anuradha l> Radhaknshnan 
Department of Medical 
Ilospil.11 ~;"ngal Bulub 
Documents received and reviewed with reference to the above study: 
, Study Proposal. Datud 18 September 2009 
2 Information rorm lor Client Questionnaire and BloodSarnple 
- English & Mntoy 
3. Leller of Indemnity, dated 8 Apnl 2009 
~ CliniC-Ali Tllul Agreement. MOHICHC/CTA0221280509 
5. Currrculum Vitae of Investigators 
1 he Medical Research & Elhlcs Committee, Ministry of Health Malaysia operates In accordance to the 
Ir)tomahonal Conference of Harmonizabon Good Clinical Practice Guidelines 
Comm .<It:. (If any) From the elil/cal aspects o( the study design, the MREC has no objection to 
the conduct of the study. However t/IIU6 are sensItive Issues pertaining to this study 7 refugee 
Sl.ltu" and Its .1ssoclalion with national security issues; the concern on the interpretation of the 
study Ifnd Its findings especl~lIy the future presentation, utilization and dissemination of the 
findlflgs 
PrOject Sites Hospital Sung;)i Buluh 
DeciSion by Modlcal RCS3arch & Ethics Commlltee: 
(,' ) Approved 
( ) Conditionally Approved 
( ) Disapproved 
o t OIO(lCIsion : 29 SeptembElf 2009 
DATO' OR CHANG KlAN MENG 
Chairman 
Medical Research & Ethics Committee 
Ministry of Health Malaysia 
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11n51111,11<, ror HealHl Managc~clIl _ i__ _ 
01 Male x 
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Dr Ho lzu MlnO 
Ms ROktah Don 
Dr Abd"'Ui"'K'iiiiar Ghapar 
Mr Raz.rAbdul ALIi. 
Mdnl Wong YOkO Ylng 
In5111ulo For Ilealth ~chavloJral 
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Senior nesearch Officer 
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Head, Department 01 Cardiology 
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Female 
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Female 
Male 
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x 
Mt Ra71f AtxJul AzJz 8. Mdm Wong Yoke Y1ng Are The Lay Persons In Tile Medical Research & Cthics 
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NA TlONAL INSTITUTES OF HEALTH APPROVAL FOR CONDUCTING RESEARCH 
IN THE MINISTRY OF HEALTH MALAYSIA 
PENGESAHAN INSTlTUSI PENYELIDIKAN NEGARA UNTUK MENJALANKAN 
PENYELIDIKAN 01 KEMENTERIAN KESIHATAN 
nus 1$ an auto computer - generated document.lt is issued by one of the research institute under the 
Nabonal lnstrtutos of Health (NIH). These are the Institute for Medical Research (IMR), Clinical Research 
Centre (eRC), Institute of Public Hea~h (IPH), Institute for Health Management (lHM) , Institute for Health 
Systems Research (IHSR) , and Institute for Health Behavioural Research (IHBR) 
Dokumen In; edalah cetakan berkomputer. Borang ini dikeluarkan o/eh salah satu insfitusi dibawah National 
Inshtlltes of He,lIh (NIH) iaitu Insfitut Penyelidikan Perubatan (IMR), Pusat Penyelidikan Klinikal (eRG), 
Insfrtut K8$lh,t,n Umum (lKU), Institut Pengurusan Kesihatan (IPI<) , Institut Pergurusan Sistem KesihatBn 
(IPSK). Insiltut Penye/ldlk,n Tingkahlaku Kesihat8n (IPTK) 
Unique NWRR 
"lMRR-09-239-3275 Reglstratton 10 : 
INombOr Pend. aran) 
R rch TIlt. : ~sesslng aanerence 10 nlgnly aCllve anlirelroVirallnerapy \t1fV\1'\ I ) In relugee aoo nosl populallons 
fTa J 
Protocol Number If 3275 1\1 I ble : 
(f"«ltI1IlOo ProtokOI pkZJ 
ldal 
" 
Iny stig tor Name Institution Name 
[[Name Penyelldlk] [Nama Instltusl] 
, M.radre P Rsdhaknshnan Sungal Buloh Hospital 
2 Joshua Mendelaohn United NatiOns High CommiSSIOner ror Rerugees London School 
UI 'YIiI"'''' <211U I I UIJIVC21 M"UI<;lfle 
IlIav reviewed the abOve titled research, and epprove or Its design and conduct 
k b k saya /eIah menyemax Sjlan yang ertaJu seperN dl atas clan meluluskan rekabentuk dan perlaksanaannya. 
Name of Olrector : 
[;N~a~rohl Dr lim Teck Onn 
NIH Institute (IMR. eRe. IPH, 
IHM, IHSR and IHBR) Clinical Research Centre (CRG) (Nema Ins/llusl dl bewah NIH] 
Slgnature & O"lclal stamp : ThiS 16 computer generated document, 
thererore no signature is reqUIred 
(Tandatangan dan Cop 
RasfmJ 
Date ! 29-072009 
(Tan hl 
(Nole Thl I 8 computer generaled documenl It may not carry any Signature) 
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Inforlmltton Sheet for Client Questionnaire and Blood sample (You wHl beQNen a copy of this mforrratlOfl sheet) 
.nd contact detaIls (J 
Assessing adherence to highly active antlretrovlral therapy (HAART) In refugee 
and host populations 
Joshua Mendelsohn MSc, Or Anuradha Radhakrtshnan MBBS MRCP, Or SUsheela 
Balasundaram MBBS 
UNHCR Malaysia, No. ~70, Jalan Buklt Petallng, P.O. Box 1018~ , 
00706 Kuala Lum pur, Malaysia 
Tel: 03-21411322 ext. 492 
Medical Research and Ethics Committee (MREC), Malaysia 
Clinical Research Centre (CRC), Malaysia 
London School of Hygiene and Tropical Medicine Ethics Committee 
London School of Hygiene and Tropical Medicine 
We,.,..,le you 10 take part In this research project on how people take their anllretroviral medicatiOn You should only take part 
you Wlnt 10 It IS up to you to decide whether or not to take part If you decide to take part you are stoll free to WIthdraw at 
.ny II ..... nd Without gMng • raison If you choose not to participate or to Withdraw ~ Will inllolve no panalty or loss of 
benefit'S to wtolch you ere otherWIse entitled Tha standard of care you receille will be unaffected This onformatlon sheet Will 
now be INd 10 you .nd you Will be gIVen an opportunIty to ask quesllons and have answers prOVIded We would like you to 
coMider IIlung part today but If you Wish, you may take this informatIon sheet home for consideratIon If you deCIde to take 
part you Will be goven thIS Information sheet to keep and be asked to SIgn a form stating that you agree to take part on the 
stUdt 
Alms of r .... rch: The purpose of the research IS to understand how often people lake theIr HIV medicatiOns (Highly Active 
M r t1O'v1rel Therepy or ·HAARr) and to understand factors that help people to take the" medIcatIOns or make rt more 
dlf oc:un PartICIpants WlIlIn<:lude refugees and MalaYSIans who attend the same clinIC 
Your role : Today you are beong asked to partIcIpate on a client quesbonnatre and to prOVIde a blood sample If you choose to 
partlClpele you Will be IntervIewed for approxImately 1 hour here at Sungai Buloh Hospital and we Win ask you to gMB a blood 
sample artelWlrds uSing the procedures normally used at the hospItal The Interview WIll seek onformatlon about your 
edheAlnce to HAART and challenges you may have faced whIle takong HAART The blood sample Will be used to test how 
II'aIch HIV rus IS In your blood and may also be tested for resIstance to your medIcation and other HIV or other infectiOus 
do .. sa-rei. ted tests III futuna tIme Your blood sample WIll be stored for 5 years at MalaYSIan L,ver Foundation laboratones 
before beIng destroyed We WIll also ask you to allow us to consuh your medical records for up to three years on Ihe past and 
for up to fMI years In the future 
Conftdentlallty: InteMeW1S WIll be pnvate and confidentIal. Your name Will not be written on the inteMew quesbonnalre or on 
the blood sample specImen Instead, a number Will be used to protect your identity. All onformation obtamed from inteMews 
and the blood Simple WIll be used in an anonymous way end may be used enonymously in future research In the short term, 
the Informabon you prOVIde WIll be stored safely on Kuala lumpur, Malaysia In the longer term, rt WIll also be stored safely In 
London, UnIted Kingdom If you choose 10 WIthdraw from the sludy blood samples and data you may have prOVIded WIll be 
I1Ilalned un'-s you Wish otherwose 
Incentlv,,: If you IgrM to parbclpete you Will be offered a snack or bell9rage dUring the InteMew and a maXImum 
rell!\bYrwment 0130 MalaYSIan RInggits for travel expenses Incurred You Will not receive any fInanCIal mcennw We hope 
thalllllS ,. ... rch WI. help the chnlc 10 develop ways 10 make It easIer for people hke you to take their HIV treatment 
Risks : Some questiOns may ask for personal mformatlon whIch may cause discomfort You may choose not to answer these 
questJOns It .. Important that you communICate WIth the researcher In the evenl that you become very uncomfortable or 
.nxlOus GMng blood presents the possibIlIty of bnuislng or swellIng at the sile and runs a mInimal risk of infectIOn DIscomfort 
tends to be bnef and tranSient 
follow~p : There IS the potential we WIll InVIte you to partiCipate In a follow-up interview at a different bme If so we WIll ask 
you .t the end of thIS InteMew or be In touch Within two weeks In such instances, InformatIon will be prOVIded and your 
consenl WI. be sought eglon 
Thank-you for takIng the tIme to consIder pertlclpebng In this study Please contact the Investigator named at the top of thIS 
VI"! t you h .... Iny questions In the future relaled to your particlpallon, rights or ~ you have any complaints 
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Informed Consent Form for Client Questionnaire and Blood sample (ThIS form 13 10 be COfTJllefed by lhe 
perlICIptnl. . ,*tng '''' InlomwfJOn ~t and/or havlfIQ lIStened to an explanaflon about the ___ 00) 
T 01 Pra,Kt 
~tIW. IIddr and oontact 
_ 0/ "'asLgator 
Sludr __ 
PIrtlCIPInt'1 Statlment 
Assessing adherence to highly active antlretrovlral therapy (HAART) In refUgee and 
host populations 
Joshua Mendelsohn MSc. Dr Anuradha Radhakrlshnan MBBS MRCP. Or Susheela 
Bala.undaram MBBS 
UNHCR Malaysia 
No. 1570. Jalen Buklt Petallng. P.O. Box 10IB~. 
150706 Kuala Lumpur. Malaysia 
Tel: 03·21411322 elrt. 492 
Medical Research and Ethics Committee (MREC). Malaysia 
Clinical Rtlearch Centre (CRC). Malaysia 
London School of Hygiene and Tropical Med icine Ethics Committee 
London School of Hygiene and Tropical Medicine 
• I he., rMd the ,"fo~toon sheet concemlng this study landfor have understood the verbal explanaUon) and I understand 
_t WI be requlfed 01 me and what Win happen to me If I take pan In ~ 
• My q"etbOn. concerning thIS study hive been answered by: Name: .................. .. ................... Position:. ..... ... .. 
• I understOnd thel al Iny lime I may Wllhdraw from thiS study Without giVing a reason and wrthout affecting my normal care 
Ind m8n1g1tnanl 
• I ~ 10 ill U$8 01 my personal .,formatlon for the purposes mentioned in the informabon sheet only and ilal II WI. not 
be UiMd lor Iny other purpose I understand thai such Info,"",IlOn Will be lIealed as .Inctly contidenba! 
• I undemand Ih I QCN1fldenba"Iy and anonymity Will be maintained and II Will not be posSIble 10 Identify me from any 
pu I ..... 
• , und nd ilal d I choose 10 wrthdraw from the study, blood 58mples and data thai I may have provided "". be retained 
.", I .. , h oiIalWll8 II I do nol ""thdraw, my blood 58mples will be destroyed alter 5 years 01 slorage at the Malaysoan 
l ' f Fo..ndatoor1 Laboralon.s and all data provided by me Will be malnlalned In stne! confidence 
• I egr .. to be contacted In Ihefuture by re58archers who would like to IOvlte me 10 participate In follow-up studies 
• I eg_ to tak. part In thIS lIudy 
Nlm. (pnnled) 
Client code: ICIUNHCR number: 
SlgnlniUre (or thumbpnnt) 10 -U[JD 000000000000 
Oate (ddlmmlyyyy); 
InY'tStlgllOf'S S~tlm.nt 
I COItf'rm that I ha •• ClrefuPy axplalned the purpose 01 the study 10 Ihe partlClpani and oullined any reasonably foreseeable nsks or 
be (wtoere epphC:lblel 
N ml (PrInted): 
Reseancher code: ICIUNHCR number: 
Signanture, DO 000000000000 
0." (ddlmmlyyyy). 
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Information Form for In-depth Interviews with Clients (You 'Mil be given a copy of thIS mformabon sheet) 
Toue 01 Pro,ect 
me edc! ... and contact details d 
.... nllglfO< 
ThIl stIICIr II .. _ applOlled by 
Assessing adherence to highly active antiretrovlral therapy (HAART) In refugee 
and host populations 
Joshua Mendelsohn MSc, Dr Anunldha Radhakrishnan MBe:; MRCP, Dr Susheela 
Balasundarem MBBS 
UNHCR Malaysia 
No. 570, Jalan Buklt Petallng , P.O. Box 10185, 
50706 Kuala Lum pur, Malaysia 
Tel: 03-21411322 ext. 492 
Medical Research and ethics Committee (MREC), Malaysia 
Clinical Research Centre (CRC), Malaysia 
London School of Hygiene and Tropical Medlcfne Ethics Committee 
London School of Hygiene and Tropical Medicine 
We invite you to take part in Ihls research project on how people take their antlretroviral medication You should only 
ta • pelt you want 10 It IS up 10 you to decide whether or not to take part If you decide to take part you are still free to 
w Maw at any time and without giVIng a reason If you choose not to partiCipate or to wllhdraw It Will Involve no 
penalty Of 10 01 beneftls to whtch you are otherwise entitled The standard of care you receive Will be unaffected This 
triormallOn sheel Will naN be read 10 you and you Will be gIVen an opportunity to ask questions and have answers 
provided We would \Ike you to consider laking part today but ~ you Wish, you may lake thts Informallon sheet home lor 
cor.tdenItiOf1 t! ~ou decide to take part you WI/I be given thiS InformatIOn form to keep and be asked to Sign a form 
tanng thet you agree to teke part In the study 
Alms of research: The purpose of the research IS to understand how often people take their HIV medications (Highly 
ActIVe ArirretroVlfel Therapy or 'HMRT'), and to understand factors that help people to take their medicatiOns or make 
It more dl~ocUt PartICIpants Will Include refugees and Malaysians who attend the same cllmc. 
Your role: Today you ere being asked to participate In an In-dej:th Interview to take pface at If you 
chooM to partICIpate, you Will be Intervtewed for no more than 2 hours If you give us permiSSion, we would like to tape 
record you InterVIew ThiS recording WIll only be used for research purposes. The interview will seek InformatIon about 
yoU' ecllerence to HMRT and ohallenges you may have faced while taking HAART. 
Conndentfallty: Interviews Will be kept strictly confidential All InformatIOn obtained from Interviews WIll be used In an 
enonymoUi way and may be used llnonymously In future research In the short term, the informabon you provide WIll 
be stored safely In Kuala Lumpur, MalaYSIB In the longer lerm, It Will also be stored safely in London, United Kingdom 
If you ChOO to Wlthdnlw from the study data you may have proVIded Will be retained unless you Wish otherNlse 
Incenbves: If you agree to partiCipate In thiS study you Will receIVe a maximum reimbursement of 30 MalaYSian Ringgits 
for tnI ..... 1 expenses B lunch. and a beverage You Will not receIve any financial Incentive We hope that thIS research Will 
helP the c Inrc to develOp ways to make It easier for peopfe like you to take their HIV treatment 
Risks: Some of the ISSues discussed may be senSItIve and could cause some discomfort It IS Important that you 
COITYT1uncate wllh the researcher In the event thaI you become very uncomfortable or anxIous 
Follow-up: We may InVIte you to partiCIpate In a follow-up interview at a later time In such Instances, further 
",ormatIOn will be prOVIded end your consent Will be sought again 
Think-you for tllklng the time to consider partlclpaling In this study Please contact the investigator named at the top of 
th. sheet If you have any questIOns In the future related to your partiCipation, fights or if you have any compfalnts 
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Informed Consent Form for In-depth Interviews with Clients (ThIs form IS 10 becompleled by Ihe pwbclpBnl an", 
/Md11lQ 1M InformalJon Sheelendlor havmg Ilslened to an IJxplllnalion aboullhe research) 
TCle 01 ProJ8Ct 
N.me. addr .... nd contaet 
deta~s of "","tlQator 
Th. 5Iudy has been .pproved 
by 
Sludy Sponsor 
Plrtlclpant's Statement 
Assessing adherence to highly active antlretrovlraltherapy (HAART) In refugee and host 
populations 
Joshua Mendelsohn MSc. Dr Anuradha Radhakrishnan MBBS MRCP. Dr SUsheeia 
Balasundaram MBBS 
UNHCR Malaysia 
NO. ~70. Jalan Buklt petallng , P.O. Box 1018~. 
50706 Kuala Lum pur, Malaysia 
Tel; 03·21411322 ext. 492 
Medical Research and Ethics Committee (MREC). Malaysia 
Clinical Research Centre (CRC), Malaysia 
London School of Hygiene and Tropical Medicine Ethics Committee 
London School of Hygiene and Tropical Medicine 
• I have read the InformatIon sheet concerning this study [and/or have understood the verbal explanation) and I undemand 
.....n.t ""M be required of me and what ""II happen to me If I take part in it. 
• My queslrons concernlllQ this study have been ansW!!red by; Name: .. . .................................... Position: .. .................... .. 
• I understand that at any bme I may WIthdraw from this study WIthout gIVIng a reason and without affecting my normal care 
.nd menagemenl 
• I COf1sent to the use 01 my personal informahon for the purposes mentioned in the information sheet only and that it wiU not 
be ueed lor any other purpose I unde",tand that such informatIOn WIll be treated as stnetly oonHdentlal 
• I understand that confidentiality and anonymrty v.ill be maintained and ~ ""II not be poSSible to Identify me from any 
publicabOf'lS 
• I understand that If I withdraw from the study, data thai I may have provided v.ill be retained unless I v.ish otherwise. If I do 
not 'Mthdraw, .11 data provided by me ""II be maintained in strict confidence 
• I agree to be contacted In the future by researche", ""0 would like to Invne me to partlcipa1a In follow-up studies 
• I agree to the Interview being tape recorded (Please fick yes or no) ; Yes .. ". No ..... 
• I 'Or .. to be quoted anonymously in research reports and publications. I understand that it will not be possIble to identify 
me from any of these quotatIOns. (Pleese lick yes ""no) ; Yes .. ". No ..... 
• I egree to take pert ,n this study 
Name (Printed): 
Client code: IC/UNHCR number: 
Signature (or thumbprtnt): 10 -000 OOOOOOOOODOD 
o te (dd/mmJyyyy): 
Inllestlgator's Statement 
I conhrm that I have carefully explained the purpose of the study to the partiCipant and ouilined any reasonably foreseeable n&ks or 
benefits (where applicable) 
Name (Prtnted): 
Researcher code; IC/UNHCR number; 
Signature: DO DOODOODDDDDD 
CIte (dd/mmtyyyy). 
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REPUBLIC OF KENYA 
NATIONAL COUNCIL FOR SCIENCE AND TECHNOLOGY 
T.I ,u",, '·SCIENCETECH". Nall'<lbl 
T. ,ephone lS •. 010. H I Ht. 1213101 
154.010· )1 OS71 . 1113113. 
fu154 ·010.11I31I$. ) IIl.S . 118H9 
When ... ,I,ln, pl .... quo,e 
Dr. Jo hua Mendelsohn 
London ch I of Hygiene & Tropical Medicine 
1 -0 KINGDOM 
P.O. lox 30623·00100 
NAIJl.OI).l<ENYA 
Web.ltt: www.nc:n.co.k. 
Date: 
30th November 2010 
• Ilowing your application for authority to carry out research on 
, dherence to HAART in refugees and surrounding host communities: 
I displacement a barrier to adherence?" I am pleased to inform you that 
y u and y ur co-researcher, Dr. John Wagacha Burton have been 
luth rized to undertake re earch In Turkana Dlsbict for a period ending 
31" October 20ll. 
You and your co-re eaTcher are advi cd to report to the District 
onunis joner, the District Education Officer, the Medical 
uperlntendent, Turkana District and the Commissioner, United 
adons High ommi loner for Refugees before embarking on the 
re earcb proj l. 
On completion of the re earch, you are expected to submit one hard 
copy and onc soft copy of the re earch report/thesis to our office. 
opy to: 
Th Oi trict Edu ation Officer 
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Turkana District 
The Medical Superintendent 
Turkana District 
The Commissioner 
United Nations High Commissioner for Refugees 
NAIROBI 
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TIn : mRf(~l()R, COH Il 1/'-> 
' lSI rtI \ 
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n \lUU fR '10 \))111 RE 'e E'! 
'J1JLq IS I., .,tOrl" Y')IJ It. 'd ,rillg :he 111;1" me('III'~ "till\' I\F~!R!/ERl' ml'\'!lOg h",ltI on J9'h 
<ktober ;0010, h.· ,.b<,,~ ~tlld'y \\iUS ,,,viewed 
1 ~ ilm Itt en""" 'h .. , Ih., 11m of Ihl' Hhl)VC n'I~ ... mc"d slllJns thrcdold: 
I 1 Q cVIlllali' Ilk\RT .\\th~('('nn', rN,'utioll nnd del,lUltl~A at Kukutna refuIlI"P <'an,!, 
., 10 HI\ .flgat ~ Illt"ton; thl11 rl.f\' ~!"iu(.'iatt1] '" lh !'nh,IJw(·d or rc.~th'i'd l,dhercl1('\.' t') HAART 
rt'!ugt'h 
j. r lInd .. U ',. a prl'llInlll,lI) qIlJntltil\1'e un"ly'" Jllil nlOn- d."all~d qCIlI!itnti\p UltlnlUt of 
d,n"",I1 ... ' )II "dlwl'"l-nr,- In H AA1{T hcl"Cl'lI r~1\'ges ;md "UITolllhlJnl\ h,l'! rli~1ll WOIiI" 
W~) :1(' ... ' !\ tht' m.·dl('O\'IUn!i fllHn shrsn'r! tli[1tc:'l 
~lldlY nt.:he Ih .. 'illhf.'! In lh~ t~C:;,' of tI h ':,t'dh .. h participant that cannot ft'ad (")r write all imp,\rti,t! 
'\ltel!'>/! "'111 t ... r<'tllI!!,;;,1 to ~I! In tiowlIglH1ut the (Ilnscn ting proccs..' to a.('I'rtJUll that the) hlud) 
ul> CC1) I~ ,10 IIl1d'-rst~ndIllR of \\ hal Ih('y JI',' ill tOI 
1>u .. ,·ons.d 't:\l'"m luis I"' .... " g.wn tIJ "th":,,l i ,,"~~ and the ~tudy ,s hereby gran tl!d unnllal 
rent.'wal tf,'\."I,\ '1m :.17''' du\' of O(·tobl'r 2010, for a (ll'l'Iod oftW\-]", (12) month. , 
PI I n, te tl nt ,r lIhlJll1llltnn t .. '!lel,"'l thl •• tl,d" "ill nln[,n\,llllnll) f'Xr1re OI~ 26'h Qt.toher 
~,. J 1 'f VOII I j.1II " .. (' I:t'illll. \'Vl!h daf.J ('qllp· lion or ilnJI) ~I,t\ h(,)'f)n(l thb U.th\ plt .... ,'-,· ~Hhm]tHl 
r.' "nt ("r lOllt1l1,,:nA "I'PI"'1l1 hI rlt" r:RC :'rnlJ'lrnl hy 8"' September 2011 
R ",- "ifill "',1 t. 
"ORI SFClU;T, NY, 
I(I:' jRI/. S I'!Oj 'M •. HTJII<'<; Rl':'\l£w_CQ..'l:fMrrn~l: 
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E 
K£ IR 
TO 
THRO' 
R 
VA EDICAL RESEARCH INSTITUTE 
OR. J 
THE DIRECTOR, (13M" 
M 
November 22. 201 'l 
o 
S C NO.11184 (R"QUfsr!!OR ANNUAL RENEWAL): ADHERENCE OF Ht.ART IN 
REfUG f.~ AIliD SURROUNOING HOST COMMUNITIES: IS DISPLACEMENT A BARRIER 
o AOHHI£NCf) 
iunng Ih!' l~!) ml'etmg 01 tho! Ki.MRI/1 He meeting held on I 1e 22'" of Nov~mber 
I • (00'11 lJ~~.lU"~.lnnl.ul.!..c!tvlew jlOd jlppr9ved the 03hovf' referenced .1rpl!cd(lon fOf 
W nOll'thl S (tie (1u.)1 proJ~c( year and tilat the !<,quest for COntlfludtIOr1.S to allow 
,hr n Iys. ,,",j ,iI>St>rTlln.l\i()l. 
)1 IS ... dire 1110d<1y November 2.2, 2011 through to November 21.2012. Please flote that 
:) to conl.i'.JCt thiS stUdy will automatically e~plre 01' NOllember 21.2012 If you plan to 
on'll"~ Wlt~ a a cell .:.t.on oldndlysi~ beyond this date plea.e submIt an apphca Ion for cOfltll1uing 
"'h me $e , t r'at bj' September 1.2012. 
V I. QI It'rllo ~ Ibm!1 anI' .l.l. lldml'J1t~ 10 thj~ PlotOCO! i.tnd other Inform:ltion pertinetlt to human 
p rt IP Hor II t, ,', ~\ldV to thE' .,~C Joel ERe for (t)vipw pnor 10 10111;)1100. 
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Information Form for Client Questionnaire and Blood sample 
(You .. JIbe gwn If copyollhd IflfomIatlOfl sheet 
Name add,eu and contact details d 
"",esbg.1Or 
Tlu. sMy hIS been approved by 
Assessing adherence to highly actl .... antiretrolllral tharapy (HAARTJ In refugM 
and hOst communities 
Joshua Mendelsohn MSc 
UNHCR Kenya , P. O. Box 43801-00100 
Nairobi, Kenya 
Kenya Medical Rasearch InstKuta Ethical RaView Board 
London School of Hygione and Tropical Medicine Ethics Committee 
London School of Hygiene and Tropical Medicine 
W. Il1IIItt you to take pert In th" research prOject on how people take the" annrelTOViral medICatIOn You should only lake part 
d you want to It IS up to you to decide Whether or not to takl part. If you decide to take part you are .bll free 10 WIthdrew at 
any limo and Without gIVIng a reason It you choose not to parllClpete or to Withdraw rt wrllinvolve no pvna lty or lOiS of 
benefits to Which you are othtrwlse entl~ed The standard of cara you rec8M! Will be unaffected ThiS Information sheet Will 
now be read to you and you Will be glvln an opportunity to ask questions and have answers proVIded We would ~ke you to 
consider taking part tOday, but d you wiSh, you may laka this Information sheet home for consideration If you decide to take 
pert you will be OMin th iS Information form to keep and be asked to sign a form stating that you agree to take part In the study 
Alms of research : The purpose of the research IS to understand how often people take therr HIV medrcabons (Highly Act,.". 
Antlretrovlral Therapy or "HAARr), and to unde,..land factors that help people to take therr medICatIOns or make It mora 
afficult Partlclpents Will Include refugees and Kenyans who attend the same cliniC 
Your rola: TOday you Ire being asked to participate In a client questionnaire and to provide a blood sample If you choose to 
pertrc'pate. you Will be interviewed for approximately 1 hour hara attha ComprehenSive Cara CliniC (l<akuma) and we woll ask 
)'011 to gMll bloOd spot sample afterwards We do thIS by pnckmg the skin of your finger(s) andlor heel(s) and collecting f"'" 
small dtOps of blood onto pepsr The Interview woll seek onformabon .bout your adh.rence to HMRT and challenges you mey 
have f.ced While taking HAART The blood sample will be used to test how much HIV Virus Is In your blood and may also be 
tested for res',lance to your medicatIOn and other HIV or other Infectious disease-<elated tests at a future time Your bloOd 
sample Will be &tored for 5 yea,.. at thl Kenya Medical Research Institute! Centres for DIsease Control Laboratones (KlSurnJ) 
before being destroyed We Will also ask you to allow us to consult your medical records for up to three years In the pest and 
for up to fMl ynrs In the future 
Conndtntlallty: Intervoews Will be pnvate and confidential Your name Will not be wnttan on the Interview quesbOnnalre or on 
the blood sample specimen I nstead, a number Will be used to protect your Iden~ty All InformatIOn obtained from IntelVlews 
and the blood 58mple Will be used In an anonymous way and mey be used anonymously In future research In the short term, 
the Informabon you prOVIde Will be stored safely In Nairobi and Kisumu, Kenya . In the longer term. 4 Will also be stored safely 
In London UK If you choose to wrthdraw from the study, blood samples and data that you already provided Will be retained 
unless you Wish otherwISe 
tneanlivas: If you agree to lake part you Will be offared a snack or beverage and snack dunng the Interview and 200 KSH to 
help you With transport end for any missed meals dunng Interviews You Will not receive any financral,ncenbve We hope that 
th iS research woll help the cliniC to develop ways to make It easl.r for people like you to take therr HIV treatment. 
Risks : Some quesnons may ask for personal Information whICh may cause discomfort You may choose not to answer these 
questions It IS Important that you communicate with Ihe researcher In the event that you become very uncomfortable or 
anxIOus Grvlng dried blood spot samples presents a minimal risk of Infection Discomfort tends 10 be bnef and transient 
Follow~p: There Is the potential we Will Invite you to participate In a follow-up Intervrew at a dlfTerent Ome. If so we Will ask 
you at the end of this InteMew or be in touch within two weeks. In such instances. Information will be proVided and your 
consent Will be sought 8gain 
Thank-you for taking the time to consider partiCipating In this study Please conlact the lovesOgator named at the lOp of thIS 
sheet t you have any questions In tha futllre related to your participation, nghts or ~ you have any complaints. 
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Informed Consent Form for Client Questionnaire and Blood sample 
(Tlw lam '" 10 "- f:OfT¥I/eted by 1M parllCtpeni eller rHdlfltJ lhe Informebon Sheel end)or havlfIg 1 .. 1Med 10 ~,' ex".".'''''' .bout ". 
fNewdI) 
Tille ot PrOjllCt AsslSslng adherence to highly active antiretroviral therapy (HAART) In refug .. and host 
communltl •• 
arne, eddr.., and 
contac1 delll'. ot 
""'MIlgalO< 
Joshua Mandelsohn MSc 
UNHCR Kanya, P. O. Box 43801-00100 
Nairobi, Kenya 
Kenya Modlcal Research Institute Ethical Review Board Th ... tudy ha. been 
Ipproved by London School of Hygiene and Tropical Medicine Ethics Committee 
London School of Hygiene and Tropical Medlclnl 
PartiCipant', Stltement 
• I have reid the InformatIOn .heel concerning th .. study [andlor have understood the verbal explanabon] and I understand 
lM'oat WI. be reqUired of me Ind lM'oat WIll happen to me ~ I take part In It 
My que$l'ons concerning th,i study have been ons_red by Name: PO.,llon . 
I unden;tand that at any time I may 'Mthdraw from thiS study WIthout glvong a reason and wthout affecbng my 1'l0I111II1 care 
end I1"'Ienagement 
I COI1sent to the use or my personal Information for the purposes menboned In the information s'-t only and I understand 
thet C WIll nOl be used for any other purpose I under5land that such In/ormatlon ",II be treated as stnctfy conhdentJal 
I unden;tand that conhdent .. hty and anonymity ",II be maintained and It WI. not be possible to odentlly me from any 
publications 
I undeostand that It I choose to WIIhdr.w from the Rudy, blood samples and data that I may have provided MI be retained 
unless I WISh othelWlSe If I do not WIthdraw, my blood samples WIll be destroyed after 5 years of slofage at the Kenya 
Medical Research Instrtute I Centres for Disease Control LaboratOries (K .. umu) and all data provided by me WI. be 
n-.lntained In strict confidence 
I agree to be contacted In the future by re .... rche .. who 'Mluld like to inVite me to partJc:opate on follow-up stud .. 
I agree to take part In th .. study 
Name (Printed) : 
SIgnature (or thum bprfnt): 
If thumbprint, signature of 
1m partial witness: 
Date (dd/mmlyyyy): 
Investigator'S Statement 
Client code: Identity number. 
20-000 000000000000 
I conform that I have carefully explained the purpose of the study to the partiCipant and outlined any reasonably foreseeable nsks or 
benefits (lM'oere applICable) 
Name (Pnnted). 
Signature: 
oat. 
(dd/mmlyyyy)' 
Researcher coda: Identity number. 
DO DDDDDDDDODDD 
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Information Form for In-depth Interviews with Clients 
(you wtll ". 0"'''' • copy of th~ Informellon ~t 
Ttle of Pro,ect 
Nlme. addr.s. and conlact details of 
onvastJgalDr 
Th study hiS been approved by 
SlUdy Sponsor 
Assessing adherence 10 highly leU", antiretrov,",' therapy (HAARn In refug .. 
and host communities 
Joshua Mendelsohn MSc 
UNHCR Kenya, P. O. Box 43801 -00100 
Nairobi, Kenya 
Kenya Medica l Research Institute Ethical ReView Board 
London School of Hygiene and Tropical Medlclne ethics Committ .. 
London SchoOl of Hygiene and Tropical Medicine 
We IrMle you to take part In this research project on how people take their anttretrovtrat medicatIOn You should only 
taka part If you want to IllS up 10 you to deCide whether or nollO take part If you deCide to take part you are sid free to 
Withdraw at any lime and Without giving a reason if you choose not to participate or to Withdraw It w lll involva no 
penanyor 106S of beneflt1; to which you are otherwise entitled The standard of care you receive will be unaffected ThIS 
lI"IormatlOn sheet will now be read to you and you will be given an oppertunlty to ask questions and have answers 
proVided We would like you to consider taking part today, but If you wish, you may teke thiS Informabon sheet home for 
conslderetlon If you decide to take part you Will be given thiS Information form to keep and be asked to sign II fonn 
stabng that you agree to take part In the Study. 
Alms of res.arch: The purpese of the research IS to understand how often people take their HIV medlCalions (Highly 
ActIVe Antlfetrovlfal Therapy or "HAART") , and to understand factors lhat help people to take their medicatiOns or make 
It more dlfficun PIIrtlClpantS Will Include refugees and Kenyans who attend the same clintC 
Your role: Today you Bre being asked to participate in an in-depth interview to take place at the COmprehensIVe Gare 
CliniC, Kakuma If you choose to partiCipate, you will be Interviewed for no more than 2 hours If you gIVe us perlTllsslOn, 
we w?uld like to tape record your Interview ThIS recording Will only be used for research purposes The Interview Will 
seek Informalion about your adherenoe to HAART and Challenges you may have faced while taking HAART 
Confidentiality: Interviews Will be kept strictly confidential All Information obtained from interviews Will be used In an 
anonymous way and may be used anonymously In future research In the short term the Information you provide Will 
be stored safely In Nairobi , Kenya, In the longer term, It Will also be stored safely ',n London, UK If you choose to 
Withdraw from the study, data that you already prOVided Will be retained unless you Wish othelWlse 
Incentives: If you. agree to take part In thiS, study, you Will be offered a snack and beverage dUring the Intervtew and 200 
KSH to help ,you With transport and for any missed meals during interviews You Will not receive any financial incenbve We 
hope that this research Will help the chnlc to develop ways to make rt easier for people like you to take thelf H IV 
treatment 
Risks: Some of the ISSues discussed may be sensitive and could cause some discomfort It IS impertant that you 
communICate With the researcher In the event that you become very uncomfortable or anxious 
Follow-up: We may Invite you to partiCipate In a follow-up interview at a later time In such Instances, further 
Informabon Will be proVided and your consent will be sought again. 
Thank-you for taking the lime to consider participating In this study. Please contact the Investigator named at the top of 
thIS sheet If you have any questions in the future related to your partiCipation, rights or If you have any complaints 
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Informed Consent Form for In-depth Interviews with Clients 
(TIt/~ form .. 10 ~ oompleted by 1M partJopenletter I'HdI/lO lhe Inlormebon ShNt a_ hev/tll1 /.s lIMed to en ecpl_1Jon about 
lM~h) 
rCle 01 ProjeCt 
ame. addr ... and OO<1lact 
deta ,1 01 onveslJgllor 
Th. study hIS been 
Ipproved by 
Study Sponsor 
Particlplnt'S Stallment 
Assessing adherence to highly active antlrotrovl",1 the",py (HAART) In netug .. Ind hoSt 
communltJes 
Joshua Mlndllsoh n MSc 
UNHCR Kenya, P. O. Box 43801·00100 
Nairobi, Kenya 
Kenya Medical Rlsearch Institute Ethical Review Board 
London School of Hygiene and Tropical Medicine Ethics Committe. 
London School of Hygiene and Tropical Medlcln. 
• I have reid \I1e Inlormallon sheet concerning IhlS study [andlor hIVe undelStood the verbal explanabon] and I understand 
WIll WIll be required 01 me and what WIll happen 10 me II I lake part In II 
My questions concerning thIS study have been ans_red by Nama: Posruon: 
I understand thaI II any time I may WIthdraw from this study WI\I1oul gIVing a reason and WIthout affeCIJng my OOImal earl 
and managemenl 
I consenl to the use of my perwonal Inlorma~on for the purpose. mentioned In the Infonmatlon sheet only and I underWland 
th.t • WIll not be u~ for any other purpose I understand that such Information WIll be Ireated _ stnct!y conhdenual 
I understand that oonhdenballty and anonymity WIll be maintained and It WIll not be possible to tdentJfy me from I ny 
publlC8b0n5 
I understand that If I Wlthdrow from \I1e study. dati that I may have provided will be retained unless I .... sh 01helWlse 
I agree to be contacted In the future by researchers who IM)uld like to Invne me to par\lc)Jpate In follow-up stud_ 
I agree to the inl8rvlew being tape recorded (PfeMe lICk ye~ or no) yes..... No ..... 
I ag;ee to be quoted anonymously In research reports and publtcatlons. I undersland thai rt WIll not be poMIble to Jdenafy 
me rom any of !hese quotatIOns (PIee.e IICk}'$S ex no) yes..... No ..... 
I agree to lake part In this study 
Name (Printed): 
Signature (or thumbprint): 
If thumbprint, Signature of 
Impartial witness: 
Date (dd/mm/yyyy): 
Investigator's Statement 
Client COde: 
20 -000 
IdentlfY number: 
OODOODornODD 
I oonfirm that I have carefully explained the purpose 01 the study to the partiCipant and outlined any reasonabty foreseeable nsks or 
benefits (whete applicable) 
Name (Printed): 
Reseancher code: Identity number: 
Signature: 00 ODOODDOOJODD 
Date (dd/mmtyyyy) : 
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